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A. Einstein 
Because science can play a double-edged knife in the future challenge we´ll 
have to face: 
 
- Ne fais rien contre ta conscience, même si c’est l’Etat qui te le demande. 
 
- La possession de merveilleux moyens de production n'a pas apporté la liberté, mais 
le souci et la famine. 
 
 
 
Because the best involvement is our behavior in our day to day life:  
 
- Nous savons de la vie quotidienne que nous existons d'abord pour d'autres 
personnes, car de leur sourire, de leur bien-être dépend notre propre bonheur. 
 
- Trois idéaux ont éclairé ma route et m'ont souvent redonné le courage d'affronter la 
vie avec optimisme: la bonté, la beauté et la vérité.  
 
 
 
Because science is not everything: 
 
- La seule chose absolue dans un monde comme le nôtre, c'est l'humour. 
 
- Un homme qui n'est plus capable de s'émerveiller a pratiquement cessé de vivre. 
 
- L'imagination est plus importante que le savoir. 
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Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on Nanomaterials 2014, 4(2), 408-438 
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1. Nanotechnology in Medicine 
1.1 Nanomedicine 
Nanotechnology studies materials and systems whose structures and 
components exhibit novel or significantly improved physical, chemical and 
biological properties, phenomena and processes due to their nanoscale size 
(according to the definition given by the US Nanotechnology Initiative in 
2000).
1
 This definition based on size, is very broad and includes a large panel 
of different entities, from physical devices to molecular self-assemblies, for a 
wide range of applications in numerous areas. 
 
Figure I.1 Size of different biological entities in comparison with nanoparticles. 
When nanotechnology is used specifically for medical applications, we 
refer then to “Nanomedicine”. It is nowadays mostly related to the application 
of nanostructures for treatment, diagnosis, monitoring and control of biological 
systems according to the National Institutes of Health in USA.
2
 The most 
remarkable property of the nanomaterials for medicine is their ability to work at 
the frontier of the molecular and cellular levels (Figure I.1). It allows 
4 
 
overcoming many biological barriers and acting in the process of the disease, 
as a bridge between the biomolecular pathways and the microscopic cells or 
pathogenic agents. Moreover, nanoparticles have a high ratio of surface area 
to volume allowing a high versatility for their engineering. The fruitful marriage 
of nanotechnology and medicine has been already demonstrated with many 
examples published or in the clinic but the most promising perspectives are 
still to come.
3
 Besides, it seems that the importance of nanomedicine is taken 
with great attention as NIH classified it among the top priorities and more than 
$3.8 billion is allocated in research and development for nanotechnology each 
year.
4
 
____________________________________________________ 
Key to understand: A piece of history of nanomedicine 
Starting in 1959 with the famous talk of Richard Feynman at the annual 
meeting of the American Physical Society where he developed the vision of 
manipulating and controlling things on a small scale,
5
 nanoscience 
progressively grow up to become one of the most important field in research 
and investment (2 billion euros estimated for 2015)
3
 Although the application 
of nanoscience to medicine is relatively new, several basic approaches were 
published a few decades ago. The pioneer example of lipid vesicles, knows 
today as liposomes, date from 1965. An example of the controlled release of a 
drug was proposed in 1976. The 80´s witnessed the popularisation of metallic 
nanoparticles for medical imaging. First long circulating stealth polymeric 
nanoparticle was proposed in 1994 showing the beginning of a more complete 
vision (considering the physical and biological behavior) in the investigation of 
the nanoparticle.
6
 More recently, we have witnessed the apparition of quantum 
dots in 1998 and up-converting nanophosphors and nanowire sensors in 
2001.
7
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Table I-1 shows examples of the most common nanomaterials 
commercially available or in advanced phases of clinical trials. This table 
includes just a few of the most remarkable nanomaterials.
2
 A complete table 
would take several pages since the number a type of nanoparticles is endless; 
a clear demonstration of how active this field is these days. Due to their 
versatility, these nanomaterials are being used in vitro for. e.g. tests of 
biological samples based on nanoparticles (urine pregnancy, human 
immunodeficiency virus or polymerase-chain reaction assays)
2
 and in vivo 
where nanoparticles find multiple applications as contrast agents for different 
medical imaging techniques and as drug-delivery platforms.
6
 For instance, 
nanoparticulate contrast agents can accumulate passively in tumours by the 
enhanced permeability and retention effect (leaky vasculature around the 
cancerous cells) for diagnostic imaging.
8
 Labelling studies in preclinical 
applications also employ nanomaterials which includes radionuclides or 
fluorophores in their coating.
1
 Nanomedicine is also widely used for drug 
delivery. Again a major application is related with controlled-release or delivery 
of anticancer compounds. Drug release polymers, liposomes or viral and 
protein structures are examples of common classes preferentially used as 
nanovectors in drug delivery research.
9
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Table I.1 Example of nanomaterials on the market and in clinical trial. 
Nanomaterial Trade 
Name 
Applicati
on 
Target Current 
Status 
Metallic     
Iron oxide Rienso 
Combidex 
Nanotherm 
 
MRI contrast 
Cancer 
therapy 
Liver 
Lymph nodes 
Various forms 
FDA approved 
Phase 3 clinical trials 
Phase 3 clinical trials 
Gold Verigen 
Aurimmune 
In vitro 
diagnostic 
Cancer 
therapy 
Genetic 
Various forms 
FDA approved 
Phase 2 clinical trials 
Nanoshells Auroshell Cancer 
therapy 
Head and 
neck 
Phase 3 clinical trials 
SemiConductor     
 QDots, 
EviTags, 
nanocrystal 
 Molecular 
sensing 
structure 
Research use only 
Organic     
Protein Abraxane Cancer 
therapy 
Breast FDA approved 
Liposome Doxyl/Caelyx Cancer 
therapy 
Various forms FDA approved 
Polymer Oncaspar 
CALAA-01 
Cancer 
therapy 
Leukemia 
Various forms 
FDA approved 
Phase 2 clinical trials 
Dendrimer VivaGel Microbicide Cervicovaginal Phase 2 clinical trials 
micelle Genexol-PM Cancer 
therapy 
Various forms Phase 4 clinical trials 
The term Nanoparticle (NP) is used in medicine in a generic way 
including a wide range of distinct nanostructures some of them hybrid or 
combination of different ones. When used in the literature it can means a 
plethora of very different chemicals; micelles, liposomes, dendrimers, 
polymeric nanoparticles, nanobubbles, metallic nanoparticles, silica particles, 
carbon nanotubes, quantum dots, viral based nanoparticles, etc. In this work 
we have focused in metallic nanoparticles since they show very interesting 
properties for imaging. Hereafter, the term NP we will be used to call mainly 
metallic nanoparticles. 
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1.2 Characteristic of nanoparticles for nanomedicine 
NP have special structures which places them at the cross of many 
different disciplines. They are basically composed of a metallic core 
surrounded by an organic coating bound to the surface (Figure I.2).
10
 To fully 
understand their physicochemical and biological properties both components 
must be fully characterised. The metallic core provides the size-dependent 
properties for which the material is most well-known. This is the case for the 
three types of nanomaterials and associated properties that we will describe in 
this work; superparamagnetism, surface plasmon resonance and up-
conversion fluorescence. Table I.2 shows the type of NP currently used for the 
most important imaging techniques; ultrasound (US), magnetic resonance 
imaging (MRI), computed tomography (CT), positron emission tomography 
(PET) and optical imaging (OI).
11
 Thus, the research in nanomedicine is 
usually centred in one of three aspects: new properties of the nanomaterial 
core, new bioconjugation techniques on the surface or new applications.
10
 
The surface of the NP is of paramount importance, it determines the 
targeting capabilities, colloidal stability and much of the in vivo fate of the 
NP.
12
 Most recent advances deal with the term functionalisation; the 
attachment of molecules on the surface of the particles to provide colloidal 
stability and/or biological targeting.
13
 Surface coating is responsible for a 
range of specific requirements for the in vivo biological use of the NP, which 
concern multidisciplinary fields such as biochemistry, molecular and cell 
biology, pharmacokinetics or toxicity.
14
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Table I.2 Type of NP used in the different imaging techniques. 
Technique Advantages Disadvanta
ges 
Nanoparticles 
used 
US Easy to perform / cheap 
Non invasive 
Nonionizing radiation 
Low resolution 
high reflection and 
attenuation 
Emulsion s and 
gadolinium oxide NP 
CT Wide field of view 
Cross sectional images 
Differentiation of body 
tissues 
Lack of contrast 
agent 
Radiations 
Costs 
Gold and silver 
nanoparticles, iodine 
based products. 
PET Can image biochemical 
anf physiological 
phenomena 
Radiations 
Motion artifact 
Resolution 
Expensive 
NP tagged or conjugated 
with radioisotopes (19F, 
68Ga, 89Zr) 
MRI Higher resolution 
Anatomical details 
Not ionizing 
Expensive Iron oxide NP  or NP 
tagged with gadolinium 
chelates  
OI High sensitivity  
High resolution 
Easy to perform /cheap 
Low penetration, 
almost only limited 
to pre-clinical 
applications 
NP tagged with organic 
fluorophores 
Up-converting 
nanophosphors 
We detail below the structure (Figure I.2) and main features of the 
coating of metallic NP in relation with the purposes they require to fulfil. The 
possibility of introducing several imaging agents and/or biological targeting 
moieties and drugs, summarize under the expression “multifunctionality” is 
one of the unique features of this new type of chemistry. However, this 
multiplex incorporation still presents some challenges, particularly the need to 
reduce numerous sequential steps of the synthesis for reproducibility and 
scaling-up production issues.
15–17
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Figure I.2 Schematic representation of the structure of metallic nanoparticles. 
Biodistribution and pharmacokinetics: The coating has to provide a 
good colloidal stability to the NP in physiological media and minimise their 
natural tendency to aggregation. Another important role is to protect the probe 
from a rapid opsonisation and clearance by the immune system before its bio-
action.
18
 Polymers surfactants (also called “stealth” layer) like dextran, 
polyethylene glycol (PEG) or poly(lactic-co-glycolic acid) (PLGA) are examples 
of coatings designed to extend blood circulation times in vivo and reduces NP 
uptake by the reticuloendothelial system or mononuclear phagocyte system, 
and are now widely used for the synthesis of blood pool agent.
19
 It has also 
been demonstrated that toxicity of the NP can be modulated by the help of 
suitable coatings.
20
 Liposomes and micelles are other very popular organic 
coating nanostructures. They are amphiphilic non covalent organic assemblies 
and can integrate the NP either in the hydrophilic or lipophilic portion of the 
assemblies according to the hydrophilicity of the NP. These structures present 
important advantages especially when used at the same time for drug delivery 
and excellent properties for encapsulation of imaging probes.
21,22
 Finally 
protein carriers have been also proposed for NP transport and colloidal 
stabilisation.
23
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Targeting: Another important feature is the possibility of adding to the 
coating a targeting ligand towards a biomolecule associated with a disease, 
enabling the ability of a selective recognition. A plethora of biomolecules has 
been assessed for directing NP in vivo. Small organic molecules, peptides, 
proteins, antibodies or aptamers conjugated to the coating have successfully 
implemented targeting abilities via ligand/cell receptors interactions (Table 
I.3).
24
 Development of new specific or selective ligands is nowadays a hot 
topic in the whole nanomedicine research, as well as all the chemistry for the 
surface modification with these ligands.
25
  
Table I.3 Examples of targeting ligand receptors combined with NP. 
Type Name Target Application 
Small 
molecules 
Folic acid 
Methotrexate 
Non peptide RGD 
mimetic 
Mimetic of the sialyl 
Lewis 
 
Folate receptor 
Folate receptor 
Avβ3 Integrin 
E-selectin 
Breast cancer imaging 
Brain tumour imaging and 
therapy 
Integrin positive cell imaging 
inflammatory disease imaging 
Peptides RGD 
Chlorotoxin 
 
Synaptotagmin 
VHSPNKK 
Avβ3 Integrin 
MMP-2 
 
Phospholipids 
VCAM-1 
Breast cancer imaging 
Brain tumour imaging and 
therapy 
 
Apoptosis imaging 
Cardiovascular disease 
imaging 
Aptamers A 10 RNA aptamer 
 
Thrm-A and Thrm B 
DNA aptamer 
Prostate-specific 
membrane antigen 
Alpha-thrombin 
protein 
Prostate cancer imaging 
 
Serum protein dection 
Proteins Annexin V 
Luteinizing hormone 
relasing (LHRH) 
Transferrin 
Phosphatidylserine 
LHRH receptor 
 
Transferrin 
receptor 
Apoptosis imaging 
Breast cancer imaging 
 
Breast cancer imaging 
Antibodies Monoclonal antibody 
A7 
Herceptin 
 
Rituxan 
Colorectal 
carcinoma 
Her2/neu 
 
CD20 antigen 
Colon cancer imaging 
Breast cancer imaging  and 
therapy 
Lymphoma imaging therapy 
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Multimodality: Medical imaging is now reaching an inflexion point by 
combining different techniques. The aim is to get simultaneous or sequential 
images of improved quality and complementary information. For instance 
PET/MRI and PET/CT hybrid systems were developed with the idea of gaining 
sensitivity and improved spatial resolution. The metallic core of NP usually 
provides one or several (for instance the UpConverting Nanophoshors or the 
core/shell structure) imaging ability.
16
 Surface modification of the coating is 
also a preferential way to integrate other organic imaging modules especially 
chelates for radioisotopes (for PET/SPECT imaging) or Gd
3+
 (MRI contrast 
agent) and fluorophores for OI (Table I.2).
26
 
Drug loading: Nanoassemblies, often called nanovectors or 
nanocarriers when used in the drug delivery field, today are probably one of 
the most promising options in the drug delivery research.
27
 It offers many 
benefits among others: targeting, pass through various biological barriers, 
local action (allowing reduced dosage and fewer side effects), better drug 
stability, possibility of sustain and controlled release, overcome drug solubility 
issue, etcetera. The core of metallic NP provides an imaging possibility itself, 
and thus tracking of the delivery is also possible. 
9
 
______________________________________________________________ 
Key to understand: Theranostic 
The new field of theranostics refers to the simultaneous integration of 
diagnosis and therapy aiming at a rapid, selective and more efficient 
therapeutic intervention. The term derived from thera(py) and (diag)nostics to 
merge both fields for advanced applications. The main features of the NP, 
multifunctionality and targeting, appear ideal for this new trend.
28
 
Nanotheranostic, represents then, a NP which gathers diagnostic and 
therapeutic functions. In fact, considering the main applications and uses of 
nanomedicine described above, this opportunity emerged as the natural 
12 
 
evolution of the field. Again, if targeting properties are added, it is possible to 
obtain highly elaborated probes for the future.
29
 Advanced theranostic 
nanomedicine is multifunctional in nature, capable of diagnosis and delivery of 
therapy to the diseased cells with the help of target. Consequently, many 
structures are proposed, they gather one or several imaging modalities 
(principally for MRI, PET, CT, US, OI) with a therapeutic function, many times 
encapsulating a molecular or biological drug or just designates an additional 
physicochemical property of the NP itself that can be used for therapy 
(hyperthermia or photothermal).
30
 Almost all the NP cited reported in Table I.2, 
have been applied as well as nanotheranostic agents. 
2. Iron oxide Nanoparticles 
Because of the importance of iron oxide nanoparticles (IONP) in 
nanomedicine and as this work mainly focus on the synthesis and biological 
application of new IONP, we will briefly describe the main features of this kind 
of NP. Two additional sections will also briefly described the up-converting 
nanophosphors (UCNP) and gold nanoparticles (AuNP) which also appear in 
this research work. 
2.1 Properties of Iron oxide Nanoparticles 
IONP are particles of iron oxide of with a core size usually between 2 
to 50 nm, exist under two main chemical forms: magnetite (Fe3O4) and its 
oxidised relative, maghemite (γ-Fe2O3) which are biocompatible and with very 
low toxicity.
31
 Because of their nanometric size, both hold the particularity to 
be superparamagnetic, a type of magnetism. The magnetism in a solid 
basically depends on the type of electrons and the type of occupied orbitals in 
the atoms of the material. For some materials, by applying an external 
magnetic field, the electrons generate magnetic dipoles that, on average, align 
with the field creating a net magnetic moment. The phenomenon of 
superparamagnetism appears when the size of the NP is smaller than the 
13 
 
magnetic domain. Then the magnetic moments are randomly oriented, due to 
Brownian motion, until an external field is applied. In this case, typically for 
MRI applications, all the NP align with the external field generating a 
permanent dipole much stronger than the one generated in paramagnetic 
compounds (i.e. gadolinium chelates). Once the field disappear, the magnetic 
moments (NP) come back to be randomly oriented and the dipole (net 
magnetisation) disappear.
32
 This property is the origin of the applications for 
which are used the IONP such as MRI, magnetic delivery, isolation/purification 
of biomolecules.
33,34
 The last application introduced in the field is magnetic 
particle imaging, a new preclinical imaging technique that still need further 
technical development.
35
 
2.2 Applications of Iron oxide Nanoparticles 
Because of the superparamagnetic aspect combined also with the 
general features of the NP (section 1.2), IONP serve at numerous exciting 
applications in biomedicine.
36–38
 
Contrast agent for MRI :  
______________________________________________________________ 
Key to understand: Magnetic resonance imaging
39
 
MRI is a routine non-invasive medical imaging technique for diagnostic 
applications in the clinic. MRI is based on the principles of nuclear magnetic 
resonance (NMR) spectroscopy. To perform NMR studies, we need a set of 
nuclei, a very powerful external magnetic field and radiofrecuency pulses to 
perturb the resultant magnetisation aligned with the magnetic field. The 
resulting response to the external perturbing electromagnetic field is the 
phenomenon that is exploited in NMR spectroscopy and MRI (although for 
imaging we need extra gradients to code the information spatially). All nuclei 
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with a nonzero nuclear spin experience this phenomenon, but the most 
frequently used in biomedicine are the ones of spin ½, in particular the protons 
of the water. When the nuclear spin is of ½, the presence of a powerful 
external magnetic field leads to an energy splitting in two different energy 
levels. At the thermal equilibrium, the two energy states corresponding to this 
energy splitting are not equally populated, and a net magnetic moment is 
established. Upon application of an additional electromagnetic fields this 
energy states are perturbed and the effect of relaxation is to take 
magnetisation back to original net magnetic moment at thermal equilibrium. 
The time dependence on relaxation is different for longitudinal and transverse 
magnetisation; Longitudinal relaxation tends to a constant value M0, decaying 
to M0 exponentially with a time constant T1. Transverse relaxation tends to 
zero, decaying exponentially with a time constant T2. They both depend on the 
main magnetic field, temperature, intrinsic properties of the sample (proton 
density in the tissue, diffusion) and the type of sequences of the additional 
radiofrequency pulses. Consequently, relaxation times are different according 
to the tissue and when they are monitored by an MRI scanner, produce 
different intensity to create an image. Contrast agents affect this relaxation 
process to change the signal intensity in the neighbouring tissues (Figure I.4). 
Figure I.4 Basic principles of MRI. 
Because of their magnetism, IONP will alter the magnetic field 
interacting with the local magnetic field produced by the spins of protons. It 
causes a shortening of the longitudinal and transversal relaxation times (T1 
and T2) of these protons after their submission to external magnetic field 
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stimuli. This effect is traduced in contrast enhanced MRI either by a positive 
or, more frequently, a negative or signal void in the area where the 
superparamagnetic IONP have accumulated. In the case of IONP, they 
normally shorten considerably T2 which explains they acts as negative 
contrast agent in the traditional MRI sequences. Alteration of the T1 process 
require a closer interaction with the contrast agent and only ultrasmall IONP 
can acts for positive signal enhancement, although some special MRI 
sequences have been also showed to get positive enhancement.
40
 This last 
decade, the investigation of functionalised IONP has executed in parallel with 
the technical advances achieved in MRI, with the possibility of visualising 
biological events at the cellular level.
41
 Several ferrofluids are already on the 
market or in clinical trials (Table I.1) but also above all plethora of 
functionalised IONP have been proposed for advance applications in 
preclinical research. For instance, integral targeted IONP for multimodal 
cancer imaging which integrate a therapeutic function are regularly proposed, 
we refer here to the excellent review of McCarthy and Weissleder on this 
topic.
42
 IONP have been also proposed as MRI contrast agents for several 
other clinical applications in cardiovascular medicine via their uptake by 
macrophages in inflamed areas, stem cell tracking or diabetes.
43,44
  
Drug delivery vehicles and therapy: As described before, because of the 
possible “multifunctionality” character of the NP, IONP can be designed to 
release conventional drug/therapeutic loaded/integrated in its assemblies, with 
the normal advantages associated to the NP structure (Figure I.2).
45
 From the 
applications specific to the IONP, the main ones are magnetic drug targeting 
and hyperthermia. The first one uses a local magnet field (either external or 
implanted internally) to drive the IONP until the region of interest by magnetic 
attraction. For applications with tumours, several successful studies in small 
animal models and clinical trials have already reported demonstrating partial 
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remission.
46
 On the contrary, the treatment with targeted hyperthermia is 
based on the fact that abnormal cells or bacteria suffer apoptosis if exposed to 
slightly higher temperatures. The main limitation is the low discrimination 
between healthy and malignant cells with concomitant harmful effects. Iron 
oxide cores can produce a local heating if submit to an alternating magnetic 
field and reach only the affected zone if pretargeted beforehand. Magnetic 
hyperthermia treatment is now in some clinical phase II studies and highly 
used in preclinical research.
47
 
Finally, nanoparticle driven gene therapy with optimised transfection or 
biosensing (detectors sensible to the presence of a biomolecule) are others 
non-negligible applications of IONP.
48,49
. Moreover, the chemical engineering 
of the organic coating is under constant development to improve/enhance the 
complex route of synthesis or in vivo behavior of the probe to reach the final 
biomedical objective of the probe.
31,36,50
 
2.3 Synthesis of Iron oxide Nanoparticles 
Due to the relevance and wide spectrum of applications with IONP, there 
has been a tremendous increase in the synthetic methodologies in the past 
years. The most relevant approaches include methods such as 
coprecipitation
51
, thermal decomposition
52
, sonolysis
53
, sol-gel processes
54
, 
spray and laser pyrolysis
55
, hydrothermal and high temperature synthesis
56,57
, 
nanoreactors such as protein cages
58
, vesicles
59
, microemulsions
60
 and 
microwave-assisted synthesis
61–63
. For the sake of simplicity, we will focus 
here only on the most interesting ones from the biomedical point of view: 
coprecipitation, thermal decomposition and microwave-assisted synthesis. 
Particularly, thermal decomposition has a higher prevalence and projection in 
the field and it is the method we have applied throughout this work. 
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Co-Precipitation Method. This is one of the most employed methodologies 
for the synthesis of IONP for biomedical applications. This process involves a 
reaction of the aqueous mixture of Fe
2+
/Fe
3+
 salt solutions with a base. Under 
these conditions, magnetite NP are formed by aggregation of primary particles 
within a Fe(OH)2 gel. This methodology, developed by Massart et al., was 
carried out initially without the incorporation of any stabilizing molecule on the 
surface of the nanoparticles.
64
 In this pioneered work, authors reported the 
controlled preparation of IONP through alkaline precipitation of FeCl3 and 
FeCl2. Magnetite (Fe3O4) particles formed were roughly spherical with 
diameter of 8 nm. In this approach magnetite is prepared by adding a base to 
an aqueous mixture of Fe
2+
 and Fe
3+
 salts in a 1:2 molar ratio. The overall 
reaction may be written as follows, leading to the precipitation of black 
magnetite:
64
  
Fe
2+
 + 2Fe
3+
 + 8OH
−
  Fe3O4 + 4H2O 
A wide variety of parameters must be considered in this method in order to 
control size, magnetic characteristics and colloidal stability in the solution. 
Magnetisation can vary drastically with synthesis variations even within 
particles of similar size, due to incorporation of impurities into the crystal 
structure and involvement of surface effects.
65
 Generally, saturation 
magnetisation values of magnetite NP obtained by this method are in the 
range of 30–50 emu/g; lower than the 90 emu/g reported for their bulk form.
66
 
In addition, an exhaustive control of different parameters in both the synthesis 
and purification steps, such as the pH, is essential to obtain NP with specific 
size.. As a result, the production of narrowly dispersed particles remains a 
significant challenge in this method.
67
 Other factors like the fine adjustment of 
Fe
3+
:Fe
2+
 ratios, heating regimes, and the coating–iron ratios must also be 
strictly controlled.
68
 After the initial development by Massart et al., the number 
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of coatings that have been used, vary from polymers
69,70
, to dendrimers
71
 and 
organic acids
72
. The main advantage of the co-precipitation process is that large 
amount of water-stable NPs are obtained. However, the control of particle size 
distribution is limited, because only kinetic factors are affecting the growth of 
the crystal. This leads to the synthesis of somehow heterogeneous samples in 
terms of size and shape. Another problem that can be found with this 
approach is the weak attachment of the surfactant to the surface and the 
reduced number of functional groups that can be found on the surface. All 
these drawbacks complicate the final functionalisation of the NP for 
biomedical applications. 
Thermal Decomposition of Organic Precursors. High temperature 
decomposition of iron organic precursors mixed with surfactants in organic 
solvents is progressively becoming the standard way for the preparation of 
IONP. This method yields NP of narrow size distribution, good crystallinity and 
high magnetisation saturation values (Figure I.5).
31
 The first synthesis 
introduced by Aliviastos et al. reported the injection of FeCup3 (Cup:N-
nitrosophenylhydroxylamine) solutions in hot trioctylamine resulting into NP of 
4 to 10 nm average diameters as a function of the temperature (250 °C to 300 
°C) and the quantity of iron precursors added.
73
 A second method consisted in 
the preparation of iron NP by injection of the organic Fe(CO)5 precursor in the 
surfactant mixture followed by an in situ oxidation phase to produce highly 
crystalline and monodispersed maghemite NP with sizes from 4 to 16 nm.
74–76
 
Although the hot injection technique guarantees instant nucleation and 
homogenous growth for an optimal quality of the NP, it also shows drawbacks 
mainly related to safety and toxicological issues.
77
 Heating up processes were 
then proposed with iron oleate, an intermediate prepared from FeCl3 and the 
mechanisms of crystallisations studied.
78,79
 In 2002, Sun et al. described a 
single step synthesis using iron acetilacetonate thermal degradation by 
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progressive heating in diphenyl ether in presence of alcohol, oleylamine and 
oleic acid surfactants.
52,80
 The magnetite NP prepared with this method have 
dimensions in the 3 to 20 nm range adjusted by a control of the reaction time 
or the amount of the low complexing reactants. A summary of the most 
relevant approaches using the thermal decomposition of organic precursors 
can be found in Table I.4. 
 
 
 
 
 
Figure I.5 TEM images of 16 nm size IONP synthesised by the decomposition of 
organic precursors:  (A) a monolayer assembly, (B) a multilayer assembly, (C) HRTEM 
image of a single Fe3O4 NP. 
The size and morphology of the NP are the resultant of the growth 
mechanism during the thermal decomposition method. We will focus here only 
on the influence of the different reaction conditions, further details of the 
growth mechanism models have been reviewed in several occasions like in 
Gao et al.
33
 For instance, the time of reaction for the growth phase clearly 
regulates the size.
81
 Also, IONP prepared with higher temperatures lead to 
larger sizes; successfully employed by heating with various solvents of high 
boiling points.
78
 Another critical variable on the structural features of the NP is 
the surfactant or mixture used for emulsifying the systems and to control 
nucleation. It was observed that the size of the NP is inversely proportional to 
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the tendency of the surfactant to coordinate with the iron atom.
82
 Thus, 
common methods often control the size of the NP by addition of a low 
complexing surfactant.
83
 Sizes can also be modified depending on the molar 
proportion Fe:surfactant.
84
 It has also been shown that the affinity properties of 
the solvent for iron can play a major role in this process.
73
 Finally, although 
few studies have also assessed the influence of the organic iron precursors, 
preliminary observations showed that a narrower and controlled particle size 
distribution is favoured with a specific iron intermediate complex before the 
generation of the cores.
85
 
Shape-controlled synthesis of iron oxide IONP with this method can 
be performed under thermodynamic or kinetic control. Thermodynamic control 
is the key aspect when working with low concentration of precursors, yielding 
spherical NP to minimize the surface energy. When working at high 
concentration conditions, kinetic control will lead to the formation of particles 
with other morphologies such as cubic or elongated particles.
73,79,86
 
The above described thermal decomposition synthesis is a powerful 
method to produce IONP of higher quality than the ones prepared by the 
aqueous routes.
83
 One drawback of this approach is that the hydrophobic 
character of the NP makes compulsory a second step to transfer IONP to 
water. The requirement of rendering hydrophilic nanomaterials for in vivo 
applications has boosted the appearance of new efficient chemical routes for 
the functionalisation of NP. Before the use of these new alternatives, the 
efforts focused in the modification of the thermal decomposition method with 
hydrophilic surfactants and/or polar solvents to provide hydrophilic IONP in a 
one-pot synthesis route. Gao’s group first reported the use of 2-pyrrolidone, a 
strong polar organic solvent.
87
 In a first attempt, 2-pyrrolidone had also the 
role of surfactant with Fe(acac)3 as the iron precursor. This method was 
assessed also with FeCl3∙6H2O as precursor to obtain IONP with average size 
between 4 to 60 nm.
88
 In order to synthesize IONP stable in physiological 
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solutions, mono or di carboxylic-terminated poly(ethylene glycol) polymers 
were introduced as surfactant.
89,90
 
Table I.4 Main aspects of the synthesis of IONP by Thermal Decompostion methods. 
Iron 
precursors 
Surfactant Solvent T/°C 
Shape 
and Size 
FeCup3 Octylamine Trioctylamine 
250–
300 °C 
4–10 nm 
Fe(CO)5 Oleic acid Dioctyl ether 300 °C 4–16 nm 
Fe(CO)5 TOPO or DDA 
Ortho-
dichlorobenzene 
180 °C 
12 nm 
variation 
possible 
(diamond, 
triangle, 
spherical) 
Fe(acac)3 
Oleic acid 
Oleyl amine 
Phenyl ether 
or benzyl ether 
259–
298 °C 
<20 nm 
Seed 
mediated 
growth: 20 
nm 
Fe(oleate)3 
from FeCl3 
and sodium 
oleate 
Oleic acid 
1hexadecane or 
trioctylamine  
274–
365 °C 
5–22 nm 
FeO(OH) Oleic acid 1-octadecene 320 °C 6–30 nm 
Fe(acac)3 
FeCl3 
2-pyrrolidone 
2-pyrrolidone 
2-pyrrolidone 
2-pyrrolidone 
245 °C 
5 nm 
Seed 
mediated 
growth: 11 
nm 
Fe(acac)3 
 
m PEG-COOH 
d PEG-COOH 
2-pyrrolidone 
2-pyrrolidone 
240 °C 
240 °C 
12–30 nm 
Fe(acac)3 PVP 
N-vinyl-2-
pyrrolidone 
200 °C 4–40 nm 
FeCl3 PAA Diethylenglycol 220 °C 3–12 nm 
The amphiphilic character of the PEG coating confers on IONP 
important properties such as high stability and solubility in different media.
87
 
Moreover di-substituted carboxylic polymers have the advantage of showing a 
reactive group on the surface for further functionalisation. These results 
opened a range of new studies assessing others polar organic solvents and 
surfactants such as Polyacrylic acid, N-vinyl-2-pyrrolidone, glycols or diphenyl 
oxide.
91,92
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Microwave-Assisted Synthesis. In general, most of the synthetic 
reactions to obtain IONP include heating through traditional heat transfer 
systems, such as oil baths, sand baths and heating jackets. These heating 
techniques are, however, rather slow and a temperature gradient can develop 
within the sample leading to local overheating spots. All these parameters may 
have an important effect both in the nucleation and growing steps of the 
synthesis. A fundamental aspect of the microwave approach is the dielectric 
heating; under these conditions the energy is introduced into the reactor 
remotely. The microwave radiation passes through the walls of the vessel and 
heats only the reactants and solvent and not the reaction vessel itself. In 
modern pressurised equipment, the temperature increase is uniform 
throughout the sample, and facilitates heating far above the conventional 
boiling point of the solvent. All these features allow for the synthesis of IONP 
with greater control/reproducibility of size and dispersity, as well as enhanced 
crystallinity. The characteristics we just highlighted are attracting the attention 
of many scientists working in the synthesis of NP. Currently there are 
examples in the literature on the use of microwaves for the synthesis of 
maghemite NP
61,62,93
, mixed maghemite and magnetite NP
94
 and pure 
magnetite
63
. Due to the novelty of the approach most of the recent 
publications focused more in the synthesis of the nanoparticle core and rather 
poorly in the colloidal stability of the synthesised NP in water. This is gradually 
changing and there are examples already using PEG and dextran as 
surfactants for biomedical applications.
57,95,96
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2.4 Biofunctionalisation of Iron Oxide Nanoparticles 
When developing nanoparticles for biomedical applications, one of the 
key point is the functionalisation of the nanoparticles’ surface. Ideally, this 
functionalisation should confer NP with very good colloidal stability in the usual 
conditions for in vivo administration (i.e., 0.9% NaCl, PBS, etc.) and as many 
as possible functional groups to facilitate the binding of target or specific 
biomolecules. The strategy is different depending on the hydrophilic character 
of the initial IONP. For those obtained by the coprecipitation method, the next 
step after the synthesis is eventually the attachment of the biomolecule of 
interest. This sometimes can be a problem since the number of functional 
groups on the surface is usually low. For those obtained by thermal 
decomposition, a previous step of aqueous stabilisation is first required. Since 
the IONP obtained by the thermal decomposition are usually of superior 
quality, we will detail in this section the three main different approaches for the 
phase transfer of the hydrophobic IONP to aqueous based solution: the ligand 
exchange, the use of amphiphilic nanostructures and the direct chemical 
modification of the organic surfactant (Figure I.6). These approaches can at 
the same time include the conjugation of biomolecules of interest but it is also 
possible, as for the initial hydrophilic NP, to perform additional steps for 
biofunctionalisation, following classic interface chemistry techniques like direct 
NP conjugations, linker chemistry conjugations or physical adsorption.
24
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Figure I.6 Steps in the synthesis of IONP for preclinical imaging. and scheme of the 
different approaches and steps for the phase transfer to a water-based solution. 
Ligand exchange. The ligand exchange approach is based on a 
mixture of hydrophobic IONP with a very high concentration of the hydrophilic 
molecule. In such conditions, the hydrophilic ligands eventually displace the 
hydrophobic surfactant due to its affinity towards IONP surface and thus 
yielding aqueous stable NP.
97
 The most remarkable aspects of this approach 
is the simplicity and versatility due to the enormous number of hydrophilic 
ligands that can be used for this purpose, like carboxylates, phosphates, 
polymers and inorganic materials. 
18,98,99
 However, this approach also 
presents some disadvantages. One of them is the degree of exchange. If this 
is not high, the surface of the nanoparticle will contain hydrophobic moieties 
leading to stabilisation problems and most importantly, to a significant 
reduction in the number of reactive functional groups for further 
functionalisation.
50
 In general, the ligands utilised in this approach can be 
classified as small organic molecules and large polymeric compounds. In 
small organic molecules group, dimercaptosuccinic acid due to the carboxylic 
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groups, shows for instance a high affinity towards the IONP surface, thus 
providing high stability in aqueous media and enough free functional groups 
for further biomolecule conjugation with many applications.
100
.
 
 These NP are 
widely employed for MRI
104
 and also drug delivery
105
. Citric acid is another 
carboxylic-based ligand for the ligand exchange approach of common use. 
This acid may be adsorbed on the surface of the magnetite nanoparticles via 
one of the two carboxylate groups, depending on steric hindrance and the 
curvature of the surface. This leaves at least one these functional groups 
exposed to the solvent, which should be responsible for making the surface 
negatively charged and hydrophilic.
31
 Another kind of ligands with good 
properties for the exchange approach are silanes. These compounds present 
the general chemical formula X-(CH2)n-SiR3, where SiR3 is the anchor group 
having good affinity for the surface of the nanoparticle, (CH2)n is the 
hydrophobic chain and X is the head group providing the hydrophilicity. 
Further surface modifications are possible depending on the X group.
101 
Other 
small molecules that have been used in this approach are phosphonates of 
several compositions.
102
 The utilisation of large polymeric compounds for the 
exchange approach includes dendrimers, polyacrylic acid and PEG. In the 
case of dendrimers the most common is poly(amido)amine. This dendrimer 
has been conjugated with targeting ligands, imaging moities and drug 
molecules for its application in cancer therapy.
103
 Moreover, poly(amido)amine 
coated IONP are a suitable platform for further functional modifications to 
increase the circulation time of the NP in blood.
71
 Polyelectrolytes such as 
poly(acrylic acid) and poly(allylamine) are also polymers employed to replace 
the original hydrophobic ligands on the surface of IONP. As we have 
mentioned before, nanoparticle PEGgylation is well-established to optimize 
the stabilisation of NP and to prolong their circulation time in blood after 
administration.
104,105
 Regarding the utilisation of this polymer by the ligand 
exchange approach, one of the best examples is the use of Dopamine-PEG-
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COOH, a synthetic compound produced from the polyethylene glycol diacid 
formulation, in which, one of the acid groups reacts with the terminal free 
amine of dopamine through a conventional N-hydroxysuccinimide reaction. 
After the ligand exchange reaction, water stable NP are achieved even with 
different length chains of PEG. These probes have proven much less uptake 
by macrophages, indicating that these can evade recognition from the cells of 
the immune system.
106
 
Amphiphilic nanostructure. The utilisation of amphiphilic structures for 
the stabilisation and functionalisation of IONP is a second approach usually 
selected when synthesizing these compounds by thermal degradation 
method.
22,107,108
 This method takes advantage of the structure of these 
amphiphilic molecules. The formation of weak van der Waals interactions 
between the hydrophobic part of these molecules and the organic tail of the 
nanoparticle coating, to minimize the interaction with water, produces very 
stable NP with excellent reproducibility (Figure I.7). Furthermore the possibility 
of a previous modification on the amphiphilic molecule allows for the 
stabilisation and functionalisation of the IONP to be carried out in a single 
step, although this opportunity has not been fully addressed. To obtain such 
micelle-like structures, usually the first option is to use a polymeric amphiphilic 
compound. The hydrophobic structure is inserted between the hydrophobic 
chains of the surfactant/ligand adsorbed on the IONP, while the hydrophilic 
part stands around the outer surface to assure the dispersion of the IONP in 
biological media. Many kinds of polymers have been assessed, like 
pluronic
109,110
, poly(maleic anhydride alt-1-tetradecene)
111
, cyclodextrins
112
, 
PEG-phospholipids conjugates
113,114
, or other triblock polymers
115–117
. Other 
advantages of the method are the possibility of further crosslinking for better 
stabilisation or encapsulation of small hydrophobic drugs in the hydrophobic 
bilayer that is created (as well as small organic fluorescent molecules). Final 
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stability of the structure depends mainly on the nature of the polymers, i.e., 
amphiphilic balance, molecular weight, length of the chains or conformation.
115
 
To achieve the insertion of the polymers several methods are possible, such 
as reverse evaporation 
118,119
, progressive increase of the solvent polarity
115
 or 
nanoemulsion
120
. The encapsulation of hydrophobic NP in polymeric micelles 
is very similar to the insertion option.
121
 Many examples are in the bibliography 
using diblock polymers, such as polylactide-b-poly(ethylene-maleimide) 
22,122
, 
poly(styrene-block-acrylic acid)
115
, poly(e-caprolactone)-b-poly(ethylene 
glycol)
123
 or dendrimers
124
. Control of self-assembly structures can be 
achieved from micelles to vesicles, based on the nature of the solvent used 
and other different conditions.
117
 Liposomes, vesicles composed of a lipid 
bilayer, are for instance another important structure based on amphiphilic 
compounds and an excellent platform for drug delivery and imaging 
applications. We refer to the review of Torchilin et al. in 2005 and Alen et al. in 
2013  for explanations in detail of their utilisation, advantages and applications 
in the design of IONP probes.
21,125–127
 High density lipoprotein-liked 
nanoparticles were also developed by Fayad and Mulder et al.
128
 with 
multimodal imaging properties, by including additional labels in the corona of 
the particles, such as iron oxides, gold and quantum dots. Protein or viral 
based carrier of hydrophobic IONP can also in a sense be included to the 
amphiphilic nanostructure approach. 
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Figure I.7. Examples of amphiphilic nanostructures for the aqueous stabilisation of 
IONP prepared by thermal degradation method. 
Chemical Modification of the Surfactant. This is a new approach 
based on the direct chemical modification of the surfactant, usually oleic acid. 
Although different alternatives can be foreseen, the most logical one is to 
perform chemistry on the carbon-carbon double bond. The final intention of 
this method is to bring all organic chemistry tools for the synthesis and 
functionalisation of hydrophilic molecules. This approach was demonstrated 
for the first time in IONP, by using the very well-known double-bond oxidation 
with KMnO4 to generate a carboxylic group. The reaction is performed in a 
two-phase system, a mixture of organic solvent, where the oleic acid NP are 
dispersed, and an aqueous phase where the KMnO4 is soluble and where the 
IONP are eventually dispersed. In this procedure, a phase-transfer catalyst is 
used to get enough concentration of the MnO4
−
 ion in the organic phase. This 
modification renders water-stable particles, and at the same time, also, a 
functional group ready for further binding of biomolecules, from small organic 
molecules to dyes and proteins.
129,130
 Two of the most remarkable features of 
these modifications are that the nanoparticle is always protected by a layer of 
surfactant, thus minimizing the aggregation and that, by using an excess of 
the oxidant, a complete transformation of the oleic acid is achieved. A second 
recent initiative is the direct modification of oleic acid using another well-
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known reaction in organic chemistry, the olefin cross-metathesis. The idea 
behind this is to take advantage of the functional group in the oleic acid. 
However, with the olefin metathesis option, one step further can be passed. 
Since it is possible to incorporate a terminal olefin in many peptides, proteins 
and biomolecules, it can be utilised for, in a single step, transfering the NP to 
water and providing specificity for biomedical applications.
131
 
3. Up-Converting Nanophosphors (UCNP) 
Recently, a new class of nanomaterial, the rare-earth upconversion 
nanophosphors (UCNP) has been described as an interesting alternative for in 
vivo fluorescence imaging.
132
 It shows the unique feature of converting low 
energy near infrared (NIR) light into higher visible light and/or NIR emission 
through 2 or 3 sequential photon absorption, together with energy transfers 
(Figure I.8).
7
 This overcomes the drawbacks of classical luminescent probes 
and confers very attractive advantages to a UCNP-based fluorescence 
imaging: less harmful excitation, no autofluorescence, high fluorescence 
lifetime, narrow emission spectra, no toxicity, low cost techniques and, last but 
not least, very low excitation power densities for a high penetration depth.
133
 
For all these reasons, the knowledge used for the engineering of common 
metallic NP was rapidly applied to UCNP to get multifunctionalised targeted 
probes for pioneering fluorescent or multimodal pre-clinical imaging studies.
134
 
Phototherapy and drug released triggered by fluorescence also take 
advantage of this new class of metallic NP. Great attention was initially paid 
on the β-phase host lattice NaYF4 NP doped with a combination of Yb3
+
 and 
Er
3+
/Tm
3+
 ions because it was proved to be the most efficient UC host 
materials under a 980 nm laser excitation.
135
 Multiple methods for the 
synthesis of NaYF4 UCNP and applications have been published in the last 
years.
136,137,138
This has led to an improvement in the thermal degradation 
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synthesis that has boosted the interest for other classes of UCNP.
139
 Among 
others, addition of passive shells on the nanoparticles
140
 and the use of 
different lanthanides have improved the UC fluorescence
141
 of the probes and 
opened the way to multimodal UCNP-based contrast agents.
142
  
 
 
 
 
 
 
Figure I.8 Comparison of the principles of the traditional and up converting 
fluorescence. 
We have focused on the promising β-NaGdF4:Yb,Tm@β-NaGdF4 
nanomaterial because of its very good NIR to NIR UC luminescence and the 
possibility of use as MRI probe due to the presence of gadolinium.
143,144
 On 
this regard non-doped NaGdF4 has been described as an efficient T1 MRI 
contrast agent with several advantages compared to the traditional gadolinium 
chelates contrast media (e.g. Gd
3+
 leaking problem, easier 
functionalisation).
145
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4 Gold Nanoparticles (AuNP) 
Colloidal gold is a suspension of nanometer-sized particles of gold 
(AuNP). The colour of this solution can vary from strong red to blue in function 
of the shape, size of the NP and environment. AuNP exhibit interesting optical 
properties because in the presence of an electromagnetic field, the free 
electrons of the metallic NP undergo oscillation with respect to the metallic 
lattice that is resonant at a particular frequency of the light. This phenomenon 
is known as surface plasmon resonance causing the absorption or reflection of 
certain bands of the visible spectra. After absorption the surface plasmon can 
suffer radiative (light scattering) or nonradiative decay processes (conversion 
of the light adsorbed into heat).
10
 Because of this, the range of applications 
using AuNP includes: coloured based sensor, drug delivery, targeted thermal 
therapy and many other.
146
 The strategies of synthesis of AuNP follow a 
similar pattern than those seen for other metallic NP. Thus, it exists common 
hydrolytic routes which use the reduction of chloroauric acid followed by 
possible functionalisations with various organic ligands and thermal 
degradation approaches which led to AuNP of much better quality but with a 
second step needed for aqueous stabilisation similar to the ones exposed in 
section 2.3 for IONP. 
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As we have explained in the introduction, the investigation on the coating 
of NP is facing exciting challenges (e.g, reproducibility, simplicity, flexibility, 
etc.) both in surface chemistry for easier synthesis or functionalisation of NP, 
and prediction and control of the in vivo behaviour and knowledge of the 
interaction with the biological interfaces for improved bioapplications. The 
main goals of this thesis are then:  
1- Synthesis of NP with long in vivo circulating times provided by innovative 
coatings.  
2- Understand how the interactions of the NP with the proteins of the blood 
affect its in vivo fate. 
3- Design NP aimed at specific advanced bioapplications as contrast agent for 
detection and characterisation of tumour or atherosclerosis plaques. 
4- Development of new easier generic and standardised synthetic approaches 
for different hydrophobic NP of different composition. 
5- Design and synthesis of a theranostic NP gathering detection and therapy 
of tumours. 
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Abstract 
 
We report the synthesis of micellar Phosphatidylcholine-coated 
Superparamagnetic Iron Oxide Nanoparticles as a new long circulation 
contrast agents for magnetic resonance imaging. Oleic acid-coated Fe3O4 
nanoparticles were first prepared via thermal degradation and then 
encapsulated into small clusters with a Phosphatidylcholine coating to obtain 
hydrophilic nanomicelles. A thoroughly characterisation confirmed the 
chemical nature of the coating and the excellent colloidal stability of these 
nanomicelles in aqueous media. Magnetisation and relaxivity properties 
proved their suitability as MRI contrast agent and in vitro cell viability data 
showed low toxicity. Vascular lifetime and elimination kinetics in liver were 
assessed by blood relaxometry and in vivo MRI in rats and compared with 
“control” particles prepared with a polyethylene glycol derivative. These 
micellar particles had a lifetime in blood of more than 10 hours, much longer 
than the control nanoparticles (~ 2 hours) really remarkable considering that 
the coating molecule is a small biocompatible zwitterionic phospholipid. The 
protein corona was characterised after incubation with rat serum at different 
times by high-throughput proteomics, showing a higher proportion of bound 
apolipoproteins and other dysopsonins for the Phosphatidylcholine particles. 
The antibiofouling properties of this corona and its resistance to the adsorption 
of proteins corroborate the observed enhanced stability and prolonged 
systemic circulation. 
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1. Introduction 
Iron oxide nanoparticles are widely used for preclinical and clinical 
applications, especially as contrast agents in magnetic resonance imaging.
1
 
One of the key challenges in the development of IONP for biomedical 
applications is their functionalisation to ensure good colloidal, circulating and 
targeting properties in vivo.
2,3
. High-temperature decomposition of organic iron 
precursors in organic solvents yield the best IONP in terms of size, size 
dispersion, crystallinity and reproducibility of the synthesis.
2
 However, this 
method yields IONP that are only stable in organic solvents, thus requiring a 
second step to make them stable in aqueous media suitable for in vivo 
applications. The main approaches used for this are direct chemical 
modification of the oleic acid structure, ligand exchange, and stabilisation 
within a hydrophilic coating matrix.
4–6
 These hydrophilic coatings should 
minimise the natural tendency of IONP to aggregate while conferring reduced 
toxicity and good biocompatibility to the probe.
7
 Polyethylene glycol
8
 and 
dextran
9
 are established examples of such biocompatible surfaces that confer 
aqueous stability and hinder IONP from the reticuloendothelial system (RES). 
Small zwitterion molecules begin also to be proposed as an alternative coating 
with antibiofouling properties. However they are generally anchored or 
covalently conjugated to the surface of other type of inorganic NP
10–12
 and few 
studies have reported IONP stabilisation within micelles made of only small 
molecules
13,14
 mainly because encapsulation of inorganic NP inside such 
micelles is a chemosynthetic challenge. Indeed, the hydrophilic/hydrophobic 
balance of the coating is crucial for the formation of hydrophobic IONP 
encapsulated micelles, a requirement that often makes small amphiphilic 
molecules unsuitable, leading to unstable structures which form aggregates, 
or fail to incorporate the IONP cargo.
15
 Consequently micelles formed from 
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amphiphilic polymers whose hydrophilic part often includes PEG chains, like 
di-block copolymers or lipid-derived polymers,
15–17
 are often preferred for their 
ease of synthesis, good drug-delivery properties and long circulating lifetimes 
as antibiofouling coatings.
18
 We report here oleic acid OA IONP encapsulated 
into nanomicelles of small phosphatidylcholine (PC) molecule by a 
nanoemulsion method and we investigate whether physicochemical 
properties, in vivo behaviour and vascular circulating times comparable to 
micelles of PEG coating can be obtained. We selected zwiterionic PC because 
it plays important biological roles as the major component of mammalian cell 
membrane. Also, its phospholipid structure allows easy formation of a micelle 
over the OA of the hydrophobic Fe3O4 NP as shown by its usual inclusion in 
solid lipid NP, microbubbles or liposome formulations.
19
 For comparison, we 
selected the PEG derivative polysorbate 80 (P80), a polymeric coating known 
by its blood pool properties.
18
 After a detailed characterisation of the probes 
especially as possible MRI contrast agent, the vascular lifetimes of the both 
nanomicelles were estimated by relaxometric techniques. We also studied the 
rate of PC IONP elimination in the liver by MRI in rats.  The biological fate and 
uptake of NP by the RES is strongly influenced by the composition of the 
protein corona i.e the set of plasma proteins that adsorb onto their surface 
upon intravenous injection, this one being specific to each nanomaterial.
20,21
 It 
is now an ongoing issue to understand better how the IONP synthetic identity 
influence the composition of the corona to improve the biological fate of the 
probes.
22
 To investigate the correlations between the difference in the 
vascular lifetimes obtained with the PEG and PC IONP with their protein 
corona, we resolved by proteomic analysis, the composition of the corona of 
the both nanomicelles incubated in vitro with rat serum. 
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____________________________________________________ 
Key to understand: Protein Corona  
Definition. When nanoparticles enter in the vascular system, they first contact 
with the entire set of the plasma proteins (> 3000) and the other components 
of the blood. Therefore some of these proteins or other biomolecules compete 
to adsorb to the surface of the nanomaterial leading to what is called “protein 
corona”. This protein corona provides a biological identity to the nanoparticles 
which will have an important role in the physiological response, in particular for 
the opsonisation and clearance.
20
  
Structure. The adsorption of proteins on the surface of NP evidently depends 
of protein-nanoparticles binding affinities but also on protein-protein 
interactions. The current model stands that the corona can be subdivided in 
two parts. The “hard” corona names the component that adsorb with high 
affinity to the surface of the NP while the “soft” corona designates the loosely 
bound proteins, which interact principally with the proteins of the “hard” 
corona. Studies are focusing principally on the composition of the “hard 
corona” as it seems the most influent part that influences the physiological 
response. During biophysical events, soft corona rapidly dissociate during 
translocation while hard corona shows much larger exchange times.
23
 
Dynamic evolution. An important notion is that the proteins adsorbed on the 
NP are in a continuous state of exchange. This means that the corona has a 
dynamic composition and constantly changes along time. This competitive 
adsorption of proteins on the surface is referred as the “Vroman effect” and is 
a complex result of different variables such as incubation time, concentration 
and lifetime of a protein in plasma as well as its binding affinity for the 
nanoparticle´s surface.
24
 For instance, proteins of high abundance in plasma 
rapidly adsorbed to the surface but are finally replaced with other proteins that 
have lower abundance but higher affinity; on other hand proteins of high 
affinity can also be exchanged with others of slower association rates but 
longer residence time. This illustrates how difficult is to predict the composition 
of the protein corona. Thus, it is usual to distinguish the “early” and “late” 
stages of a protein corona for a better understanding of the biological 
behaviour of the nanoparticles.
25
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Composition. The composition of a protein corona is unique to each material. 
However, from the different studies, general trends have been clarified. A 
general structure draws a group of about ten proteins adsorbed in high 
abundance together with plenty others adsorbed in low abundance. Albumin, 
apolipoproteins, immunoglobulins, coagulation factors and fibrinogens are 
class of proteins frequently found in the corona.
20
 
Biological effects of the protein corona. Protein corona is part of the biological 
identity of the nanomaterials, which determines its interaction with 
biomolecules and biological barriers of the body. It has strong consequences 
in signalling, kinetic and biodistribution of the probes. A strong correlation has 
been observed between the cells uptake of the NP and their protein corona. 
Especially, the protein corona is associated with the biological process of 
opsonisation and consecutive uptake by the cells of the reticuloendothelial 
system and mononuclear phagocyte system (macrophages). Importantly, it 
has been demonstrated that the presence of opsonins and/or dysopsonins in 
the corona either favour the clearance or increase the vascular lifetime of 
nanomaterials.
26
  
Factors of the NP affecting the protein corona. Multiple parameters can have 
an effect on the composition of the protein corona. In fact, all the 
physicochemical characteristics of a NP, termed as synthetic identity, will 
affect the protein corona and biological identity. Controlling and understanding 
these factors are crucial in order to improve the final biological role the probes 
are designed for. Among all the parameters, we highlight surface charge, 
hydrophobicity, size, shape and nature of the coating.
23
  
Characterisation. Elucidation of the protein corona associated to a NP is a 
very complex process. As the corona is dynamic, its description only 
corresponds to a given time. The experiments are realised most of the times in 
vitro, by incubation of the NP with serum. It has been observed that many 
parameters can dramatically affects the results, above all the concentration of 
the NP used during the experiment. Moreover isolation of the proteins is very 
difficult and it is almost impossible to make an exhaustive characterisation. 
The two techniques most use, differential centrifugation or size exclusion 
chromatography, will inevitably disturb the composition and cause a loss of the 
weakly bound proteins. Concerning the identification step, great progress has 
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been performed. The apparition of liquid chromatography coupled to high 
throughput mass spectrometry (MS) overcomes many limitations of the 
previous technique (electrophoresis followed by traditional MS) for greater 
sensitivity. Other secondary characterisations like protein corona thickness, 
surface charge, density and strength of protein interaction can be described by 
dynamic light scattering (DLS), transmission electronic microscopy, 
colorimetric or calorimetric titration.
27,28
 
2. Results and discussion 
2.1 Synthesis of oleic acid coated magnetite nanoparticles, OA 
IONP 
 
Figure 1.1 a) Hydrodynamic size and b) TEM of OA IONP. 
Oleic acid-coated magnetite OA IONP were synthesised by thermal 
decomposition method addressed previously in detail in the section 2.3 of the 
Introduction. We used here the decomposition of iron(III) acetylacetonate at 
high temperature in an oleylamine (OM)-OA mixture following a well-known 
method described in the Materials and Methods section of this first chapter.
29
 
NP were uniform, with a polydispersity index (PDI) of 0.24, and had a 
hydrodynamic size of 10 ± 3 nm and a core diameter of 7 ± 2 nm (Figure 
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1.1a). Transmission electron microscopy (TEM) showed the particles to be 
spherical and well-dispersed (Figure 1.1b). In the diffractogram obtained by X-
ray diffraction XRD tool (Figure 1.2), we observed clearly the peaks 
corresponding to the crystalline structure of the magnetite phase Fe3O4 
(Powder Diffraction File Card No. 16-0629).  
 
Figure 1.2 Typical XRD for OA IONP nanoparticles obtained in this work. 
Surfactant coating has been characterised by Fourier Transformed Infrared 
Spectroscopy (FTIR) shown in Figure 1.3. Spectrum displayed the 
characteristic vibration peaks of the OA. The ones of the aliphatic moieties 
were found at 2920 cm
-1
 (νa C-H) and 2850 cm
-1
 (νs C-H) while the ones of the 
carboxylic group appeared at 1625 cm
-1
 (ν C-O) and 1530 cm
-1
 (ν C-O). In 
comparison to the free carboxylic group, these last peaks were found at 1) a 
frequency lower than the C=O vibration band but 2) higher than the frequency 
of the C-O vibration band, also 3) the differences between the two bands were 
less than 110 cm
-1
. All these information suggest that the carboxylic group of 
the oleic acid is coordinated to the iron atoms of the surface of the magnetite 
core through a bidentate complex with the oxygens. Indeed, as already 
mentioned, OA has a high affinity for the iron ions. Finally the stretching band 
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at 590 cm
-1
 is characteristic of the Fe-O bound of the inorganic crystalline core 
structure.  
 
Figure 1.3 Typical FTIR of OA IONP obtained in this work. 
Coating can be also characterised by mass spectroscopy (MS). The 
mass spectrum of the OA IONP is clearly representative of the OA adducts 
with peaks at m/z = 208 and 563 g.mol
-1
, respectively the MW of OA 
subtracted of one proton and its double multiple. No peaks representative of 
OM, a side products used in the reaction and weak cheating ligand of 
magnetite core, were detected with MS highly sensitive technique. It confirmed 
the surfactant recovering the NP is made of only OA. (data not shown) 
Finally thermogravimetric analysis (TGA) shows that the organic 
coating (corresponding to the removal of OA surfactant between 190ºC and 
300ºC) represents 15 % of the total weight of OA IONP (Figure 1.4). This also 
indicates a high strength of union formed by the complex between carboxylic 
acid of OA and Fe, as no loss of surfactant is observed before 190ºC. First 
slight decrease of the weight between 0 and 190ºC is due to the combined 
evaporation of the remaining water and un-adsorbed OA.  
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Figure 1.4 TGA of OA IONP. 
One of the most important properties of the Fe3O4 NP further taken 
advantage of for bioapplications especially MRI, is their magnetism (Details in 
Introduction, Section 2.1. One of the characterisations is performed with a 
vibrating sample magnetometer (VSM). On the figure 1.5, it can be easily 
observed a superparamagnetism behaviour (no hysteresis loop and coercivity) 
with a high saturated magnetisation of 70 emu.g
-1
. 
 
Figure 1.5 Magnetisation curve for OA IONP used in this work. 
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2.2 Synthesis and characterisation of Phosphatidylcholine coated 
iron oxide nanoparticles, PC IONP 
OA IONP were then stabilised within a micelle composed of the 
amphiphilic molecule PC. We used a nanoemulsion method which involved 
mixing a small volume of the OA IONP in n-hexane within a larger volume of 
aqueous phosphate buffer containing PC. This entails the formation of a PC 
monolayer, which forms spontaneously at 1% hexane. Attempts with other 
solvents such as CHCl3 were unsuccessful.
30
 Under sonication and stirring, an 
oil-in-water emulsion is formed that converts progressively into a single 
aqueous solution after hexane evaporation.
31
 In this process, the hydrophobic 
fatty acid PC tails surround the OA aliphatic chain of the OA IONP through 
hydrophobic interactions, while the hydrophilic choline heads line up around 
the outer surface of the micelle, providing water-dispersibility by masking the 
hydrophobic layer (Figure 1.6).  
 
Figure 1.6 Method for the synthesis of PC IONP. 
The nanoemulsion method presents several advantages over 
common reverse evaporation procedures for micelles preparation, including 
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reproducibility, simplicity, speed, and a narrow micelle size distribution. 
Successful formation of hydrophilic nanomicelles was first indicated by the 
observation that PC IONP did not re-disperse after mixing with hexane (Figure 
1.7, inset). The nanomicelles had hydrodynamic size of 74.9 nm with a PDI of 
0.14, showing that the method yields a very homogeneous dispersion (Figure 
1.7).  The difference in hydrodynamic size between OA IONP precursors and 
the PC IONP is attributable to the formation of micelles containing several OA 
IONP packed together, confirmed in TEM images showing OA IONP in small 
assemblies of overall diameter around 80 nm. High resolution transmission 
electronic microscopy (HRTEM) showed the lattice fringes on the Fe3O4 cores, 
demonstrating excellent crystallinity (Figure 1.7).
3
 
 
Figure 1.7 a) Hydrodynamic size of PC IONP. (inset photo of a 1:1 mixture of hexane/ 
PC IONP in water). b) TEM of PC IONP at two magnifications. 
To evaluate the stability and colloidal properties of the nanomicelles, 
we measured zeta potential (ζ) variation as a function of pH and the effect of 
different high-salt-content buffers on hydrodynamic size. PC is a zwitterionic 
molecule, with a negative charge due to the glycerophosphate group and a 
positive charge due to the trimethylethanolammoniun group. Accordingly, the 
measured value of ζ (Figure 1.8a) predicts excellent stability of PC IONP over 
the whole range of pH below and above pH 5, at which the micelles surface 
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has no net electrical charge. Such good colloidal properties are confirmed in 
literature concerning the zwitterionic coatings.
12
 At physiological pH we 
obtained a negative potential of -11.5 mV, which stabilises the micellar 
preparation through repulsive electrostatic interactions. The nanomicelles also 
showed excellent stability in the commonly used culture media Dulbecco's 
Modified Eagle's Medium (DMEM) and Roswell Park Memorial Institute 
(RPMI) and in Phosphate buffered saline (PBS), with no increase in 
hydrodynamic size over time, even in 10x PBS (Figure 1.8b). 
 
Figure 1.8 a) Zeta potential of PC IONP as a function of pH. (b) Change of 
hydrodynamic size of these nanomicelles with time in high ionic strength solutions. 
The composition of PC IONP (1.1) was fully characterised by FTIR, 
TGA and MS (Figure 1.9). PC IONP showed the characteristic absorption 
spectrum of PC, with bands at 2920 cm
-1
 (νa C-H), 2850 cm
-1
 (νs C-H) and 
1625 cm
-1
 (νs C=O) for the fatty acid chains of the PC, which superimposed 
with the signals of the aliphatic chain of OA. Specific absorption bands of PC 
corresponding to the choline head were found at 1150 cm
-1
 (ν P=O) and 1000 
cm
-1
 (ν N-C). TGA displayed that PC coating degraded from 200 to 400ºC and 
represented less than 10% of the total weight of the nanomicelles (after 
subtraction of the OA contribution to the total organic weight). This low weight 
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suggested that a single cap of PC intercalate with fatty chains of OA. The 
mass spectrum of the PC IONP organic coating (diluted in MeOH/H2O and 
analysed in an acidic mixture to promote ionisation, with m/z=760) was 
representative of the expected PC and OA adducts, the two organic molecules 
in the composition of the micelles. 
 
Figure 1.9 (a) FTIR spectra of OA IONP and PC IONP, (b) TGA of OA IONP and PC 
IONP and (c) MS of PC IONP. 
Magnetic properties of the PC IONP as MRI contrast agent. IONP are 
mainly used as contrast agents for MRI, so the magnetic properties of the 
synthesised nanomicelles are essential for further applications. The PC IONP 
maintained a superparamagnetic behaviour with a saturation magnetisation 
value of 60 emu g
-1
, which is of the same order as the hydrophobic OA IONP 
precursors (70 emu g
-1
) (Figure 1.10a). This illustrates that there was low 
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surface oxidation of the iron core during the nanoemulsion procedure for 
micellar preparation. The good superparamagnetic behaviour of 1.1 is mostly 
a consequence of the thermal preparation step, which provides highly 
crystalline iron oxide cores. Saturation magnetisation is also enhanced by the 
encapsulation and formation of clusters.
32
 To assess the efficacy of the 
nanomicelles as contrast agents for T2-weigthed MRI, NMR relaxometric 
properties were investigated. The longitudinal (R1) and transverse (R2) 
relaxation rates were measured as a function of the iron concentration for a 
set of diluted PC IONP (Figure 1.10b). Good linearity was observed and the 
longitudinal (r1) and transverse (r2) relaxivities were calculated from the slope 
of the linear regression, yielding values of 1.3 s
-1
mM
-1
 and 147.4 s
-1
mM
-1
, 
respectively. The r1 value is much smaller than the typical value for hydrophilic 
IONP with a dextran coating (from 3 to 10 s
-1
mM
-1
) due to the lower 
accessibility of water and limited influence of the IONP in the middle of the 
cluster.
33
 The major factors contributing to the high r2 value are the size and 
crystallinity of the iron oxide core. Cluster size has a strong influence on r2, 
with an optimum value of 80 nm, precisely in the range of our nanomicelles.
34
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Figure 1.10 (a) Magnetisation curve at 298 K and plot of (b) longitudinal (T1) and (c) 
transverse (T2) relaxation rates against iron concentration of PC IONP. 
Cytotoxicity effects. The potential toxicity of PC IONP was evaluated 
by incubation with C57BL/6 mouse embryonic fibroblasts (MEFs) over 72 
hours. Iron uptake analysis confirmed that the MEFs effectively internalised 
the nanomicelles in a time and concentration-dependent manner (Figure 
1.11a). Cell growth and viability analysis (propidium iodide staining of necrotic 
cells) showed low toxicity for the 40 μg/mL dose (Fig. 1.11b). Detailed 
cytometry analysis confirmed that a small proportion of MEFs exposed to 1.1 
underwent apoptosis (Fig. 1.12) possibly caused by the high internalisation of 
PC IONP inside the cells. These results were confirmed by cell proliferation 
experiments (Fig. 1.11c), which showed a slight inhibition of cell population 
growth in the presence of 40 μg/mL PC IONP at 48h (at 72 hours, stabilisation 
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of population growth of control cells reflected cell confluence). These toxicity 
data suggest that low-doses of PC IONP can be safely used in vivo as a T2-
MRI contrast agent. Low cytotoxicity for 1.1 could be anticipated because PC 
(a component of lecithin) is nontoxic and extensively used in a wide range of 
applications.
35
 This low toxicity is also indicative of the robustness of the 
micellar assembly, since liberation of hydrophobic OA IONP would have toxic 
effects. 
 
Figure 1.11 (a) Iron uptake by MEFs incubated with PC IONP (at 10 µg.ml
-1
 and 40 
µg.ml
-1
 iron concentrations; 24, 48, 72 hours). (b) Cell viability of MEFs incubated with 
PC IONP (at 10 µg.ml
-1
 and 40 µg.ml
-1
 iron concentrations; 24, 48, 72 hours). (c) 
Number of MEFs cells after incubation with these nanomicelles (at 10 µg.ml
-1
 and 40 
µg.ml
-1
 iron concentrations; 24, 48, 72 hours). 
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Figure 1.12  Relative proportions (%) of viable, early apoptotic, late apoptotic and dead 
cell populations of MEFs incubated with PC IONP (at 10 µg.ml
-1
 and 40 µg.ml
-1
 iron 
concentrations; 24, 48, 72 hours). 
2.3 Circulation lifetime and in vivo MRI of PC IONP 
An essential requirement for the intravenous use of NP in targeted 
nanomedicine, for example as drug-delivery agents, is the ability to remain in 
the bloodstream until the target organ is reached 
36
. This is equally a 
requirement for the use of NP as blood pool contrast agents for tumour 
perfusion or detection of angiogenesis. Long circulation times favour passive 
tumour targeting via the enhanced permeability and retention effect (EPR).
37,38
 
To assess the performance of PC IONP (1.1) we compared them with 
nanomicelles P80 IONP (1.2), prepared by the same nanoemulsion method 
but coated with the PEG-derivative P80, a large nonionic molecule with a 
lipophilic OA moiety attached to PEG polyether groups 
39
 PEG is described as 
a golden standard for coating providing good blood pool properties to NP.  
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Table 1.1. Comparison of the physicochemical characterisation of micellar PC and P80 
IONP. 
 PC IONP P80 IONP 
Hydrodynamic size (nm) 74.9 25 
Pdi 0.14 0.19 
Zeta potential  (pH=7.1) (mV)  -11.5 -4 
Saturation magnetisation 70 65 
Relaxivity (s
-1
.mM
-1
) r1: 1.3 
r2 : 147.4 
r1 : 2.3 
r2 : 127.2 
Estimated vascular life time (relaxometric method) 10 h 2h 
Detailed characterisation of the P80 IONP micelles (1.2) are 
presented in Figure 1.13. These main physicochemical properties of P80 
IONP are compared with PC IONP in Table 1.1. The control P80 IONP had a 
hydrodynamic size of 25 nm, an almost neutral charge at physiological pH, 
and magnetic properties of the same order as the PC IONP. 
Vascular lifetime after intravenous administration (i.v.a) of PC IONP 
was first estimated by T2 relaxometry of rat blood samples. After i.v.a of the 
probe, blood aliquots were collected at different times post-injection and their 
transverse T2 relaxation times measured (Figure 1.14a). T2 shortening below 
basal levels is an index of the presence of the iron-containing nanomicelles in 
the blood aliquots. The analysis showed extended circulation of injected PC 
IONP (1.1) for about 10 h. This circulation time, significantly longer than 
described for other IONP in literature, was confirmed by measuring the 
clearance rate in rat liver from the loss of the MRI signal in this organ. The 
decrease in signal intensity in the liver was measured at different times after 
i.v.a. by averaging signal intensities from a selected region of interest (ROI) 
and normalizing to the basal image (Figure 1.14b and 1.14c). We observed, 
by in vivo liver MRI, a signal reduction reaching a minimum 19 hours after 
injection. These data complement the ex vivo NMR relaxometric 
measurements. 
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Figure 1.13 Characterisation of the control P80 IONP typically obtained in this  study. 
(a) Hydrodynamic size (inset: photo of a 1:1 mixture of hexane/P80 IONP in water). (b) 
TEM images; scale bars, 30 nm and 25 nm (b2). (c) FTIR spectra of P80 IONP (d) 
FTIR spectra of P80 IONP. (e) Plot of the longitudinal (1/R1) and (f) transverse (1/R2) 
relaxation rates of P80 IONP against iron concentration. (g) Magnetisation curves of 
these nanomicelles at 298 k. (h) T2 relaxation times in rat blood samples after i.v.a. of 
P80 IONP over time plotted against the T2 baseline value. 
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Due to their size, IONP (> 50 nm or average around 80 nm) are 
rapidly taken up by the RES; also known as the mononuclear phagocyte 
system (MPS). Consequently in vivo applications are currently limited to the 
organs of this system (liver, spleen, bone marrow, and lymph node).
40
 This 
limitation has prompted the development of nanoparticle systems with 
coatings and sizes that support longer circulation lifetimes (for example, a half-
life >5 h in rats) and that are optimised for drug delivery or use as contrast 
agents for imaging. To achieve steric stabilisation, different carriers have been 
surface-engineered with large neutral polymeric molecules, such as PEG, 
which shields and minimises the particle surface opsonic modification with 
blood proteins and makes particles less susceptible to ingestion by phagocytic 
cells. Yet even the best PEG-ylated IONP candidates, including polymeric 
micelles, liposomes or lipoplexes, have a vascular lifetime in rats of only a few 
hours.
41
 Longer circulating times are achieved with ultrasmall 
superparamagnetic iron oxide NP (< 50nm), which have reported lifetimes of 
dozens of hours, within the intensity limitation range detected here 
42
. In 
comparison, even despite their smaller size, the vascular lifetime of P80 IONP 
(1.2) in rats after i.v.a., determined by the same relaxometric technique, was 
around 2 hours only (Figure 1.13g and Table 1.1). The PC coating thus 
provides micellar IONP with properties that ensure a significantly longer 
circulation time. This significantly improved resistance to blood clearance has 
been already shown for PC-coated gold NP.
43
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Figure 1.14 a) T2 relaxation time of rat blood samples after i.v.a. of PC IONP plotted 
over time relative to the T2 blood baseline value (black line). b) Signal decrease is 
observed for a set of ROI in rat liver and c) liver MR Images after i.v.a. of PC IONP. 
 
2.4 Serum protein identification and quantification of the corona 
of PC and P80 IONP 
When NP enter the vascular system, plasma proteins and other 
biomolecules rapidly adsorb to their surface, leading to the formation of a 
dynamic protein corona that significantly determines the in vivo biological 
behaviour. In particular, the uptake of the NP by the phagocytes of the RES is 
strongly associated with the presence of specific proteins in the corona.
21
 The 
composition of this corona is highly dependent of the physicochemical 
features of the NP (size, superficial charge, nature of the coating). For 
instance, a PEG coating reduces the total amount of nonspecific protein 
adsorbed on the nanoparticle surface.
44
 Zwitterionic ligands or polymers are 
also reported to resist the adsorption of nonspecific plasma proteins, and this 
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may contribute to the long circulation times of the PC IONP.
45,46
 To 
characterise the composition of the hard protein coronas (i.e the strongly 
adsorbed proteins) of PC and P80 IONP, we incubated in vitro the 
nanomicelles in rat serum for 15, 90 and 180 min, isolated the NP-protein 
complexes, and analysed them by high-throughput liquid chromatography 
(LC)-MS. The incubation times were chosen in accordance with the estimated 
vascular lifetime of the probes and based on representative changes found in 
the literature.
28
 The sensitive analysis used allowed us to identify ≥300 
proteins in each corona, with a false discovery rate (FDR) below 1% (Results 
of the proteomics characterisation. The bioinformatic analysis of the results 
showed that the identified proteins are representative of pathways related to 
inflammation and the immune system, among others.  
 
Figure 1.15 a) Qualitative comparison of protein coronas over time (15, 90 and 180 
min) for the PC and P80 IONP. The charts show the numbers of same proteins (SPC 
>2, FDR>1%) present in the coronas at the three times of incubation, at two times of 
incubation, and exclusive to one time of incubation. b) Qualitative comparison of PC 
and P80 IONP coronas at each time. The charts show the numbers of same proteins 
common to both nanomicelles types or exclusive to one (SPC >2, FDR>1%). 
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The corona compositions of the two IONP were qualitatively similar at all 
three incubation times (Figure 1.15), which is expected since both IONP are 
micellar structures. Proteins exclusive to the corona of one micellar IONP type 
were generally detected in lower abundance, with a spectral peptide count 
(SPC) <4.
47
 These lower-abundance proteins are unlikely to have a significant 
influence for the in vivo behaviour of the micelles. For semi-quantitative 
analysis, the percentage in weight of each corona protein was estimated on 
the assumption that the number of peptides identified per protein is roughly 
proportional to its concentration after normalisation.
48
 Proteins with reported 
fouling (opsonins) and antifouling (dysopsonins) properties were grouped and 
classed according to their biological function in the circulatory system. Both 
types of micellar IONP showed a decrease over time in the relative amount of 
dysopsonins in the corona (Figure 1.15), as we could expect in a progressive 
opsonisation process. However, at each time point, 1.1 bound more 
dysopsonins than 1.2. In contrast, opsonin levels were lower in the PC corona 
at the 15 and 90 min incubation times. Thus, the in vivo opsonisation shall be 
slower and less pronounced for longer circulating times in PC IONP. Similar 
studies also concluded that a strong representation of dysopsonins in the 
corona of NP favour their longer vascular circulation times.
21,23,49
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Figure 1.16 Relative % weight of the proteins with known (a) antibiofouling properties 
(dysopsonins) and (b) biofouling properties (opsonins) classified by their biological 
function in the coronas of micellar PC and P80 IONP at 15, 90 and 180 min in vitro 
incubation in rat serum. Data labels represent the % weight of the single ApoB 100. 
For further details, we listed the key proteins which underlie these 
differences in the biological fates of PC and P80 IONP, looking among the 
abundant coronal proteins (relative proportion in weight > 0.6 %) those that 
were at 15 min incubation time significantly more abundant (threshold 
set>1.25 fold) in the PC IONP corona than in the P80 IONP corona. Most of 
these proteins have antifouling properties, many of them being apolipoproteins 
or regulators of the complement immune system (Table 1.2a) and are also 
reported to interact with phospholipids. Many of the specific proteins 
associated with the PC IONP corona showed significant decreases in 15 to 
180 min incubation times (relative fold threshold set< 0.8, Table 1.3), 
confirming the important role of this set of proteins in delaying opsonisation. 
We also observed that the amounts of the dysopsonin apolipoprotein B100 
(the most abundant protein in all the coronas) decreased sharply over time in 
the P80 IONP corona while remaining stable in the PC one, thus ensuring a 
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more sustained antibiofouling behaviour for 1.1 (Figure 1.16). Moreover, at 
180 min incubation times, the listed key proteins, which bound in a 
significantly higher proportion to the P80 IONP (threshold >1.25, Table 1.2b) 
have been reported with biofouling roles, particularly in relation to vesicular 
transport and endocytosis . This can justify the faster and stronger 
opsonisation of P80 IONP. In this case, this set of proteins was not correlated 
with the profile of proteins, which abundance significantly increased in the 
corona over time. The proteomics analysis, with caution due to the in vitro 
aspect of the experiments, thus provides general evidences that (i) 
dysopsonins/lipoproteins have a strong representation in the PC IONP corona, 
because of a special affinity for the coating and (ii) protect these nanomicelles 
from opsonisation which (iii) follow a similar pattern than P80 IONP but, with 
an effect that is delayed and less pronounced. These preliminary proteomics 
characterisations are correlated with the longer vascular lifetime of the PC 
IONP.  
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Table 1.2 Coronal proteins with a relative % weight > 0.6% that were significantly more 
abundant (quotient of relative % weight > 1.25) in (a) PC IONP at 15 min incubation 
time, and (b) P80 IONP at 180 min incubation time. 
a) 
PC IONP at 15 min relative % 
weight in 
PC corona 
relative % 
weight in 
P80 corona 
fold classification 
Apolipoprotein A-IV  1.96 1.50 1.31 Lipoprotein 
Apolipoprotein A-I  1.72 1.31 1.31 Lipoprotein 
Protein Cfh 1.57 0.47 3.37 Regulator 
Complement 
T-kininogen 1  1.05 0.84 1.25 Acute phase 
Protein Dsp 1.05 0.28 3.74 Cellular junction 
Ig gamma-2B chain C  0.81 0.65 1.24 Immunoglobulin 
Alpha-1B-glycoprotein 0.76 0.47 1.63 Lipoprotein 
Plasminogen 0.72 0.47 1.53 Coagulation 
inhibitor 
Oxidation resistance 
protein 1  
0.62 0.19 3.32 Stress response 
b) 
P80 IONP at 180 min relative % 
weight in 
P80 corona 
relative % 
weight in 
PC corona 
fold classification 
Transferrin receptor 
protein  
1.75 1.28 1.37 Endocytosis 
Thyroglobulin 1.46 0.90 1.62 Interaction with 
Heat shock 
Clathrin heavy chain  1.10 1.17 1.22 Endocytosis / 
cytoplasmic 
vehicle 
     
75 
 
Table 1.2 (Cont.)     
Cytoplasmic dynein 1 
heavy chain  
1.10 0.85 1.29 Degradation / 
Transport 
Major vault protein 0.94 0.37 2.95 Transport 
Heat shock cognate 
protein 
0.77 0.69 1.35 Degradation/ 
Transport 
Band 3 anion transport 
protein 
0.61 0.48 1.61 Transport 
Integrin 0.61 0.48 1.27 Coagulation 
Table 1.3 Proteins with a relative % weight >0.7 % in the corona of the PC IONP at 15 
min incubation which showed the strongest decreases in relative % weight over time 
(quotient of relative % weight between 180 and 15 min < 0.8). Proteins in bold are 
those already presented in Table 1.2. 
PC IONP relative % weight 
at 15 min 
relative % 
weight 
at 180 min 
Relative 
fold 
decrease 
Serum albumin 2.67 1.33 0.50 
Serotransferrin 2.19 1.17 0.53 
Apolipoprotein A-IV 1.96 1.54 0.79 
Apolipoprotein A-I 1.72 0.90 0.53 
Protein Cfh 1.57 0.37 0.24 
Hemopexin 1.24 0.64 0.51 
Murinoglobulin-1  1.05 0.74 0.71 
Haptoglobin 1.05 0.59 0.56 
T-kininogen  1.05 0.32 0.30 
Ig gamma-2B chain C region 0.81 0.64 0.79 
Fibrinogen-like 2 0.81 0.53 0.66 
Alpha-1B-glycoprotein 0.76 0.37 0.49 
Plasminogen 0.72 0.27 0.37 
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3. Conclusions 
A popular method for aqueous stabilisation of OA IONP prepared by 
thermal decomposition is the use of organic micelles formed through 
intercalation of amphiphilic polymers or loading in polymeric micelles. 
Nanoemulsion is an easy and convenient synthesis method allowing precise 
control of the micelles. Here we developed an alternative probe for T2 MRI by 
encapsulating OA IONP into nanomicelles composed of the small zwitterionic 
molecule PC. The PC IONP are easily and reproducibly prepared, and their 
final hydrodynamic size of ~ 80 nm (pdi 0.14) is mostly made up of small 
clusters of the encapsulated OA IONP. The PC IONP have equivalent or 
superior physicochemical, colloidal and magnetic properties than most of the 
reported micellar-stabilised IONP micelles with organic polymers. Above all, 
the PC IONP have a prolonged circulation time in blood (> 10 hours in rats), 
which was reflected by the composition of the protein corona with high affinity 
of a set of dysopsonins for the PC coating and resistance against the 
adsorption of nonspecific proteins (opsonisation). Keeping NP in the 
circulation, together with the EPR effect, e.g. accumulation in tumours or 
target other diseases, in which the endothelium becomes leaky, are promoted. 
Hence these nanomicelles are promising contrast agents for preclinical and 
clinical in vivo MRI. Moreover, small hydrophobic drugs or molecular imaging 
probes can be easily encapsulated in the nanomicelles together with the OA 
IONP leading to potential candidates for multimodal drug delivery platform. 
Interactions of the PC coating with phospholipid pathway associated to 
pathologies may also be sought. 
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4. Materials and Methods 
Materials  
All chemicals for the preparation of the nanomicelles were purchased from Sigma-
Aldrich Co. (St. Louis, USA). All reagents were of analytical grade except for the 
phosphatidylcholine (90%) and were used without any further purification. Distilled 
water (milliQ) or phosphate buffered saline PBS were used throughout the 
experiments. 
 
Synthesis 
Synthesis of OA IONP 
Protocol described in Chapter “General Materials and Methods” 
Synthesis of micellar phosphatidylcholine coated superparamagnetic iron oxide 
nanoparticles (PC IONP), (1.1) 
Phosphatidylcholine (60 mg, 0.078 mmol) was first dispersed in 15 ml of PBS (pH=7.2, 
5 mM). A 1 ml aliquot of OA IONP (10 mg Fe/ml) dispersed in hexane was then added 
to the solution and the resulting mixture was sonicated (Branson 250, 42 +/- 6 KHz) 
under robust stirring for 20 min at 37 ºC. The oil in water (o/w) nanoemulsion was kept 
under sonication for a further 1h to evaporate all traces of hexane, resulting in the 
formation of a homogenous aqueous solution. Aggregates were removed by filtration 
(0.22 µm, MILIPORE, Sterivex-GP) and excess phosphatidylcholine was removed by 
gel filtration in a PD-10 column (GE Healthcare).  
 
Synthesis of micellar polysorbate 80-coated superparamagnetic iron oxide 
nanoparticles (P80 IONP), (1.2). 
Polysorbate 80 (150 mg, 0.11 mmol) was first dispersed in 12 ml of PBS (pH=7.2, 5 
mM). A 1 ml aliquot of OA IONP (10 mg Fe/ml) dispersed in hexane was then added to 
the solution and the resulting mixture was sonicated (Branson 250, 42 +/- 6 KHz) under 
robust stirring for 20 min at 37 ºC. The oil in water (o/w) nanoemulsion was kept under 
sonication for a further 1h to evaporate all traces of hexane, resulting in the formation 
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of a homogenous aqueous solution. Aggregates were removed by filtration (0.22 µm, 
MILIPORE, Sterivex-GP) and excess polysorbate 80 was removed by gel filtration in a 
PD-10 column (GE Healthcare) 
39
. 
 
Cell toxicology 
Cell lines and media.C57BL/6 mouse embryonic fibroblasts (MEFs) were grown in 
DMEM (Dulbecco’s Modified Eagle Medium) supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin-streptomycin and 1 mM sodium pyruvate. Cytotoxicity and 
iron uptake were assessed in MEFs exposed to PC IONP at different Fe 
concentrations (10 or 40 µg.ml
-1
) and times of incubation (24h, 48h and 72h). Control 
cells were treated with vehicle (water). 
Cytotoxicity assays. In the presence of Ca2+, annexin V binds to phosphatidylserine 
residues exposed on the outer surface of the plasma membrane of apoptotic cells. We 
collected 106 cells in 500 µl PBS and washed them. Cells were pelleted and 
resuspended in 195 µL binding buffer (10mM HEPES/NaOH, pH 7.4; 140 mM NaCl; 
2.5 mM CaCl2). APC-Annexin V (BD PharmingenTM) was added (5 µl) and cells were 
incubated for 15 minutes at 25ºC in the dark. The viability marker propidium iodide was 
then added to a final concentration of 0.001% (w/v), and cells were analysed by flow-
cytometry using the BD FACSCanto™ II system. All experiments were performed in 
triplicate. As a result, viable cells are negative for both APC Annexin V and PI; early 
apoptotic cells are APC Annexin V positive and PI negative; and late apoptotic and 
dead cells are both APC Annexin V and PI positive. Cytotoxicity was estimated by 
comparing the proportion of viable cells in populations exposed to the PC IONP with 
that in control cells.  
Iron uptake quantification. Approximately 1x106 treated cells were lysed with 300 µl 
lysis buffer (50 mM NaCl, 50 mM TrisCl pH 8, 0.2% SDS) for 3 h at 55 ºC and mixed 
with the same volume of 10 mM HCl. Then, 150 µL 1.4 M HCl and 150 µL 4.5% 
KMnO4 were added. After 2 h at 60ºC, 90 µl of a detection solution containing 6.5 mM 
ferrozine, 6.5 mM neocuproine, 2.5 M ammonium acetate and 1 M ascorbic acid was 
added. The absorbance at 550 nm was measured after a further 30 minutes. The 
concentration of internalised Fe was calculated from a standard curve of FeCl3 (0 to 
300 uM). 
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Vascular circulating times and clearance 
All animal experiments conducted in this work were approved by the ethics and animal 
welfare committee at CNIC and were developed according to the Spanish and UE 
legislation. 
Blood relaxometry. Rats (n = 2, Wistar male, 6 weeks old) were anesthetised with 2% 
isoflurane in a mixture of N2/O2 (80:20). The baseline blood sample (200 µl) was 
collected through the tail vein before administration of PC IONP (0.15 mg.kg
-1
). Blood 
samples (200 µl) were collected at intervals from 5 min to 24 h. T2 relaxation times of 
the samples were measured in a Bruker Biospec spectrometer with a T2 Carr-Purcell-
Meiboom-Gill sequence (Bruker Biospec 47/40, 1.5 T, Bruker Biospin, Germany) and 
plotted against the T2 of the baseline blood sample. 
Evaluation of nanomicelles uptake in liver by MRI. Rats (n = 2, Wistar male, 6 weeks 
old) were anesthetised with 2% isoflurane in a mixture of N2/O2 (80:20). Baseline 
images were acquired before intravenous administration of PC IONP (0.15 mg.kg
-1
). 
MR images of rat liver were acquired at intervals from 5 minutes up to a few hours after 
injection. The images were acquired with a 7 T Agilent/Varian 7T DD1 spectrometer 
(Agilent 2) with a 31 cm horizontal bore, using a 72 mm inner diameter quadrature 
birdcage volume coil (Rapid Biomedical GmBH, Germany). Rats were kept 
anaesthetised with the isoflurane-gas mix via a facial mask and placed prone in a 
customised plastic holder. Body temperature was kept constant by delivering warm air 
to the magnet bore, and the respiratory cycle was monitored constantly. For each 
animal, 8 axial 1 mm thick slices were acquired to image the liver. Images were 
acquired in free-breathing animals, using a gradient echo sequence with 4 ms/40 ms 
echo/repetition times, BW of 100 kHz, FOV of 6 cm x 6 cm, for a total acquisition time 
of about 80 seconds; the flip angle (FA) was fixed at 20 degrees. 
 
Characterisation of the protein “hard corona” of PC IONP and P80 IONP 
Experiments. PC IONP or P80 IONP (200 µl in PBS, 0.1 mg.ml
-1
 iron concentrations) 
were incubated in 80% rat serum (800 µl) at 37ºC with gently stirring at 100 rpm. After 
incubation for 15 min, 90 min or 180 min, the micelle-protein corona complexes were 
immediately separated from the serum by centrifugation (2h, 16000 g, 10ºC). Pellets 
were collected and redispersed in PBS before another centrifugation cycle. After three 
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similar washing steps the micelle-protein corona complexes were processed for 
proteomics.  
Protein Digestion. Control of the sample quality was previously performed with state of 
art SDS polyacrylamide gel electrophoresis. The proteins of the corona bound to a 
fixed amount of NP were eluted by boiling in Tris-SDS gel loading buffer containing 50 
mM DTT, and loaded onto 10% SDS-polyacrylamide gels to concentrate the proteins in 
a single band at the stacking/separating gel interface. Briefly, after band visualisation 
with colloidal Coomassie Brilliant blue staining, the acrylamide band was cut into 1mm
3
 
plugs for protein digestion. Gel pieces were incubated with 10 mM DTT (Sigma Aldrich) 
in 50 mM ammonium bicarbonate (99% purity; Sigma) for 30min at 56ºC. After 
reduction, samples were alkylated with 55 mM iodoacetamide (Sigma Aldrich) in 50 
mM ammonium bicarbonate for 20min at RT. Gel plugs were washed with 50 mM 
ammonium bicarbonate in 50% acetonitrile (gradient, HPLC grade, Sigma), and dried 
in a Speedvac. Dry gel pieces were then embedded in sequencing grade modified 
porcine trypsin (Promega, Madison, WI, USA) at a final concentration of 20 ng/µL [at 
40:1 protein:trypsin (w/w) ratio ] in 50 mM ammonium bicarbonate and 5% acetonitrile. 
After digestion at 37 ºC overnight, peptides were re-extracted with 30% acetonitrile in 
0.5% trifluoroacetic acid (99.5% purity; Sigma Aldrich), dried in a Speedvac, and finally 
desalted onto C18 Oasis-HLB cartridges (Waters) and dried-down 
50
. The digested 
samples were resuspended in 10µL Buffer A (0.1% (v/v) formic acid) for LC-MS/MS 
separation and analysis. 
Mass spectrometry data collection and analysis Samples were analysed by LC-MS/MS 
using a nano-HPLC system (EASY-nLC 1000, Thermo-Proxeon) coupled to an 
Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). Peptides were separated 
using an Acclaim PepMap 100 C18 nano-column (75 µm I.D. x 25 cm, 2 µm particle 
size; Thermo Fisher Scientific) with Buffer A at a flow rate of 200 nl min
−1
, and eluted 
with a linear gradient from 0-40% Buffer B (90% acetonitrile, 0.1% formic acid (vol/vol)) 
for 120 min. A survey scan was performed in the Orbitrap analyzer using a mass range 
of m/z 390–1,500, followed by data-dependent MS/MS scans of the twenty most-
intense ions in profile mode. The survey scan was done at 35,000 resolution using a 
target value of 1,000,000 ions, 60 ms of injection time, and 1 microscan. Fragmentation 
was performed by CID with a 1.5 Da isolation mass width, 17,500 resolution, a target 
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value of 50,000 ions, and 80 ms of injection time. Proteins were identified using the 
SEQUEST algorithm (Proteome Discoverer 1.4, Thermo Fisher Scientific). The raw 
MS/MS files were searched against the rat Complete Proteome database (Uniprot at 
July 23th, 2013; 49,050 sequences) and a pseudo-inverted version of the same 
database. SEQUEST searches were performed allowing optional modifications 
(methionine oxidation) and fixed modifications (cysteine carboxamidomethylation), 2 
missed cleavages, and 600 ppm and 1.2 Da ppm of mass tolerance for precursor and 
fragment ions, respectively. False discovery rate (FDR) was determined by the 
probability ratio method 
51
, followed by a post-search 12 ppm precursor mass filtering 
and the refined FDR calculation method 
52
. Only peptides with FDR below 1% and 
identified with at least two peptides were selected for further analysis. Statistical 
analysis of data were performed using QuiXoT 
53,54
. 
 
5. Bibliography 
(1) Reddy, L. H., Arias, J. L., Nicolas, J., and Couvreur, P. (2012) Magnetic 
Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, 
Pharmaceutical and Biomedical Applications. Chem. Rev. 112, 5818–5878. 
(2) Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., and Muller, R. 
N. (2008) Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, 
Physicochemical Characterizations, and Biological Applications. Chem. Rev. 108, 
2064–2110. 
(3) Mahmoudi, M., Sant, S., Wang, B., Laurent, S., and Sen, T. (2011) 
Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface 
modification and applications in chemotherapy. Adv. Drug Deliv. Rev. 63, 24–46. 
(4) Herranz, F., Morales, M. P., Roca, A. G., Desco, M., and Ruiz-Cabello, J. (2008) A 
New Method for the Rapid Synthesis of Water Stable Superparamagnetic 
Nanoparticles. Chem. - Eur. J. 14, 9126–9130. 
(5) Veiseh, O., Gunn, J. W., and Zhang, M. (2010) Design and fabrication of magnetic 
nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliv. Rev. 62, 284–
304. 
(6) Sun, C., Lee, J., and Zhang, M. (2008) Magnetic nanoparticles in MR imaging and 
drug delivery. Adv. Drug Deliv. Rev. 60, 1252–1265. 
(7) Longmire, M., Choyke, P. L., and Kobayashi, H. (2008) Clearance properties of 
nano-sized particles and molecules as imaging agents: considerations and caveats. 
Nanomed. 3, 703–717. 
(8) Sun, C., Du, K., Fang, C., Bhattarai, N., Veiseh, O., Kievit, F., Stephen, Z., Lee, D., 
Ellenbogen, R. G., Ratner, B., and Zhang, M. (2010) PEG-Mediated Synthesis of 
82 
 
Highly Dispersive Multifunctional Superparamagnetic Nanoparticles: Their 
Physicochemical Properties and Function In Vivo. ACS Nano 4, 2402–2410. 
(9) Tassa, C., Shaw, S. Y., and Weissleder, R. (2011) Dextran-Coated Iron Oxide 
Nanoparticles: A Versatile Platform for Targeted Molecular Imaging, Molecular 
Diagnostics, and Therapy. Acc. Chem. Res. 44, 842–852. 
(10) Muro, E., Pons, T., Lequeux, N., Fragola, A., Sanson, N., Lenkei, Z., and 
Dubertret, B. (2010) Small and Stable Sulfobetaine Zwitterionic Quantum Dots for 
Functional Live-Cell Imaging. J. Am. Chem. Soc. 132, 4556–4557. 
(11) Estephan, Z. G., Jaber, J. A., and Schlenoff, J. B. (2010) Zwitterion-Stabilized 
Silica Nanoparticles: Toward Nonstick Nano. Langmuir 26, 16884–16889. 
(12) Breus, V. V., Heyes, C. D., Tron, K., and Nienhaus, G. U. (2009) Zwitterionic 
Biocompatible Quantum Dots for Wide pH Stability and Weak Nonspecific Binding to 
Cells. ACS Nano 3, 2573–2580. 
(13) Liu, J., Yang, X., Wang, K., He, Y., Zhang, P., Ji, H., Jian, L., and Liu, W. (2012) 
Single Nanoparticle Imaging and Characterization of Different Phospholipid-
Encapsulated Quantum Dot Micelles. Langmuir 28, 10602–10609. 
(14) Kim, D., Chae, M. K., Joo, H. J., Jeong, I., Cho, J.-H., and Lee, C. (2012) Facile 
Preparation of Zwitterion-Stabilized Superparamagnetic Iron Oxide Nanoparticles 
(ZSPIONs) as an MR Contrast Agent for in Vivo Applications. Langmuir 28, 9634–
9639. 
(15) Dubertret, B. (2002) In Vivo Imaging of Quantum Dots Encapsulated in 
Phospholipid Micelles. Science 298, 1759–1762. 
(16) Ma, Y., Tong, S., Bao, G., Gao, C., and Dai, Z. (2013) Indocyanine green loaded 
SPIO nanoparticles with phospholipid-PEG coating for dual-modal imaging and 
photothermal therapy. Biomaterials 34, 7706–7714. 
(17) Nasongkla, N., Bey, E., Ren, J., Ai, H., Khemtong, C., Guthi, J. S., Chin, S.-F., 
Sherry, A. D., Boothman, D. A., and Gao, J. (2006) Multifunctional Polymeric Micelles 
as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems. Nano Lett. 6, 2427–
2430. 
(18) Gupta, A. K., and Gupta, M. (2005) Synthesis and surface engineering of iron 
oxide nanoparticles for biomedical applications. Biomaterials 26, 3995–4021. 
(19) Al-Jamal, W. T., and Kostarelos, K. (2011) Liposomes: From a Clinically 
Established Drug Delivery System to a Nanoparticle Platform for Theranostic 
Nanomedicine. Acc. Chem. Res. 44, 1094–1104. 
(20) Walkey, C. D., and Chan, W. C. W. (2012) Understanding and controlling the 
interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. 
Rev. 41, 2780. 
(21) Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., and McNeil, S. E. 
(2009) Nanoparticle interaction with plasma proteins as it relates to particle 
biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61, 
428–437. 
(22) Mahon, E., Salvati, A., Baldelli Bombelli, F., Lynch, I., and Dawson, K. A. (2012) 
Designing the nanoparticle–biomolecule interface for “targeting and therapeutic 
delivery.” J. Controlled Release 161, 164–174. 
(23) Rahman, M., Laurent, S., Tawil, N., Yahia, L., and Mahmoudi, M. (2013) Protein-
Nanoparticle Interactions. Springer Berlin Heidelberg, Berlin, Heidelberg. 
83 
 
(24) Vroman, L., Adams, A. L., Fischer, G. C., and Munoz, P. C. (1980) Interaction of 
high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. 
Blood 55, 156–159. 
(25) Lynch, I., and Dawson, K. A. (2008) Protein-nanoparticle interactions. Nano Today 
3, 40–47. 
(26) Nagayama, S., Ogawara, K., Fukuoka, Y., Higaki, K., and Kimura, T. (2007) Time-
dependent changes in opsonin amount associated on nanoparticles alter their hepatic 
uptake characteristics. Int. J. Pharm. 342, 215–221. 
(27) Thode, K., Lück, M., Semmler, W., Müller, R. H., and Kresse, M. (1997) 
Determination of plasma protein adsorption on magnetic iron oxides: sample 
preparation. Pharm. Res. 14, 905–910. 
(28) Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., 
Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., Landfester, K., Schild, H., Maskos, 
M., Knauer, S. K., and Stauber, R. H. (2013) Rapid formation of plasma protein corona 
critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772–781. 
(29) Sun, S., and Zeng, H. (2002) Size-Controlled Synthesis of Magnetite 
Nanoparticles. J. Am. Chem. Soc. 124, 8204–8205. 
(30) Cássia-Moura, R. (1993) Activation kinetics of the incorporation of colicin Ia into 
an artificial membrane: A Markov or a fractal model? Bioelectrochem. Bioenerg. 32, 
175–180. 
(31) Yang, J., Lee, T.-I., Lee, J., Lim, E.-K., Hyung, W., Lee, C.-H., Song, Y. J., Suh, J.-
S., Yoon, H.-G., Huh, Y.-M., and Haam, S. (2007) Synthesis of Ultrasensitive Magnetic 
Resonance Contrast Agents for Cancer Imaging Using PEG-Fatty Acid. Chem. Mater. 
19, 3870–3876. 
(32) Chen, H., Yeh, J., Wang, L., Khurshid, H., Peng, N., Wang, A. Y., and Mao, H. 
(2010) Preparation and control of the formation of single core and clustered 
nanoparticles for biomedical applications using a versatile amphiphilic diblock 
copolymer. Nano Res. 3, 852–862. 
(33) Ai, H., Flask, C., Weinberg, B., Shuai, X.-T., Pagel, M. D., Farrell, D., Duerk, J., 
and Gao, J. (2005) Magnetite-Loaded Polymeric Micelles as Ultrasensitive Magnetic-
Resonance Probes. Adv. Mater. 17, 1949–1952. 
(34) Pöselt, E., Kloust, H., Tromsdorf, U., Janschel, M., Hahn, C., Maßlo, C., and 
Weller, H. (2012) Relaxivity Optimization of a PEGylated Iron-Oxide-Based Negative 
Magnetic Resonance Contrast Agent for T 2 -Weighted Spin–Echo Imaging. ACS Nano 
6, 1619–1624. 
(35) Royal Society of Chemistry (Great Britain). (2013) The Merck index: an 
encyclopedia of chemicals, drugs, and biologicals (O’Neil, M. J., Heckelman, P. E., 
Dobbelaar, P. H., Roman, K. J., Kenny, C. M., and Karaffa, L. S., Eds.) 15th ed. Royal 
Society of Chemistry, Cambridge, UK. 
(36) Corot, C., Robert, P., Idée, J.-M., and Port, M. (2006) Recent advances in iron 
oxide nanocrystal technology for medical imaging. Adv. Drug Deliv. Rev. 58, 1471–
1504. 
(37) Cole, A. J., David, A. E., Wang, J., Galbán, C. J., Hill, H. L., and Yang, V. C. 
(2011) Polyethylene glycol modified, cross-linked starch-coated iron oxide 
nanoparticles for enhanced magnetic tumor targeting. Biomaterials 32, 2183–2193. 
(38) Cho, K., Wang, X., Nie, S., Chen, Z., and Shin, D. M. (2008) Therapeutic 
Nanoparticles for Drug Delivery in Cancer. Clin. Cancer Res. 14, 1310–1316. 
84 
 
(39) Park, J., Yu, M. K., Jeong, Y. Y., Kim, J. W., Lee, K., Phan, V. N., and Jon, S. 
(2009) Antibiofouling amphiphilic polymer-coated superparamagnetic iron oxide 
nanoparticles: synthesis, characterization, and use in cancer imaging in vivo. J. Mater. 
Chem. 19, 6412. 
(40) Wang, Y. X., Hussain, S. M., and Krestin, G. P. (2001) Superparamagnetic iron 
oxide contrast agents: physicochemical characteristics and applications in MR imaging. 
Eur. Radiol. 11, 2319–2331. 
(41) Moghimi, S. M., Hunter, A. C., and Murray, J. C. (2001) Long-circulating and 
target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283–318. 
(42) Weissleder, R., Bogdanov, A., Neuwelt, E. A., and Papisov, M. (1995) Long-
circulating iron oxides for MR imaging. Adv. Drug Deliv. Rev. 16, 321–334. 
(43) Liu, X., Li, H., Chen, Y., Jin, Q., Ren, K., and Ji, J. (2014) Mixed-Charge 
Nanoparticles for Long Circulation, Low Reticuloendothelial System Clearance, and 
High Tumor Accumulation. Adv. Healthc. Mater. n/a–n/a. 
(44) Gref, Lück, Quellec, Marchand, Dellacherie, Harnisch, Blunk, and Müller. (2000) 
“Stealth” corona-core nanoparticles surface modified by polyethylene glycol (PEG): 
influences of the corona (PEG chain length and surface density) and of the core 
composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B 
Biointerfaces 18, 301–313. 
(45) Ladd, J., Zhang, Z., Chen, S., Hower, J. C., and Jiang, S. (2008) Zwitterionic 
Polymers Exhibiting High Resistance to Nonspecific Protein Adsorption from Human 
Serum and Plasma. Biomacromolecules 9, 1357–1361. 
(46) Estephan, Z. G., Schlenoff, P. S., and Schlenoff, J. B. (2011) Zwitteration As an 
Alternative to PEGylation. Langmuir 27, 6794–6800. 
(47) Groult, H., Ruiz-Cabello, J., Lechuga-Vieco, A. V., Mateo, J., Benito, M., Bilbao, I., 
Martínez-Alcázar, M. P., Lopez, J. A., Vázquez, J., and Herranz, F. F. (2014) 
Phosphatidylcholine-Coated Iron Oxide Nanomicelles for In Vivo Prolonged Circulation 
Time with an Antibiofouling Protein Corona. Chem. - Eur. J. n/a–n/a. 
(48) Ishihama, Y., Oda, Y., Tabata, T., Sato, T., Nagasu, T., Rappsilber, J., and Mann, 
M. (2005) Exponentially modified protein abundance index (emPAI) for estimation of 
absolute protein amount in proteomics by the number of sequenced peptides per 
protein. Mol. Cell. Proteomics MCP 4, 1265–1272. 
(49) Moghimi, S. M., and Szebeni, J. (2003) Stealth liposomes and long circulating 
nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding 
properties. Prog. Lipid Res. 42, 463–478. 
(50) Bonzon-Kulichenko, E., Perez-Hernandez, D., Nunez, E., Martinez-Acedo, P., 
Navarro, P., Trevisan-Herraz, M., del Carmen Ramos, M., Sierra, S., Martinez-
Martinez, S., Ruiz-Meana, M., Miro-Casas, E., Garcia-Dorado, D., Redondo, J. M., 
Burgos, J. S., and Vazquez, J. (2011) A Robust Method for Quantitative High-
throughput Analysis of Proteomes by 18O Labeling. Mol. Cell. Proteomics 10, 
M110.003335–M110.003335. 
(51) Martinez-Bartolome, S., Navarro, P., Martin-Maroto, F., Lopez-Ferrer, D., Ramos-
Fernandez, A., Villar, M., Garcia-Ruiz, J. P., and Vazquez, J. (2008) Properties of 
Average Score Distributions of SEQUEST: The Probability Ratio Method. Mol. Cell. 
Proteomics 7, 1135–1145. 
(52) Navarro, P., and Vázquez, J. (2009) A Refined Method To Calculate False 
Discovery Rates for Peptide Identification Using Decoy Databases. J. Proteome Res. 
8, 1792–1796. 
85 
 
(53) Navarro, P., Trevisan-Herraz, M., Bonzon-Kulichenko, E., Núñez, E., Martínez-
Acedo, P., Pérez-Hernández, D., Jorge, I., Mesa, R., Calvo, E., Carrascal, M., 
Hernáez, M. L., García, F., Bárcena, J. A., Ashman, K., Abian, J., Gil, C., Redondo, J. 
M., and Vázquez, J. (2014) General Statistical Framework for Quantitative Proteomics 
by Stable Isotope Labeling. J. Proteome Res. 13, 1234–1247. 
(54) Jorge, I., Navarro, P., Martinez-Acedo, P., Nunez, E., Serrano, H., Alfranca, A., 
Redondo, J. M., and Vazquez, J. (2009) Statistical Model to Analyze Quantitative 
Proteomics Data Obtained by 18O/16O Labeling and Linear Ion Trap Mass 
Spectrometry: Application to the Study of Vascular Endothelial Growth Factor-induced 
Angiogenesis in Endothelial Cells. Mol. Cell. Proteomics 8, 1130–1149. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
Chapter 2 
 
 
Atherosclerotic plaque characterisation by 
enzymatic entrapment of 
phosphatidylcholine coated nanoparticles  
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Abstract 
 
In this study, we propose iron oxide coated phosphatidylcholine micelles (PC 
IONP) (1.1) as an imaging probe for the molecular characterisation of 
atherosclerotic plaque formation. Phosphatidylcholine-specific phospholipase 
C (PC-PLC) is involved in atherosclerosis as a regulator of apoptosis and 
autophagy in vascular endothelial cells (VECs). Because PC-PLC can 
specifically degrade the polar moiety of phosphatidylcholine, we examined if 
this enzymatic regulation could trigger the accumulation of PC IONP (1.1) by 
changing their colloidal stability. We first considered the in vitro interaction 
between PC-PLC and the iron oxide micelles in order to demonstrate the 
effectiveness of enzymatic cleavage of PC coating leading to the formation of 
hydrophobic aggregates. We then showed the consequences of this 
enzymatic degradation in the uptake of PC IONP and associated cytotoxicity 
effects in cellular cultures of macrophages. Finally, we studied the intravenous 
injection of PC IONP in ApoE-KO mice for multimodal in vivo visualisation and 
imaging characterisation of atherosclerotic plaques, underlining the 
importance of the interaction of the probe with the PC-PLC enzyme and the 
uptake by macrophages. The proposed probe represents a new platform for 
targeting of atherosclerosis thanks to an original enzymatically driven 
entrapment route, which opens promising bioapplications not only for specific 
diagnosis (quantification of plaque burden) but also to predict clinical relevant 
events for potential anti-inflammatory therapies in the context of 
atherosclerosis. Our approach allows studying the regulation of this pro-
atherogenic enzyme in the plaque progression and thus contributing with new 
molecular imaging solutions to understand different biochemical processes in 
the context of atheriosclerosis. 
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1. Introduction 
Atherosclerosis is the principal origin of many cardiovascular 
diseases, the leading cause of worldwide mortality.
1
 It refers to a multi-
factorial, chronic inflammatory pathology characterised by the irreversible 
thickening of arterial walls to form atheroma plaques, a slow and silent 
process over decades.
2
 This process leads to a decrease in the supply of 
oxygen-rich blood to main organs and potential rupture of the plaques leading 
to multiple complications such as myocardial infarction or stroke.
3
 Thus, 
clinical symptoms are often lethal or the manifestation of an advanced stage of 
the disease, making treatment more complicated with high risk of recurrence.
4
 
Recent developments in drug delivery and molecular imaging techniques offer 
promising advances for combating this issue, offering early non-invasive and 
reliable diagnosis, characterisation before an uncontrolled step in the course 
of the disease and combined therapeutic solutions.
5–7
 The prolonged evolution 
and the complex composition at different stages of atherosclerotic lesions, 
offer a wide window of possible biological targets for the design of imaging 
probes.
6,8,9
 In particular, macrophages are one of the most commonly used 
targets due to their key role during inflammation, known to be present along 
the entire plaque development.
10
 Many different NP-based probes for MRI, 
PET/CT, US or fluorescence have already been described either as passive 
targeting (taking advantage of the phagocytic activities) or active, with ligands 
specific to surface receptors or molecular products of macrophages.
11–16
 Other 
important biochemical targets derived from the atherogenic process have 
been also suggested for active targeting, as circulating monocytes, adhesion 
molecules, metalloproteinases, cathepsins or angiogenesis receptors.
6,9
  
However, apart from the macrophage phagocytosis, few other 
pathways for the passive extracellular accumulation of NP contrast agents in 
plaques have been used. As far as we know, no NP which use an enzymatic 
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modification for atherosclerosis detection has been proposed, as can do 
molecular imaging probes like 
18
F-FDG for inflammatory characterisation of 
the plaque or fluorescent sensors.
17–19
 This radiochemical can detect cells with 
altered metabolism, because specific enzymatic events let a radiolabel 
substrate to be entrapped inside the disregulated cells.
20
 We hypothesised the 
use of NP to accumulate in the plaque driven by a different enzymatic 
mechanism. Phosphatidylcholine-specific phospholipase C (PC-PLC) is a 
member of the phospholipase C family which catalyses the cleavage of the 
ester linkage between the glycerol and phosphate moieties of phospholipids, 
generating two of the most important messengers in the cellular pathway.
21
 
PC-PLC is expressed in cytoplasm, nucleus and external plasma membrane 
of cells where its activity has been reported.
22
 Increasing evidence shows that 
this enzyme is implicated in several cellular signalling pathways such as 
metabolism, cell growth, apoptosis and autophagy of mammalian cells.
23–25
 In 
particular, its pro-inflammatory properties and its role in vascular endothelial 
cell apoptosis (two important parameters in atherosclerosis) have been 
recently pointed out.
26,27
 Extracellular stimuli, including hormones, growth 
factors, and neurotransmitters, promote activation of phospholipase C.
22
 
Importantly, oxidised low-density lipoprotein (oxLDL), one of the key 
atherogenic factors, has a strong effect on PC-PLC expression and activity. It 
was demonstrated for apolipoprotein E knockout mice (ApoE-KO) that PC-
PLC is up-regulated in the aortic endothelium of atherotrombotic plaques and 
involved in the progression of the pathology.
28
 Oxidised phospholipids, 
particularly oxidised phosphatidylcholine, are ligands for macrophage 
scavenger receptors implicated in vascular plaque progression where oxidised 
phosphatidylcholine is often abundant.
29
 Interestingly, the inhibition of PC-PLC 
enzymatic activity reduced the progression and promoted the stabilisation of 
atherosclerotic lesions.
30
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Therefore, we wanted to investigate whether and how the function and 
over-expression of PC-PLC in atherosclerotic plaques can be used as a new 
tool for imaging in the early detection of atherosclerosis. We addressed this 
issue by developing a long circulating PC-coated iron oxide contrast agent PC 
IONP and assessed if it can be rapidly degraded by PC-PLC into hydrophobic 
aggregates resistant to macrophage phagocytosis.
31
 We showed, in an apoE-
KO mice model, that the probe effectively accumulates within the 
atherosclerotic plaque due to the PC-PLC activity and it can be applied for in 
vivo MRI detection of atherosclerosis, also providing a future new target and 
theranostic nanoparticle in atherosclerotic plaque targeted therapy. 
2. Results and discussion 
2.1 Synthesis and characterisation of Phosphatidylcholine coated 
iron oxide nanoparticles, PC IONP. 
Synthesis and characterisation of PC IONP (1.1) have been detailed 
in Chapter 1, section 2.2. As we described, we first synthesised OA Fe3O4 
magnetite nanoparticle by thermal degradation method (as described in 
Chapter 1, section 2.1). The latter were then stabilised with a nanoemulsion 
method into a micelle made of the amphiphilic PC molecule. This resulted in 
aqueous PC IONP micelles of about 75 nm hydrodynamic size, containing 
several magnetite cores (Figure 2.1). 
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Figure 2.1. Hydrodynamic size of PC IONP (Inset TEM picture and PC IONP in a 1:1 
hexane/PBS solution in v/v). 
The main physicochemical characterisation performed is summarised in Table 
2.1. In this work, to allow multimodal visualisation, we also prepared a variant 
in which a minor fraction of a phospholipid derivative, fluorescent dye Dil(18), 
is integrated into the coating formulation of the PC IONP. 
 
Table 2.1. Summary of the main physicochemical properties of PC IONP. 
 PC IONP 
Hydrodynamic size (nm) 75 
Pdi 0.14 
Zeta potential  (pH=7.1) (mV)  -11.5 
Saturation magnetisation 70 
Relaxivity (s
-1
.mM
-1
) r1: 1.3 r2: 147.4 
Estimated vascular life time  10 h 
Apolipoprotein present among the 10 most abundant 
protein 
Apo B100, A-IV, A-I 
 
2.2 In vitro degradation of PC IONP by PC-PLC. 
First we assessed the in vitro activity of PC-PLC towards the PC IONP 
(1.1), to test whether phosphate moieties of PC can be effectively cleaved 
when PC of the probe is under a rigid micelle-like form. In the micelle 
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structure, the choline hydrophilic head around the coating guarantees 
aqueous stabilisation and good colloidal properties to the nanoparticles. 
Therefore, we hypothesised that if the enzymatic reaction occurs, PC IONP 
will progressively aggregate, with an increase in the hydrodynamic size and a 
consequent change of their relaxometric properties (Figure 2.2). To 
demonstrate this, we first followed the evolution of the hydrodynamic size of 
1.1 dispersion by DLS in presence of PC-PLC at different time points (Figure 
2.3a). Shortly after PC-PLC was added, we clearly observed the formation of 
aggregates and a wider size distribution (illustrate by increase of the pdi) while 
the size of the control dispersions without the enzyme remained stable along 
time (Figure 2.3a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Illustration of the principles of the enzymatic entrapment of PC IONP in the 
atherosclerotic plaque. 
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Relaxometry was then used for a more detailed study of the kinetics of 
the enzymatic reaction. It has been previously shown that the modification in 
the aggregation state of the NPs can be detected by changes in the relaxation 
values.
31–33
 PC IONP dispersion was mixed with different PC-PLC 
concentrations (0.1 U, 0.3 U and 0.6 U) and the T2 measured along time (1 U 
unit will liberate 1.0 μmole of water soluble organic phosphorus from egg yolk 
L-α-phosphatidylcholine per min at pH 7.3 at 37 °C.). As shown in Figure 2.3b, 
due to the formation of aggregates, T2 values linearly increase in a dose and 
time-dependent manner. In the double control samples, T2 values remained 
stable for both the blank solution (same solution with no PC-PLC added) and 
the control NPs solution (solution of control NPs inert towards PC-PLC). Up to 
0.6 U, the evolution of T2 remains the same, so we assumed that we reach the 
maximum speed of the kinetic and the saturation of the enzymatic activity. 
Altogether, these results confirm the enzyme capacity to rapidly cleave the 
ester linkage of PC present in the micelle coating, resulting in the formation of 
large aggregates in the micrometer range. This is an essential requirement to 
enable PC IONP (1.1) for in vivo enzymatic entrapment in the plaque.  
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Figure 2.3. a) Time course of the hydrodynamic sizes of PC IONP (0.035 mg Fe.ml
-1
) 
along incubation times at 37ºC in presence of PC-PLC (0.6 U) b) Time course of T2 
relaxation times of a PC IONP solution (0.035 mg Fe.ml
-1
) along incubation times at 37 
ºC in presence of PC-PLC (0.1 U, 0.3 U and 0.6 U). 
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2.3 Macrophage uptake of PC IONP micelles and influence of 
PC-PLC activity. 
There are two major macrophage (MΦ) subsets called M1 and M2 
MΦs, which are phenotypically and functionally different. Activation to M1 
(“classical” activation) often encourages inflammation, triggering the immune 
response, while M2 activation (“alternative”) decreases inflammation and 
encourages tissue repair. Both classes are infiltrated and play important roles 
in atherosclerosis plaque which is characterised by unregulated 
inflammation.
34
 We investigated the influence of PC-PLC enzymatic 
degradation of the PC IONP on their uptake in vitro by MΦ. For this purpose, 
murine macrophages were first differentiated into M1 and M2 subclasses, 
induced by treatment with interferon-gamma and tumour necrosis factor-alpha 
for M1, or with interleukin-4 for M2. The differentiated cells were subsequently 
incubated for 24h in three conditions plus control (vehicle, PBS) with: (A) only 
PC-PLC, (B) only PC IONP and (C) a mixture of both PC-PLC and PC IONP 
(PC-PLC 2mU.ml
-1
, [Fe]=0.05 mg.ml
-1
). Interestingly, in conditions (B) and (C), 
we observed for both types of MΦ, although much more pronounced for M1 
MΦ, a change in the cellular morphology while the treatment with the enzyme 
alone (condition (A)) did not produce any changes on MΦs. This modification 
of the phenotypic pattern may be an indication of NP uptake or apoptosis 
events.  
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Figure 2.4. Pictures of the MΦ cell cultures in conditions (A), (B) and (C). 
 
In detail, flow-cytometry analysis measuring side-scattered light 
indicated that in condition (B), it occurred a high increase of the cell complexity 
for both MΦ cell lines with an effect much more pronounced for M1 (SSC-H 
median of 28000) than for M2 (SSC-H median of 12000) MΦs. When 
exogenous PC-PLC was added (conditions (C)), it contributed to an additional 
increase of the complexity for M1 MΦ (SSC-H median of 41000) while for M2 
MΦ, it remained equal to condition (B) (SSC-H median of 12000).  
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Figure 2.5. Changes in cell complexity after NPs incubation. Median of Side-Scattered 
Light (SSC-H) (intensity arbitrary units) of the MΦ cell cultures in conditions (A), (B) 
and (C). 
Concerning the analysis of cytotoxicity by flow cytometry (DAPI 
staining for necrotic cells), results showed that a significant cytotoxic effect 
was observed for M1 MΦ in condition (C) (Figure 2.6). This can explain the 
additional increase of the complexity in this condition, which gathers uptake 
and cytotoxic effect. For a deeper analysis we labelled the PC IONP with the 
fluorophore “Dil(18)”. Thus, we could visualise the cell cultures in condition (B) 
by confocal fluorescence microscopy with immunofluorescence staining of PC-
PLC. These results showed that, a high proportion of Dil(18) labelled NPs co-
localised with the M1 MΦ and looked aggregated. Subcellular co-localisation 
indicates an intercalation of the probe in the external cell membranes and to a 
lesser extent in the cytoplasm (Figure 2.7). The same cell-adherence 
behaviour was previously reported in other studies for phospholipid based 
NPs.
35
 In condition (C), i.e. when PC-PLC is added to the medium, large free 
aggregates of Dil(18) labelled PC IONP were observed surrounded by PC-
PLC (indicating of the enzymatic activity on the coating of the NPs).  
 
100 
 
 
Figure 2.6. Cell viability study of the a) M1 MΦ and b) M2 MΦ cell cultures in 
conditions (A), (B) and (C). 
 
 
 
 
 
Figure 2.7 Confocal fluorescence microscopy of a) M1 and b) M2Φ in condition (B). 
We can observed nucleous (DAPI 1:1000-blue), protein PC-PLC (PC-PLC antibody 
1:30 - green) and Dil(18) labelled PC IONP. 
101 
 
We finally check the endogenous expression of PC-PLC in the two 
types of macrophage by western blot (Figure 2.8). High amount of enzyme 
was detected inside M1 MΦ whereas M2 MΦ showed a much lower 
expression. This was also the case on the confocal microscopic images (PC-
PLC staining detected inside the M1 macrophages) (Figure 2.7). This 
endogenous expression can explains that the effects caused by PC IONP 
incubation and its accumulation in macrophages are more pronounced for the 
M1 MΦ because of its proper PC-PLC enzymatic activity. 
 
 
 
 
 
 
Figure 2.8. a) Western blot assay for endogenous PC-PLC. Normalised by alpha-actin. 
b) blot quantification of the endogenous PC-PLC protein expression in M1 and M2Φ. 
Taken together, these results indicate that in vitro activated 
macrophages interact with PC IONP (1.1) at the surface membrane before 
phagocytosis; and that the exogenous enzymatic PC-PLC activity on 1.1 
promotes the aggregation of the micelles hardening their interactions with the 
MΦs. The effect is much more pronounced for the class of pro-inflammatory 
macrophage M1, probably because of a higher proportion of endogenous PC-
PLC. Because PC-PLC is upregulated in the cells of the aortic endothelium of 
atheroma plaque, we can hypothesise that PC IONP that finally penetrate 
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inside the plaque will aggregate and thus will see impaired its elimination by 
the hosting specific macrophages. This will reinforce the possibility to use PC 
IONP as a molecular agent for characterisation of pro-inflammatory responses 
that promotes atherogenesis through to their accumulation following their 
modification by PC-PLC. Moreover, the cytotoxic effects on M1 MΦ caused by 
the PC IONP enzymatic degradation (endogenous and/or exogenous) could 
be of interest for possible anti-inflammatory outcomes in the plaque, and 
serving as theranostic agent. This cytotoxicity probably comes from the sub-
products released (diacylglycerol and phosphocholine) after the cleavage of 
PC by the PC-PLC reaction. Indeed, literature already report the role of these 
sub-products as molecular messengers in apoptosis events.
29,36,37
 
2.4 Accumulation of PC IONP in atherosclerosis plaque for in 
vivo imaging.  
Encouraged by these in vitro results, we have assessed whether our 
probe can accumulate in the atherosclerotic plaque in vivo, by conducting two 
experiments. In the first experiment, PC IONP (1.1) ([Fe]= 0.5 mg.ml
-1
) were 
intravenously injected in 48 weeks old ApoE-KO mice with a high cholesterol 
diet for 18 weeks. In vivo MRI performed 24 h after injection in a 7 T scanner, 
revealed a clear hypointense region in a diseased zone of the aorta on the T2-
weigthed images (Figure 2.9a).  
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Figure 2.9. a) Transversal T2 weighted MRI slices of apoE-KO mice aorta after i.v.a of 
PC IONP at 1h and 24 h b) muscle to plaque "relative signal intensity. 
The images show the typical hypointese areas in the plaque lesion 24 
h post-injection due to the iron oxide deposition. Since sometime the so-called 
negative contrast or signal loss can be difficult to identify, accompanying 
graph (Inset, Figure 2.9b) summarizes the plaque to muscle signal intensity 
ratios , showing a more than 20% signal decrease from the basal image. As 
shown in Chapter 1, the more conclusive results obtained for PC IONP are: 1) 
a vascular lifetime up to 10h, much longer than the standard for this type of 
nanomaterials, and 2) a high proportion of dysopsonin found in its protein 
corona, in particular from the apolipoprotein class (Table 2.1).
31
 We believe 
that these two properties contribute to the penetration of PC IONP in the 
lesions. Indeed, long circulation time favours the passive diffusion and it has 
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been already demonstrated that presence of apolipoproteins in the coating of 
NP promote their accumulation in the plaques. 
 
 
 
 
 
 
Figure 2.10. Histological analysis of colocalisation between NPs, endogenous PC-PLC 
and macrophages (consecutive slides) in ApoE-KO mice with atheroma plaque. 
Inmunohistochemical staining for PC-PLC and macrophages (F480 antibody). 
To corroborate that the signal enhancement comes from the iron 
oxide deposition and to elucidate the interactions between PC IONP, PC-PLC 
and MΦ in the plaque, we conducted histological validation. Bright field 
microscopy of consecutive sections of the aorta with different 
immunohistochemistry stainings specific for iron, macrophages and PC-PLC 
was performed (Figure 2.10). These results revealed that: 1) an important 
number of NPs aggregated in the fibrous cap of the atherosclerotic plaque, 2) 
a high degree of co-localisation between the PC-PLC and the NPs (presume 
an enzymatic activity at the surface of the micelle´s coating) and 3) numerous 
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matches between the NPs and the macrophages. In the second experiment, 
Dil(18) labelled PC IONP were i.v. injected into apoE-KO mice which were 
sacrificed after 24h and perfused with PBS before their aortas were excised. 
The distribution of the Dil(18) labelled PC IONP in whole aortas was 
investigated by ex vivo fluorescence. Importantly, accumulation of the 
fluorescent probe was observed in plaque-rich regions (Figure 2.11). 
Furthermore, plaque sections were studied by fluorescence microscopy. 
Representative images displayed in Figure 2.11 revealed colocalisation of the 
NPs with PC-PLC immunostaining in the aortic root but little correlation of the 
probe with MΦ, confirming the results of the first experiment.  
 
 
 
 
 
 
Figure 2.11. a) Ex vivo fluorescence of the aorta (IVIS, DsRed ex/em filter), b) 
Confocal images of atherosclerotic plaque where we can observed nucleous (DAPI 
1:1000-blue), endogenous expression of the protein PL-C (PL-C antibody 1:30 - 
green), NPs accumulation into plaque (red) and macrophages (F480 antibody 1:20 -
yellow). 
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3. Conclusions 
Host macrophages in atherosclerosis plaques are currently the main 
biological target used for detection imaging with nanoparticulate contrast 
agents. Here, we proposed a contrast agent, designed specifically to 
accumulate passively in plaques. We show that PC IONP is rapidly degraded 
by PC-PLC, an enzyme upregulated in the vascular endothelial cells of the 
atherosclerotic lesions. The enzymatic reaction leads to aggregation of PC 
IONP because of the cleavage of the choline head, the moiety responsible of 
the aqueous stabilisation of the NPs coating. These aggregates have been 
observed to be resistant to the uptake by MΦ in vitro and so PC IONP is 
predetermined to remain in the inflamed plaque areas. This was confirmed by 
successful in vivo MR imaging of plaques in apoE-KO mice due to the 
accumulation of the contrast agent. Histology of these plaques confirms, by 
bright field microscopy and immunofluorescence, the endogenous degradation 
of the PC IONP by PC-PLC and the low phagocytosis of the probes by the 
macrophages. We believe that this new proposed method for contrast agent 
accumulation in atherosclerotic plaque opens promising bio-applications for 
improved its characterization. Enzyme modification pathway is a tool already 
applied with success for molecular imaging, and this new use with NP based 
probe can provides an early indicator of atherosclerotic plaque development. 
Finally, the in vitro cytotoxicity of the by-products of the enzymatic degradation 
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against macrophages could be a track for potential anti-inflammatory actions 
and theranostic applications, providing a new target in atherosclerotic plaque 
therapy. 
4. Materials and Methods 
Materials  
All chemicals for the preparation of the BSA-NPs were purchased from Sigma-Aldrich 
Co. (St. Louis, USA) except. All reagents were of analytical grade except 
phosphatidylcholine (90%),oleic acid and oleylamine of technical grade. They were 
used without any further purification. Distilled water (milliQ) or phosphate buffered 
saline PBS were used throughout the experiments. 
 
Synthesis 
Oleic acid coated Fe3O4 magnetite nanoparticle  
Protocol described in Chapter1.4 
PC IONP micelles. (1.1) 
Protocol described in Chapter1.4. The same protocol was used for the preparation of 
the Dil(18) labelled PC IONP except that 1mg of Dil(18) was added to the 
nanoemulsion formulation.  
 
In vitro degradation of PC IONP by PC-PLC 
Evolution of the hydrodynamic size of PC IONP dispersion in presence of PC-PLC. We 
used a solution of PC IONP ([Fe]=0.035 mg.ml
-1
) mixed with PC-PLC (0.2 U). The 
hydrodynamic size and polydispersity index were measured at different time points 
(from 5 to 380 min) at 25ºC by dynamic light spectroscopy with a Zetasizer Nano ZS90 
(Malvern Instruments, UK) using folded capillary cells.  
Evolution of the T2 relaxation time of PC IONP dispersion in presence of PC-PLC. 
Serial solutions (600 µl final volume) of PC IONP ([Fe]=0.035 mg.ml
-1
) mixed with PC-
PLC at different concentrations (0.1, 0.3 and 0.6 unit) were prepared. Reaction buffer 
used was a 50 mM TrisHCl (pH 7.5), 0.14 M NaCl, 2 mM CaCl2 solution. Thereafter 
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the addition of the enzyme, T2 relaxation times were measured at 37ºC in a Bruker 
Biospec spectrometer with a T2 Carr-Purcell-Meiboom-Gill sequence (Bruker Biospec 
47/40, 1.5 T, Bruker Biospin, Germany) at echoes from 0 to 150 min.  
 
In vitro macrophage uptake of PC IONP micelles 
Cell culture and media. The murine macrophage cell line RAW 264.7 was grown in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were cultured at 37ºC in 
a humidified atmosphere with 5% CO2. For each experiment, cells were plated at a 
concentration of 0.5 x10
6
 cells/ml in 12-well plates in complete growing medium. 
Twenty-four hours later, cells were polarised to M1 (25 ng/ml interferon gamma and 25 
ng/ml tumour necrosis factor alpha) or M2 (20 ng/ml interleukin-4) macrophages for 
additional 24 hours. Polarised macrophages were incubated with PC-IONP or Dil(18) 
labeled PC IONP (50 g Fe/ml medium) in the absence or in the presence of 
phospholipase C (2 mU/ml) for 24 hours. Control cells were incubated without 
nanoparticles (vehicle, water). 
Citotoxicity assays  
Cell viability is determined by adding DNA binding dyes. DAPI was then added to a 
final concentration of 0.001% (w/v), and cells were analysed by flow-cytometry using 
the BD FACSCanto™ II system. All experiments were performed in triplicate. 
Microscopy cell cultures stained by Prussian Blue. Cells were grown on glass 
coverslips in 12-well plates. Perls Prussian Blue staining was performed following 
standard immunocytochemical procedures. Briefly, Slides were stained with 1% 
aqueous potassium ferrocyanide in 2% solution of HCl for 15 min and counterstained 
with nuclear fast red. Labeled cells were visualised on Nikon ECLIPSE 90i- Upright 
bright field microscope (Acquisition Software: NIS-Elements 3.22.11) and then, slides 
were processed and digitalised. 
Nanoparticle Uptake assays. After 24 hours of treatment with Dil(18) labelled PC IONP, 
cells were scrapped and washed thoroughly with phosphate buffered saline (PBS) and 
harvested in 1 ml PBS. Cell populations were centrifuged at 300 x g for 5 min RT, 
washed 3 times with PBS. To determine cell viability, the resulting pellets were 
resuspended in 200 μl PBS containing Annexin V and DAPI, at a final concentration of 
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0.001% (w/v). A total of 10.000 events were recorded for each sample using the 
FACSCanto™ II system(BD Biosciences). All experiments were performed in triplicate.  
Samples are analysed with BD FACSDivaTM Software and an average of the medians 
and standard deviations was calculated using FlowJo Software. Additionally, cell 
culture was stained with Perls’ Staining to detect SPIO labeled cells. 
In vitro inmunofluorescence assays. For immunofluorescence, cells seeded on 
coverslips were washed in PBS, fixed (4% formaldehyde) and permeabilised in PBS 
with 0.1% Triton X-100, before staining with primary antibodies and secondary Alexa 
Fluor antibodies (LifeTechnologies) in blocking solution (5% BSA). Samples were 
incubated with primary antibodies rat anti-mouse F480 (1:50) and anti-mouse PLC-
gamma 1 Antibody (1:100; Novus Biologicals (2C11)) Optical sections were acquired 
using a Leica TCS SP5 confocal system. Colocalisation analyses were performed 
using LAS AF software (Leica Microsystems, Germany) and ImageJ (National 
Institutes of Health, USA). 
 
Accumulation of PC IONP in atherosclerosis plaque for in vivo imaging 
Animals. Mice were housed in specific facilities (pathogen-free for mice) at the Centro 
Nacional de Investigaciones Cardiovasculares. Experimental procedures were 
approved by the local Animal Care and Ethics Committee and regional authorities.  
Magnetic resonance imaging. In vivo MRI in mice was performed with an 
Agilent/Varian scanner (Agilent, Santa Clara, USA) equipped with a DD2 console and 
an active-shielded 205/120 gradient insert coil with 130 mT/m maximum gradient 
strength and a combination of volume coil/two channel phased-array (Rapid 
Biomedical GmbH, Rimpar, Germany). Mice were anesthetised with 2% isoflurane 
(Abbott) and oxygen and positioned on a thermoregulated (38.7ºC) mouse bed and the 
respiratory cycle was monitored constantly. Ophthalmic gel was placed in their eyes to 
prevent retinal drying. Baseline images were acquired before i.v.a of PC IONP ([Fe]=1 
mg.ml
-1
, 100 µl). Images were acquired at basal, 1hour post-injection and 24 hours 
later. For each animal, consecutive axial 1 mm thick slices were acquired to image the 
aorta. Images were acquired in free-breathing animals, using a gradient echo 
sequence with 4 ms/40 ms echo/repetition times, BW of 100 kHz, FOV of 6 cm x 6 cm, 
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for a total acquisition time of about 80 seconds; the flip angle (FA) was fixed at 20 
degrees.  
Histolological confirmation. After 24 hours of i.v.a dosis of PC IONP, 2 mice were killed 
and aortas were fixed by pefusing the animal with a PBS followed by a formalin lavage 
and was incubated in 10% formalin for 24 hours. Tissue was dehydrated and 
embedded in molten paraffin and stored at RT until the sectioning. Consecutive 
sections of the aorta were taken off for immunohistochemistry. Respectively staining 
for Hematoloxilin/Eosin staining, Perl´s Prussian Blue(Iron), PC-PLC with Ab, F4/80 for 
Mφ, and Manson thrichrome staining for fibrosis. Tissues slides were visualised on 
Nikon ECLIPSE 90i- Upright bright field microscope (Acquisition Software: NIS-
Elements 3.22.11) and then, slides were processed and digitalised. 
 
Ex vivo fluorescence and microscopy fluorescence study 
Dil(18) labelled PC IONP (100 µl, 0.5 mg.ml
-1
 [Fe]) were i.v. administrated in apoE 
mice (N=3) that were sacrificed after 24 h. After perfusion, the aortas were extracted 
and ex vivo fluorescence was performed with IVIS Imaging System 200 series 
(Xenogen®) (parameters of acquisition: DsRed ex/em filter, high level, BIN-HR, FOV 
13.3, f2, 4s).  
Immunofluorescence .Slides was deparafinised and rehydrated (xylene 5´, xylene 5’, 
100%EtOH 3’, 100% EtOH 3’, 95-90-80-70-50% EtOH 30”, dH2O: 5’).Heat induced 
epitope retrieval with citrate buffer (10 mM pH6 during 15 minutes). Slides were 
allowed to cool 20 minutes. Wash slides 5’ PBS-T (x3) and permeabilised during 15’ in 
PBS-T 0,5%. Wash slides 5’ PBS-T (x3) and non-specific binding was blocked by a 
dilution of 1%BSA+PBS-T during 1 hour. Primary antibodies rat anti-mouse F480 
(1:20) and anti-mouse PLC-gamma 1 Antibody (1:50; Novus Biologicals (2C11)) was 
added in blocking solution and incubated overnight at 4ºC. Sections was washed thrice 
with blocking solution during 5 minutes each and incubated with secondary antibody 
(Alexa Fluor antibodies,1:500) for 45 minutes. Slides were washed twice with PBS and 
dH20 and applied one drop of ProLong® Gold Antifade Reagent with DAPI. Confocal 
fluorescence microscopy images were obtained on a Leica SP5-Inverted Confocal, 
using the following objectives: HCX PL APO CS 40x 1,25 oil, HCX PL APO lambda 
blue 63x 1,40 oil. LAS-AF 2.6.0 Acquisition Software was used. 
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Parallel multifunctionalisation of 
nanoparticles: A one-step modular 
approach for in vivo imaging 
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Abstract 
 
Multifunctional nanoparticles are usually produced by sequential synthesis, 
with long multi-step protocols. Our study reports a generic modular strategy for 
the parallel one-step multifunctionalisation of different hydrophobic 
nanoparticles. The method was designed and developed taking advantage of 
the natural non-covalent interactions between the fatty acid binding sites of the 
bovine serum albumin (BSA) and the aliphatic surfactants on different 
inorganic nanomaterials. As a general example of the approach, three 
different nanoparticles - iron oxide, upconverting nanophosphors and gold 
nanospheres- were nanomemulsioned in water with BSA. To support specific 
applications, multifunctional capability was incorporated with a variety of 
previously modified BSA modules. These modules include different 
conjugated groups, such as chelating agents for 
68
Ga or 
89
Zr and ligand 
molecules for enhanced in vivo targeting. A large library of thirteen multimodal 
contrast agents was developed with this convergent strategy. This platform 
allows a highly versatile and easy tailoring option for efficient incorporation of 
functional groups. Finally, as demonstration of this versatility, a bimodal 
(PET/MRI) probe including a maleimide-conjugated BSA was selectively 
sation with an RGD peptide for in vivo imaging detection of tumour 
angiogenesis 
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1. Introduction 
Thermal decomposition is one of the most used synthetic methods 
rendering crystalline and highly monodispersed hydrophobic NP. These 
particles are stabilised with surfactants made of long aliphatic chain like oleic 
acid (OA) or oleylamine (OM), and are therefore dispersible only in different 
organic solvents.
1,2
 Consequently, the multiple steps for the final 
multifunctionalisation start with the hydrophilic conversion of the NP to obtain 
a probe stable in physiological media, by ligand exchange
3
, direct chemical 
modification of the surfactant
4,5
 or stabilisation within a hydrophilic coating 
matrix.
6,7
 The various hydrophilic coating matrix approaches proposed include 
inorganic or organic encapsulation, such as polymeric or protein based, and 
micellar or liposomal structures.
8–10
 This hydrophilic coating provides an 
improved colloidal stability to the NP, protection from opsonisation and 
biocompatibility.
11
 It is also of paramount importance that the coating allows 
stable drug entrapment or further functionalisation like attachment of targeting 
ligand and additional imaging probes.
10,14
 Bovine serum albumin (BSA) fulfills 
all of these requirements, as several research groups have demonstrated.
15
 
Albumin is the most abundant protein in the blood and has crucial biological 
functions importantly, the transport of hydrophobic molecule to the tissues.
16
 
BSA as organic nanoparticle or coating for inorganic NP has also been 
reported to improve the in vivo properties of the probe.
15,17–19
 Schäffler et al.
19
 
and others recently showed that albumin-NP conjugates not only have 
improved biocompatibility but also may be used as potential tool for organ 
targeting like brain or lungs.
20
 Nonetheless, BSA (or Human serum albumin) 
conjugation on NP is always made on an existing hydrophilic coating, bringing 
into play covalent or ionic binding or just, simple adsorption.
22–24
 As far as we 
know, no method that transfers directly hydrophobic OA/OM coated NP in 
aqueous phase with BSA has previously been described.  
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Multifunctionality is an unique characteristic of nanomaterials; the possibility 
of introducing several imaging agents, plus biological targeting moieties and 
drugs, is one of the most prominent features of this new type of chemistry. 
However, this multiplex incorporation presents some inherent problems, 
particularly the need for various complex sequential steps, in turn reducing the 
overall yield and lowering the reproducibility.
25–27
 This is nowadays especially 
relevant for creating new PET/MRI and Fluorescence/MRI agents with the 
idea of combining sensitivity and improved spatial resolution.
23,25,28
  
Following a modular approach, our proposal is different; by the hydrophobic 
interactions between fatty acid binding sites of albumin and the aliphatic 
chains on the coating of the NP we demonstrate how the parallel 
multifunctionalisation is achievable for a large variety of nanoparticles and 
coating possibilities. As for nanoparticles we apply our approach to IONP, 
UCNP and AuNP. Using each type of NP with different combination of natural 
BSA and fractions of pre-modified BSA with Alexa Fluor®647, DOTA (chelator 
for 
68
Ga), DFO (chelator for 
89
Zr) or maleimide reactive moiety; a large library 
of multifunctional contrast agents (BSA NP) was prepared. After a thorough 
characterisation of all the BSA NP the capacity of the platform for targeted 
bioimaging was finally assessed. For this, a bimodal contrast agent from the 
library was selected for RGD conjugation and its accumulation in a mouse 
model of cancer was studied by PET and MRI. 
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2. Results and discussion 
2.1 Synthesis of OA IONP, OA UCNP and OM AuNP 
Synthesis of OA IONP. Synthesis and characterisation of OA IONP 
was already described in Chapter 1, Section 2.3. 
Synthesis of OA UCNP. As addressed in Introduction, Section 3; 
UCNP refers to a family of nanoparticles comprising a wide range of different 
types of inorganic core.
6,31
 We have used a core composed of a NaGdF4 host 
matrix with ytterbium (Yb) and thulium (Tm) lanthanide dopants embedded in 
a NaGdF4 passive shell, abbreviated NaGdF4:Yb,Tm@NaGdF4 or in this 
study, OA UCNP. Oleic acid-OA coated UCNP were obtained by thermolysis 
method
27
 described as the optimal to provide nanocrystals of the highest 
quality and well dispersed in organic solvent
28
. Small solid-state crystal nuclei 
were formed at room temperature by reaction between the lanthanide chloro-
precursors and stoichiometric amounts of NH4F fluoride reagent (Scheme 1) in 
an OA/OM mixture. Posterior thermic treatment allows further growth and 
ripening of the nuclei. With a similar method NaGdF4:Yb,Tm were used as 
seed crystal to further epitaxial growth of a non-doped NaGdF4 crystal shell 
layer on the surface
29
 to obtain the core/shell structure OA coated 
NaGdF4:Yb,Tm@ NaGdF4 NP (OA UCNP). NP were uniform, with a 
polydispersity index (PDI) of 0.25, and had a hydrodynamic size of 29 nm 
measured in hexane (Table 3.1). TEM revealed the particles to be spherical, 
sometimes almost hexagonal and well dispersed. High Resolution TEM 
showed a high degree of crystallinity for the inorganic core of OA UCNP, with 
the possibility to observed different lattices of the crystal structure (Figure 3.1).  
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Figure 3.1. TEM pictures of OA UCNP at two different magnifications. 
To confirm the composition and the crystallinity of the nanocrystals 
obtained, X-ray diffraction pattern of OA UCNP was achieved. We can see 
from Figure 3.2a that the diffraction peaks and intensities of the NP were in 
good accordance with the data of the β-hexagonal phase NaGdF4 reference 
(Powder Diffraction File Card No. 27-0699). No peaks corresponding to the α-
cubic phase or other impurity crystalline phase were found thus validating the 
high crystalline quality of the NP. It is of importance that the synthesis leads to 
the hexagonal crystal structure for the core as it ensured the up-conversion 
luminescence of highest intensity.
29
 The energy-dispersive X-ray analysis 
pattern is presented in Figure 3.2b. It was checked that only the elements of 
the cores of OA UCNP were present. Not only the major components (Na, Gd, 
and F) were easily detected, but also the low content doping agents Yb were 
identified. Surfactant coating has been characterised by Fourier Transformed 
Infrared Spectroscopy shown in Figure 3.3. Spectrum displayed the 
characteristic vibration peaks of the OA. The ones of the aliphatic moieties 
were found at 2920 cm
-1
 (νa C-H) and 2850 cm
-1
 (νs C-H) while the ones of the 
carboxylic group appeared at 1625 cm
-1
 (ν C-O) and 1530 cm
-1
 (ν C-O). In 
comparison to the free carboxylic group, these last peaks were found at 1) a 
frequency lower than the C=O vibration band but 2) higher than the frequency 
of the C-O vibration band, also 3) the differences between the two bands were 
less than 110 cm
-1
. 
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Figure 3.2. a) X-ray diffraction of OA UCNP powder b) Energy-dispersive X-ray 
analysis of OA UCNP. 
All these information suggest that the carboxylic group of the oleic 
acid is coordinated to the gadoliniums atoms of the surface of the UCNP core 
through a bidentate complex with the oxygens. Indeed, as already mentioned, 
OA has a high affinity for the gadolinium ions. Finally the stretching band at 
1461 cm
-1
 is characteristic of the Gd-O bound between the inorganic 
crystalline core structure and the carboxylic acid of OA.  
 
 
 
 
Figure 3.3. FTIR of OA UCNP. 
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Coating can be also characterised by mass spectroscopy. The mass 
spectrum of the OA UCNP was clearly representative of the OA adducts with 
peaks at m/z = 208 and 563 g.mol
-1
, respectively the MW of OA subtracted of 
one proton and its double multiple. No peaks representative of OM, a side 
products used in the reaction and weak cheating ligand of UCNP core, was 
detected with MS highly sensitive technique. It confirmed the surfactant 
recovering the UCNP is made of only OA.  
Finally TGA shows that the organic coating (corresponding to the 
removal of OA surfactant between 190ºC and 400ºC) represents 30 % of the 
total weight of OA UCNP (Figure 3.4). This is a value to put in perspective in 
front of presence of free OA in the sample. Similarly, it also indicates a high 
strength of union formed by the complex between carboxylic acid of OA and 
UCNP core, as no loss of surfactant is observed before 300ºC, the 
temperature used in the thermal synthesis. The first slight decrease of the 
weight between 0 and 190ºC is due to the combined evaporation of the 
remaining water and un-adsorbed OA. 
 
 
 
 
 
Figure 3.4. TGA of OA UCNP. 
One of the most important properties of the UCNP further taken 
advantage of for bioapplications is their upconversion fluorescence (details in 
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Introduction, Section 3). The upconverting (UC) fluorescence of the OA 
UCNP, investigated under continuous wave CW excitation at 980 nm, are 
presented in Figure 3.5. It can be easily observed a strong upconversion with 
the main characteristic emission peaks at 360 nm, 451 nm, 476 nm and 800 
nm corresponding to the 1D2->3H6, 1D2->3F4, 1G4-> 3H6 and 3H4->3H6 
transitions in the system Yb,Tm 
30
 . As expected, UCL of the core/shell 
structure was significantly enhanced in the overall emission intensity. Indeed 
the inert shell made of the same non- doped material preserve the energy loss 
and transfer to the outer surface
31
. 
 
 
 
 
Figure 3.5. Fluorescence emission spectrum for 3.2 after excitation with C.W. laser at 
980 nm. Normalised UCL intensity. 
Synthesis of OM AuNP. For the synthesis of OM AuNP, we used the 
decomposition of chloroauric acid in a mixture of toluene and oleylamine 
following a well-known method describe in the Materials and Methods section 
of this chapter. NP were highly uniform with a pdi below 0.1 and had a 
hydrodynamic size of 14 ± 3 nm for a mean core diameter of 5 ± 2 nm (Figure 
3.6a). Transmission electron microscopy (TEM) showed the particles to be 
spherical and well-dispersed (Figure 3.6b). 
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Figure 3.6. a) Hydrodynamic size and b) TEM of OM AuNP. 
Surfactant coating has been characterised by FTIR shown in Figure 
3.7. Spectrum displayed the characteristic vibration peaks of the OM. The 
ones of the aliphatic moieties were found at 2920 cm
-1
 (νa C-H) and 2850 cm
-1
 
(νs C-H) while the ones of the amine group appeared at 3290 cm
-1
. 
 
 
 
 
Figure 3.7. FTIR of OM AuNP. 
One of the most prominent features of AuNP is their surface plasmon 
resonance due to the electromagnetic confinement, giving rise to their 
characteristic color variations with size. This has been extensively exploited in 
different applications (see Introduction, Section 4). The UV-VIS absorbance 
spectrum of the OM AuNP presented in Figure 3.X shows the typical broad 
absorbance band for AuNP of around 5nm core size. 
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Figure 3.8. UV-VIS spectrum of OM AuNP. 
A summary of the main characterisations and differences of the three 
hydrophobic NP prepared are presented below in Table 3.1. 
Table 3.1. Basic physicochemical characterisations of the hydrophobic NP (IONP, 
UCNP, AuNP). 
OA/OM NP Core 
diameter 
Hydrodynamic Size 
(nm) 
pdi 
OA IONP 7  10  0.24 
OA UCNP
 
20  29  0.25 
OM  AuNP 5 14  0.07 
2.2 Synthesis and physicochemical characterisation of BSA 
coated IONP, UCNP and AuNP 
The first step was to demonstrate the feasibility of aqueous stabilisation 
through BSA binding to the aliphatic chains. This was achieved, as 
represented in Figure 3.9, by adapting a simple, fast and reproducible 
nanoemulsion method.
32
 It is similar to the method described in chapter 1, 
section 2.2. It involved, mixing a small volume of NP dispersed in hexane with 
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an aqueous phase (phosphate buffer, pH 7.2), 1/10 in v/v, containing BSA 
protein. Upon homogenisation and stirring, an oil-in-water nanoemulsion is 
formed and gradual evaporation of the organic phase leads to a stable 
colloidal aqueous solution of BSA IONP (3.1), BSA UCNP (3.2) and BSA 
AuNP (3.3). Stabilisation was achieved by hydrophobic van der Waals 
interactions between the surfactant (OA or OM) of the hydrophobic NP and the 
fatty acid binding sites of the albumin. The BSA stabilised NP did not show re-
dispersion, if mixed again with hexane phase (1/1 in volume). This method is 
more flexible, easier, and faster than the widely common adsorption, 
conjugation or desolvation routes used to coat NP with albumin.
20,23,24
 To 
confirm that the stabilisation was achieved via hydrophobic interactions 
between OA and BSA fatty acid binding sites, several control reactions were 
performed. These consisted in repeating the nanoemulsion formulation with a 
pre-targeted BSA, in which, the fatty acid binding sites were previously 
saturated with free OA. As expected, the BSA was not able to bind to the 
surface, making the formation of a stable aqueous colloidal solution of 
nanoparticles 3.1, 3.2 and 3.3, impossible. This confirms that the binding 
origin is mainly through hydrophobic interactions and not simple adsorption on 
the surface of the NP. This straightforward use of the fatty acid binding sites of 
BSA simplifies the process against other synthetic strategies that use multiple 
steps and/or harsh reactive conditions. 
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Figure 3.9. a) Modules for combination in the nanoemulsion process; b) Nanoemulsion step with selected modules (many other 
combinations are possible) and c) Library of multifunctional nanoparticles synthesised in this work. 
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Final hydrodynamic sizes of 3.1, 3.2 and 3.3 were 97.2 nm, 94.3 nm and 
102.5 nm with pdi below 0.25, showing that this approach leads to very 
homogeneous dispersions with high reproducibility (Section 2.3 of this 
chapter, Table 3.2). TEM images shown in Figure 3.10a, confirms that the 
sizes match with the formation of well-defined small clusters made up of few 
hydrophobic self-assembled NP and surrounded by the BSA. Colloidal stability 
was checked by measuring the zeta-potential (ζ) variation, as a function of the 
pH (Figure 3.10b). As expected, it followed the same evolution as the electric 
charge of the BSA protein, with no net superficial charge around the BSA 
isoelectric point (pH 4.7, 25ºC) and a negative potential at physiological pH, 
preventing aggregation by strong repulsive electrostatic interactions and steric 
effects. The presence of protein on the nanoparticle surface was further 
characterised by FTIR, (Figure 3.11a), TGA (Figure 3.11b) and MS (Figure 
3.12). The three types of BSA-stabilised particles ((3.1), (3.2) and (3.3)), 
showed the characteristic absorption spectrum of the protein, with bands at 
3284, 1642, 1530 and 1391 cm
-1
 together with signals of the NP hydrophobic 
surfactant: OA/OM aliphatic chain moiety at 2920 cm
-1
 (νa C-H), 2850 cm
-1
 (νs 
C-H), 1641 cm
-1
 (νs C=O) 1576 cm
-1
, 1436 cm
-1
 (ν C-N) and 1534 cm
-1
 (ν N-H) 
and inorganic core (for example Fe-O at 580 cm
-1
 for IONP). 
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Figure 3.10. a) TEM images of BSA coated NP (3.1), (3.2), (3.3) b) Zeta potential of 
BSA coated NP (3.1), (3.2), (3.3) as a function of pH. 
TGA shows that organic coating (corresponding to the removal of protein 
and surfactant between 300 ºC - 900ºC) represents approximately 43 % (3.1), 
50% (3.2) and 27% (3.3) of the total weight of each NP. The smaller amount of 
organic phase for gold nanoparticles is most likely due to a lower amount of 
OM on the surface of 3.3 in comparison to the use of OA. MS data of the three 
kinds of NP (analysed in positive ionisation) were representative of the 
expected BSA adducts and was similar to the unbound BSA control spectrum. 
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Figure 3.11. a) FTIR spectra and b) Thermogravimetric curves of BSA coated NP 
(3.1), (3.2), (3.3). 
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Figure 3.12. Mass spectra for pure BSA and BSA NP 3.1, 3.2 and 3.3. 
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2.3 Library of multifunctional nanoparticles by modular integration 
of pre-labeled BSA 
Through traditional bioconjugation (especially succinimide-activated 
carboxylic groups) it is possible to incorporate a covalent linkage of additional 
probes and adds new functionalities to the protein. One key aspect of our 
approach is the possibility of using the nanoemulsion method with small 
fractions of modified BSA in addition to the native BSA, a straightforward 
method of obtaining water stable and multimodal NP. In this flexible modular 
approach, we have used BSA modules conjugated with i) Alexa Fluor®647 
fluorophore (optical modality); ii) DOTA chelating agent for short half-life 
isotope like 
68
Ga (PET modality); iii) DFO as chelating agent for long half-life 
isotope like 
89
Zr (PET modality) and iv) a maleimide moiety (functional group 
for easy attachment of a targeting peptide by click chemistry). Different 
combinations between hydrophobic NP and the modified BSA modules were 
performed so as to obtain a large molecular imaging portfolio of multifunctional 
contrast agents (thirteen different BSA NP, Figure 3.9). 
Table 3.2 summarises the different composition, physicochemical properties 
and imaging possibilities of each contrast agent. Hydrodynamic sizes of the 
BSA NP ranged between 78.4 and 108.9 nm with a pdi for all of them below 
0.25 and a negative zeta potential ζ at neutral pH. It demonstrates the 
versatility of this modular approach, in all cases, resulting in very 
homogeneous and particularly reproducible dispersions.  
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Table 3.2. Library of the BSA NP contrast agents. Main physicochemical properties 
and imaging modalities. 
BSA NP NP# % BSA Size 
(nm) 
pdi Zeta 
potential 
(mV) 
Imaging 
properties 
BSA IONP 3.1 n.a. 97.2 0.18 -19.7 T2 MRI 
BSA UCNP
 
3.2 n.a 94.3 0.19 -17.9 T1 MRI /  
Fluorescence 
BSA AuNP 3.3  n.a. 102.5 0.15 -9.5 UVvis/ 
fluorescence 
(Alexa647)
BSA IONP 3.4 3 % 
Alexa647  
93.0 0.15 -13.5 T2 MRI / 
Fluorescence 
(Alexa647)
BSA AuNP
 
3.5 3 % 
Alexa647  
108.9 0.22 -11.1 UVvis / 
fluorescence/ 
FRET 
(DOTA)
BSA IONP 3.6 8 % 
DOTA  
104.9 0.17 -10.8 T2 MRI / PET 
(DOTA)
BSA UCNP
 
3.7 8 % 
DOTA  
78.7 0.20 -25.7 T1 MRI /  
Fluorescence 
/ PET 
(DOTA)
BSA AuNP
 
3.8 8 % 
DOTA  
87.5 0.13 -19.8 PET / UVvis 
(Mal.)
BSA UCNP
 
3.9 30 % Mal  100.9 0.15 -23.1 T1 MRI /  
Fluorescence 
/ targeting 
(Alexa647)(DOTA)(Mal.)
BSA 
IONP
 
3.10 6 % 
Alexa647  
3 % 
DOTA  
30 % Mal  
 
90.2 0.19 -8.9 T2 MRI / PET 
/ 
Fluorescence 
/ targeting 
(DFO)(Mal.)
BSA IONP
 
3.11 20 % DFO  
20 % Mal  
91.9 0.18 -13.9 T2 MRI / PET 
/ targeting 
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Table 3.2. (Cont.)       
(Alexa647)(DFO)(Mal.)
BSA 
IONP 
3.12 6 % 
Alexa647  
20 % DFO  
15 % Mal  
78.4 0.16 -12.0 T2 MRI / PET 
/ 
Fluorescence 
/ targeting 
(DFO)(RGD)
BSA IONP
 
3.13 20 % DFO  
20 % 
RGD  
94.2 0.15 -14.5 T2 MRI / PET 
/ 
Angiogenesis 
 
Imaging modalities provided by the inorganic core of the nanoparticles. Our 
modular approach is valid for different types of nanoparticles, independently 
on the nature and physicochemical properties of each IONP, UCNP and 
AuNP. The imaging functions of each preparation, depends on the core of the 
nanoparticles, and the modified BSA modules in the coating. Thus, we first 
evaluated the characteristics of the core of the nanoparticles 3.1, 3.2 and 3.3 
as contrast agents for different imaging techniques.  
Iron Oxide core. Fe3O4 core confers superparamagnetic behaviour and 
normally high transversal relaxivity (r2) for T2-weighted MRI.
1
 BSA IONP (3.1) 
shows a large saturation magnetisation value of 70 emu g
-1 
similar to the 
hydrophobic particles, measured in a Vibrating Sample Magnetometer, both 
displayed in Figure 3.13a. This large value explains the high transversal r2 
value of 203.4 s
-1
mM
-1
 (r1 = 3.2 s
-1
mM
-1
), which confirms these particles as an 
excellent probe for T2-weighted MRI (Figure 3.13b). This was finally evaluated 
by in vitro MRI with a series of dilutions in a T2-weighted sequence (upper row 
of the Figure 3.13c). 
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Figure 3.13. a) Magnetisation curves at 298 K for 3.1 b) Plot of the T2 relaxation rate 
against iron concentration for BSA IONP (3.1); c) T2-weighted MRI phantoms for BSA 
IONP 3.1. 
Upconverting NP core. Upconverting nanophosphor cores display 
upconversion fluorescence upon 980 nm c.w. laser excitation. In our case the 
NaGdF4:Yb,Tm@NaGdF4 allows a strong upconversion at three distinct and 
simultaneous sharp emissions in uv (360 nm), visible blue (451 and 476 nm) 
and NIR (800 nm) as shown in Figure 3.14a.  
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Figure 3.14. a) Fluorescence emission spectrum for 3.2 after excitation with C.W. laser 
at 980 nm. Normalised UCL intensity. b) Plot of the T1 and T2 relaxation rate against 
Gd concentration for BSA UCNP (3.2); c) T1-weighted MRI phantoms for BSA UCNP 
3.2. 
As proof of concept of the cell labeling capabilities of the BSA UCNP, 
nanoparticles 3.2 were cultured for 24 h with HT1080 cells (expressing green 
fluorescent protein). Then the fluorescence of the internalised particles was 
studied using two-photon imaging (Figure 3.15). Images clearly show the 
signal from the nanoparticles, mainly surrounding their nucleus, when excited 
at 980 nm. Although the UCNP are mainly designed for optical imaging, here 
the presence of gadolinium in the core also confers paramagnetic properties 
and thus MRI contrast agent capability. The longitudinal (r1) and transversal 
(r2) relaxivity values of 3.2 were measured (r1 = 0.8 s
-1
mM
-1
 and r2 = 2.5 s
-
1
mM
-1
) in Figure 3.14b. The relaxometric properties are modest since a 
compromise must be reached between relaxometric and optical properties, the 
better the fluorescence the lower the r1 value (due to size effects). These 
values show that UCNP based contrast agents can also be tuned for T1-
weighted MRI applications, as the results summarised in the bottom row of the 
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Figure 3.14c demonstrates. A positive contrast is observed upon increase in 
the nanoparticle concentration in comparison with water (encircled dark 
signal).  
 
Figure 3.15. Two-photon images of HT1080 cells labeled with nanoparticle 3.2. a) 
image corresponding to the signal only in the nanoparticles channel (BP460/60 nm 
filter); b) same cell with combined signal from the nanoparticle and cell 
autofluorescence (BP609/54 nm filter); c) and d) combined images (signal from 
nanoparticles + cell autofluorescence) for different cells. 
Contrast agent AuNP-based. The most prominent feature of Gold 
nanoparticles is their surface plasmon resonance due to the electromagnetic 
confinement, giving rise to their characteristic color variations with size. This 
has been extensively exploited, particularly for in vitro applications.
29
 The UV-
VIS absorbance spectrum of the BSA AuNP (3.3) presented in Figure 3.16 
confirms, as proof of concept of the suitability of the BSA AuNP series for 
these applications. The spectrum shows the typical broad absorbance band 
for albumin around 250 nm and the one typical of gold nanoparticles of this 
size at about 590 nm.
29
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Figure 3.16. UV-VIS absorbance spectrum of BSA AuNP (3.3). 
Characterisation of the functionalities provided by the BSA modules of the 
contrast agents. The fluorescence and PET imaging properties provided by 
the different modified BSA modules were characterised.  
Alexa Fluor© 647 conjugated BSA(3.4, 3.5, 3.10, and 3.12). The 
(Alexa647)
BSA 
module was added at maximum 6 % weight of the total BSA weight used. The 
presence of the dye, in nanoparticles 3.4 and 3.5, was checked by aborbance 
spectra (Figure 3.17a) and by Fluorescence Molecular Tomography using 
several phantoms of varying concentration for nanoparticles (Figure 3.17b). 
DOTA conjugated BSA (3.6, 3.7, 3.8 and 3.10) and DFO conjugated BSA 
(3.11, 3.12, and 3.13). To obtain nanoparticles ready for PET imaging, 
radiometals and chelators are commonly incorporated in the coating.
30
 We 
have demonstrated the benefit of our proposal using a short half-life isotope 
obtained from a generator (
68
Ga, t1/2= 68 min) and a long half-life isotope 
delivered from a cyclotron (
89
Zr, t1/2= 78.4 hrs). In the case of 
68
Ga, DOTA is 
the most often used chelator.
31
 NHS-activated DOTA was covalently attached 
to BSA to obtain 
(DOTA)
BSA module, fractions of which, were added at different 
proportion into the nanoemulsion formulation for synthesis of 3.6, 3.7 and 3.8 
(Table 3.2). These particles were then labeled with 
68
GaCl3 eluted from a 
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68
Ge/
68
Ga generator. In all the cases, radiolabeling yield was up to 20% 
(Figure 3.17c), calculated after subtraction of the nonspecific 
68
Ga
 
chelation by 
the native BSA coating.  
 
 
 
 
 
 
 
Figure 3.17. a) Absorbance spectra of 
(Alexa647)
BSA, BSA IONP (3.1), 
(Alexa647)
BSA IONP 
(3.4) and 
(Mal)(Alexa647)(DOTA)
BSA IONP (3.10) b) In vitro fluorescence imaging of 
nanoparticles 
(Alexa647)
BSA IONP (3.4) and 
(Alexa647)
BSA AuNP (3.5) c) In vitro PET 
imaging of nanoparticles 
(DOTA)
BSA UCNP (3.7, 0.5 mM, upper row), 
(DOTA)
BSA IONP 
(3.6, 0.5 mM, middle row) and 
(DOTA)
BSA AuNP (3.8, 0.25 mM, bottom row), 
percentages indicate radiolabeling efficiency. 
In vitro PET imaging of phantoms for nanoparticles 3.6, 3.7 and 3.8 
were carried out showing a strong signal over the range of concentrations 
(Figure 3.17c). The intensity for nanoparticles 3.8 is clearly lower due to two 
factors; a smaller amount of 
(DOTA)
BSA module on the surface and also a 
smaller AuNP concentration (0.25 mM of Au for 3.8 in comparison to 0.5 mM 
of Fe for 3.6 and Gd for 3.7). In the case of 
89
Zr, a common chelating agent is 
DFO.
32
 A previously prepared module of BSA covalently attached to DFO 
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groups was incorporated in 3.11 and 3.12 coating and radiolabeling yield of 
the probe obtained was up to 14 %. All these radiolabeling yields are 
particularly high if we consider that the amount of 
(chelators)
BSA is no higher than 
8% in case of 
68
Ga and 20 % for 
89
Zr and that from that percentage, only a 
fraction of chelators would be available for coordination with the radioisotope.  
Maleimide conjugated BSA and biofunctionalisation (3.9, 3.10, 3.11 and 3.12). 
Maleimide is often used to attach biomolecules in a specific manner, through 
click chemistry with thiol groups.
5,33
 In the synthesis of 3.9, 3.10, 3.11 and 3.12 
a fraction of commercial 
(maleimide)
BSA module (10-20 maleimide per BSA) was 
incorporated. Presence of BSA bearing maleimide module in the coating of 
these NP was verified by FTIR with a characteristic band from the maleimide 
at 1130 cm
-1
, the example for 3.9 is shown in Figure 3.18. This module adds 
to the platform the possibility of an easy functionalisation with thiol bearing 
targeting molecule. This was further verified by the conjugation of a thiol 
derived cyclic RGD peptide on the coating of 3.11.  
 
Figure 3.18. FTIR spectra for selected BSA module and BSA NP 3.9. 
Evaluation of cytotoxic effects and biodistribution. Cytotoxicity studies were 
carried out for each type of inorganic core with a full natural BSA coating (3.1, 
3.2 and 3.3). Cytotoxicity was evaluated after incubation of each agent at 
different doses with C57BL/6 mouse adult fibroblasts (MAFs) over 72 h. As 
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displayed in Figure 3.19, in the cell viability assay we did not observe any toxic 
effect for 3.1 and 3.3, only for 3.2, when a slightly more pronounced effect is 
observed at the higher dose.  
Figure 3.19. Cell viability study of MEFs incubated with nanoparticles 3.1, 3.2 and 3.3 
at different concentration (between 5 to 50 µg.ml
-1
 of Fe
3+
, Gd
3+
 or Au
3+
). 
An additional experiment studied the internalisation of 3.4 in the MEFs 
at 40 µg·mL
-1
 over 24 h by fluorescent cytometry analysis. The presence of 
AlexaFluor® 647 conjugated BSA fraction in the coating of 3.4, enhanced the 
sensitivity for detection and thus the possibility of observing the cellular 
internalisation of the nanoparticle by flow cytometry (Figure 3.20a). Cell 
fluorescence and SSC (side-scattered light-related to cell internal complexity) 
increased in the cells treated and confirmed a high uptake of the NP (Figure 
3.20b).
37
 The strain caused on MAFs by such high internalisation can explain 
the small cytotoxic effect observed at the highest doses. Gold and gadolinium 
inorganic cores have been described as less biocompatible than iron oxide,
2,35
 
also explaining the higher apoptotic occurrence found for 3.2. As expected, 
due to the presence of BSA in the coating, the BSA NP show a very low in 
vitro toxicity. 
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Figure 3.20. a) Cell labeling with nanoparticle 3.4 (24 h) confirmed by flow cytometry 
and c) side-scattered light (SSC-H) of control cells and cells labeled with 3.4 (24 h). 
The biodistribution of BSA nanoparticles was studied by fluorescence, 
using also nanoparticle 3.4 in mice (N=3). After 24 h, mice were sacrificed and 
after saline perfusion, the main organs were extracted. Ex vivo fluorescence 
showed in Figure 3.21a, as expected, revealed a large proportion of 3.4 in the 
liver and in spleen.  
 
 
 
 
 
 
Figure 3.21. Biodistribution of nanoparticles 3.4 after 24h. a) Ex vivo fluorescence of 
different organs and b) histology of liver, spleen and kidneys (40x) with Prussian Blue 
staining. 
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Substantial accumulation of the probe was also observed in other 
organ of the RES system (kidney) and interestingly, a fraction also appears to 
target the brain. The results were confirmed by microscopy of histological 
organs sections stained with Prussian blue for iron detection (Figure 3.21b). 
2.4 In vivo targeted multimodal imaging of tumour in mice with 
selected BSA NP contrast agent 
Due to the excellent colloidal stability and in vitro MRI/PET/OI contrast 
properties, we finally examined the multimodal imaging performance of one of 
the probes from the library for in vivo biomedical application. One advantage 
of the modular approach is the ease of further tailoring for biofunctionalisation; 
for instance the addition of a targeting ligand. Arginine-glycine-aspartic acid 
peptide (RGD) binds to the ανβ3 and ανβ5 integrins that are overexpressed in 
nascent endothelial cells during angiogenesis in various tumours, and yet not 
in inactive endothelial cells.
40
 This property has been many times used for 
successful tumour and angiogenesis detection, with a wide range of probes 
from small chelators, polymeric nanoparticles, iron oxide nanoparticles, or 
quantum dots.
41
 Thus, taking advantage of the presence of maleimide-BSA 
module in the coating of 3.11, RGD modified with a thiol functionality was 
covalently linked to the protein via a covalent thioether linkage with maleimide 
group.
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(DFO)(RGD)
BSA IONP (3.13) was labeled with 
89
Zr and intravenously 
injected in tumour-bearing mice for PET/CT imaging and MRI. One hour after 
the injection high accumulation was found in the liver and spleen, as usual 
with imaging probes. It is also clear that a large fraction of the probe remained 
in systemic circulation. After 24 h, accumulation in tumour was observed with 
persistent and intense signal until 72 h, clearly delimiting the affected area 
(Figure 3.22a). For T2-weighted MRI basal image and 24 h post injection are 
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shown (Figure 3.22b). A loss of MRI signal intensity is clearly seen, especially 
delimiting the tumour.  
 
Figure 3.22. a) PET imaging of 
(89Zr)(RGD)
BSA IONP (3.13) at different time points 
postinjection in mouse bearing allograft tumour. b) Axial T2 weighted MRI located at the 
tumour before and 24 h postinjection. 
The quantification in both types of images (PET and MRI) provides 
similar results. The tumour to muscle relative signal intensity in MRI clearly 
decays 24 hours post-injection in a similar way in which the SUVmean (the 
decay corrected radioactive signal intensity from PET images) increases, in 
both cases as the 
(89Zr)-(RGD)
BSA IONP (3.13) accumulates in the tumour 
(Figure 3.23). 
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Figure 3.23. Standardised uptake value (SUV) of tumour (blue) and relative MRI mean 
intensities at different days post injection (to the intensity in a ROI located in the leg 
muscles, in red).  
Ex vivo radioactive signal of main organs was measured; Figure 3.24a shows 
the % of injected dose as function of the tissue weight for different organs. 
High signal in liver and spleen is observed, like we saw in the images, as well 
as in the tumour. Finally, bright field microscopy of different sections of the 
tumour harvested 72 h after i.v. injection revealed numerous Prussian blue 
stained areas (Figure 3.24b). It allowed investigating the localisation of 3.13 in 
the tumour. Distribution was heterogeneous (as already suggested by the PET 
and MRI) with a high uptake in the periphery, in accordance with the ensured 
RGD peptide targeting directed to the nascent endothelial cells. 
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Figure 3.24. a) Activity measured in a gamma counter of specific organs (72 h 
postinjection). b) Tumour histology slides, stained with Prussian blue after 72 h, 
showing blue dots due to the accumulation of iron oxide nanoparticles. 
3. Conclusions 
Here we present a new approach for the modular multifunctionalisation of 
different hydrophobic nanoparticles. This takes advantage of the parallel 
synthesis concept, rather than the traditional sequential process used in 
nanoparticles chemistry. In a single and rapid step, NP are conjugated with 
native/modified BSA to prepare “ready to use” multifunctional nanoparticles. 
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Using this modular albumin based platform, we have developed a wide library 
of contrast agents for cell labeling, drug delivery and non-invasive imaging. 
Because of the ease and versatility of the route, a large range of BSA modules 
and ligands can be conjugated to the surface; therefore it could convert in a 
routine methodology for preparation of a library of new molecular imaging 
agents. As an example, one of these candidates was selected and used for 
targeted PET/MRI multimodal in vivo imaging in a murine tumour model. 
Moreover, as a translational improvement in the field, the method presents 
notable advantages such as high reproducibility, facile scaling up production 
and the use of biocompatible albumin coating. Finally, since albumin plays a 
role as a drug carrier in the clinical setting, our findings can be simply 
extended to incorporate new theranostic functions due to the versatility and 
high binding capacity of this protein. This modular proposal is very helpful, 
since it simplifies complex tailored functionalisation and circumvents typical 
cumbersome problems associated to the reactions on the surface of the 
nanoparticles. 
4. Materials and Methods 
Materials  
All chemicals for the preparation of the BSA NP were purchased from Sigma-Aldrich 
Co. (St. Louis, USA) except Alexa Fluor® 647 conjugated BSA purchase with life 
technologies 
TM
. All reagents were of analytical grade except oleic acid and oleylamine 
of technical grade. They were used without any further purification.  
Animals and ethics 
All animal experiments conducted in this work were approved by the ethics and animal 
welfare committee at CNIC and were developed according to the Spanish and UE 
legislation. 
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Synthesis 
Synthesis of OA IONP, OA UCNP and OM AuNP 
These protocols are described in the chapter “General Materials and Methods”. 
Synthesis of BSA NP. Bovine serum Albumin (BSA) and fraction of modified BSA 
(Alexa Fluor® 647 conjugated BSA, DOTA conjugated BSA, DFO conjugated BSA or 
Maleimide conjugated BSA) -total BSA weight 30 mg- were first dispersed in 10 mL of 
phosphate buffer (pH=7.2, 5 mM). Then 0.75 mL of hydrophobic NP (OA IONP, OA 
UCNP or OM  AuNP) in n-hexane (5-10 mg·mL
-1
 of the metal core Fe, Gd or Au) was 
added to the solution and the resultant mixture was sonicated (Branson 250, 42 +/- 6 
KHz) under robust stirring for 20 min at 37ºC. Oil in water (o/w) nanoemulsion was 
further kept under sonication for 30 min to evaporate all traces of n-hexane resulting in 
the formation of a homogenous BSA NP colloidal aqueous solution. Aggregates were 
removed by filtration (0.45 and 0.22 µm filter unit, Sterivex-GP) and excess of BSA 
discarded by ultrafiltration with Amicon®Ultra-15 mL 100K, Merck Millipore Ltd. 
(X5000g, 10 min, 2 cycles) to obtain the purified hydrophilic BSA NP. 
Preparation of the modified BSA modules. For preparation of DOTA 
68
Ga chelator 
conjugated BSA, 5 mg of BSA were dissolved in 2 mL HEPES Buffer (1mM, pH=7.7). 
Then, 1.5 mg of DOTA-NHS dissolved in 0.5 mL of same buffer was added and the 
reaction was kept under stirring at room temperature for 2 h. After this time, excess of 
DOTA-NHS was removed by gel filtration with a PD-10 column (GE Healthcare) and 
DOTA conjugated BSA dissolved in 3 mL of PBS 1X. 
For preparation of DFO 
89
Zr chelator conjugated BSA, 5 mg of BSA were dissolved in 1 
mL of water and the pH adjusted to 8.9-9.1 with 0.1 M Na2CO3. To this solution, 22.5 µl 
of 10 mM SCN-Bz-Df in DMSO was added. Then, the mixture was incubated at 37ºC 
for 60 min in thermomixer. Finally, the mixture was purified by ultrafiltration with a 30 
kDa cutoff (Amicon®Ultra, Merck Millipore Ltd.) and DFO conjugated BSA 
resuspended in 1 mL of water.  
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Imaging properties of the BSA NP 
Imaging properties of the inorganic cores of the BSA NP contrast agents. Magnetic 
characterisation of OA IONP and BSA IONP (3.1) were carried out in a vibrating 
sample magnetometer using 100 µL of solution in a special sample holder. 
Magnetisation curves were recorded at room temperature by first saturating the sample 
in a field of 1 T. The magnetisation values were normalised to the amount of iron to 
yield the specific magnetisation (emu/g Fe). The initial susceptibility of the suspensions 
was measured in the field range ±100 Oe, and the saturation magnetisation values 
(Ms) were evaluated by extrapolating to infinite field the experimental results obtained 
in the high field range where the magnetisation linearly increases with 1/H. For 
determination of the NMR relaxometric values of based IONP and based UCNP BSA 
NP, the T2 and T1 relaxation times were measured at 37ºC in a Bruker MQ60 (Bruker 
Optics, Germany) with a T2 Carr-Purcell-Meiboom-Gill spin echo sequence and with a 
standard inversion recovery pulse sequence for measuring T1 . The relaxation rate Ri 
values (1/Ti, s
-1
,i = 1, 2), obtained from the measured relaxation times (Ti, s) were 
corrected by subtracting the water relaxation rate in the absence of the contrast agent. 
Linear fitting of the data gives straight lines whose slopes are the relaxivities (ri, s
-1
 mM
-
1
) related to the iron concentration (mM): Ri = ri0 + ri [Fe]. 
The optical measurements of OA UCNP and BSA UCNP (3.2) solutions in standard 
cuvettes were performed using a JENOPTIK laser diode source at 980 nm with 
different excitation powers. The VIS/NIR luminescence was dispersed by using an 
ARC Spectrapro 500-I monochromator and then detected with a photomultiplier tube 
with a 1 nm resolution. 
UV-Vis absorbance spectra of OM  AuNP and BSA AuNP (3.3) were performed in 
standard cuvettes using a UV-Vis spectrophotometer DUº 730 Beckman Coulter with a 
1 nm resolution from 190 to 1000 nm.  
Imaging properties of the modified BSA modules of the BSA NP contrast agents. UV-
Vis absorbance spectra of BSA NP with Alexa Fluor® 647 conjugated BSA in the 
coating were performed in standard cuvettes using a UV-Vis spectrophotometer DUº 
730 Beckman Coulter with a 1 nm resolution from 190 to 1000 nm. 
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68
Ga (t½= 68 min, β
+
= 89% and EC = 11%) was available from a 
68
Ge/
68
Ga generator 
system (ITG Isotope Technologies Garching GmbH, Germany) in which 
68
Ge (T½= 270 
d) was attached to a column based on organic matrix generator. The 
68
Ga was eluted 
with 5 mL of 0.05 M hydrochloric acid. Then HEPES (0.048 g, 0.20 mmol) was 
dissolved with 1mL of the 
68
Ga acidic eluate in a 2 mL Eppendorf. The pH was 
adjusted to 4.6-5 if necessary by minor addition of 2 M NaOH aqueous solution. 
Thereafter, 500 µl of an aqueous solution of a NP with DOTA conjugated BSA (3.6, 
3.7, 3.8) in the coating was added and the chelation was conducted at 37ºC during 30 
min. For purification from the unlabeled 
68
Ga, the reaction mixture was centrifuged 
using Amicon®Ultra-0.5 mL (Ultracel®-100K, Merck Millipore Ltd.). Total activity of the 
0.5 mL BSA NP solution obtained was finally measured with ATOMLAB
TM
 500 BIODEX 
activimeter. 
200 µl of 
89
Zr-oxalate (in 1 M oxalic) acid provided by Perkin Elmer was mixed with 90 
µl of 2 M Na2CO3 in a 2 mL Eppendorf tube and the solution incubated for 3 minutes at 
room temperature. It was then introduced successively: 0.30 mL 0.5 M HEPES (pH = 
7.2), 0.71 mL of DFO conjugated BSA IONP (3.11, 3.13) and 0.70 mL 0.5 M HEPES 
(pH = 7.2) and the resultant mixture was incubated under gently shaking for 1 h at RT. 
Solution was purified by elution on a PD-10 column (GE Healthcare) with a 0.9% 
NaCl/gentisic acid 5 mg·mL
-1
 (pH = 4.9-5.3) buffer and unlabeled 
89
Zr were finally 
discard using Amicon®Ultra-0.5 mL (Ultracel®-100K, Merck Millipore Ltd.) ultrafiltration 
to get the purified 
89
Zr radiolabeled DFO conjugated BSA. Total activity of the 0.5 mL 
solution obtained of 3.11 and 3.13 were finally measured with ATOMLAB
TM
 500 
BIODEX activimeter. 
Culture and Two-photon imaging of labeled HT1080 cells. HT1080 cells (CCL-121 from 
American Type Culture Collection number, ATCC, Rockville, MD ) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco Laboratories, Grand Island, NY, 
USA)  supplemented with 10% FCS, 100 U/mL penicillin/streptomycin, and 2 mmol/L 
glutamine. These cells were transduced with a lentiviral vector expressing the JRed 
fluorescent protein (Evrogen Joint Stock Company, Moscow, Russia) at an MOI of 5 as 
previously described (Mol Ther. 2007 Aug;15(8):1487-94). After 7 days of transduction 
6x10
5
 HT1080–Red cells were plated in p35 glass plates (MatTek, Ashland, MA, USA). 
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The cells were incubated with 400ug/ml BSA UCNP diluted in culture medium during 
24 hours. After incubation the cells were washed three times with PBS (Gibco) and 
fixed with PFA (paraformaldehyde) 4% during 30 minutes at room temperature; then 
washed again with PBS and maintained covered with PBA (PBS + 0.1% BSA + 0.02% 
NaN3) at 4ºC until imaging was performed. 
Fluorescence images were collected in raster scan mode using a 2-channels ALBA 
spectrophotometer (ISS iNC., Urbana-Champain, IL, USA) equipped with H7422 fast 
photomultipliers (Hamamatsu Photonics, K.K., Hamamatsi City, Japan). The ALBA 
module was coupled to an inverted Nikon Ti-E microscope (Nikon Corp., Tokyo, 
Japan), endowed with a Nikon, MRD07600, CFI 60x1.2 WI Plan Apochromatic 
objective, epifluorescence lamp, bright field and top stage incubator and heating 
chamber (Okolab, S.r.l., Napoli, Italy). Excitation at 980 nm was provided by a 
femtosecond-pulsed mode-locked tunable MaiTai DeepSee laser (Newport Corp., 
Irvine, CA, USA). After a blocking FF01-680/SP filter, emission was collected, using a 
blocking FF01-680/SP filter, in channel 1 after a BP460/60 filter and in channel 2 after 
a BP609/54 filter. Filters were from Semrock Inc., IDEX Corporation Lake Forest, IL, 
USA). The laser power at the objective was 10 mW. A series of 20-100 consecutive 
images of 256x256 pixels, collected at the rate of 64 us/pixels, were averaged. 
Cytotoxicity effects of BSA coated IONP, UCNP, AuNP (3.1, 3.2 and 3.3) 
Cell lines and media. C57BL/6 mouse adult fibroblasts (MAFs) were grown in DMEM 
(Dulbecco’s Modified Eagle Medium) supplemented with 1% penicillin-streptomycin 
and 1 mM sodium pyruvate in a humidified atmosphere of 5% CO2 at 37ºC. Cytotoxicity 
and nanoparticle uptake were assessed in MAFs exposed at different concentrations 
(BSA IONP (3.1) 5, 20 and 40 µg·mL
-1
; BSA UCNP (3.2) 5,10 and 50 µg·mL
-1
; BSA 
AuNP (3.3) 5 and 20 µg·mL
-1
) and times of incubation (24h, 48h and 72h). Control cells 
were treated with vehicle (water). After culturing for 24h, 48h and 72 h, the cells were 
trypsinised and cell proliferation was assessed using the Neubauer counting-chamber 
under optical microscope. 
Cytotoxicity assays. In the presence of Ca
2+
, Annexin V binds to phosphatidylserine 
residues exposed on the outer surface of the plasma membrane of apoptotic cells. 
153 
 
1x10
6
 cells were collected in 500 µl PBS, washed before they were pelleted and 
resuspended in 195 µL binding buffer (10mM HEPES/NaOH, pH 7.4; 140 mM NaCl; 
2.5 mM CaCl2). Then APC-Annexin V (BD PharmingenTM) was added (5 µl) and cells 
were incubated for 15 minutes at room temperature in the dark. Cell viability is 
determined using DNA binding dyes and DAPI was added until a final concentration of 
0.001% (w/v). Cells were finally analysed by flow-cytometry using the BD 
FACSCanto™ II system. All experiments were performed in triplicate. As a result, 
viable cells are negative for both APC Annexin V and DAPI; early apoptotic cells are 
APC Annexin V positive and DAPI negative; and late apoptotic and dead cells are both 
APC Annexin V and DAPI positive. Cytotoxicity was estimated by comparison between 
the proportions of viable cells in populations exposed to the BSA NP with the ones in 
control cells. 
Flow Cytometry Assay for determination of the BSA NP uptake by MAFs cells. 
Approximately 1x10
6
 control and treated cells with 
alexa647
BSA IONP, (3.4) (40 µg·mL
-1
) 
were collected after 24 h of incubation. Cells were trypsinised and measured in PBS. 
Because of the fraction of Alexa Fluor® 647 conjugated BSA module in the 3.4 coating, 
APC channel was used for detection. A total of 10,000 events were recorded for each 
sample using the BD FACSCanto™ II system. Samples were analysed with the BD 
FACSDiva
TM 
Software and averages of the medians were determined. Histograms 
were realised using FlowJo Software. In addition to cell fluorescence, different cell 
populations in a flow cytometer can be distinguished by the forward-scattered light 
(FSC), side-scattered light (SCC) related respectively to cell size and cell internal 
complexity. 
Biodistribution in mice of 
(alexa647)
BSA IONP, (3.4) 
3.4 (100 µl, 0.5 mg·mL
-1
 [Fe]) were i.v. administrated in mice (N=2) that were sacrificed 
after 24 h. After perfusion, the main organs (brain, heart, lungs, liver, spleen, and 
kidney) were extracted and ex vivo fluorescence was performed with IVIS Imaging 
System 200 series (Xenogen®) (acquisition parameters: Cy5.5 ex/em filter, high level, 
BIN-HR, FOV 13.3, f2, 4s). Sections of tissues of the organs were then taken off and 
stained with Perls’ Prussian blue to detect iron oxide cores. Briefly, slides were stained 
with 1% aqueous potassium ferrocyanide in 2% solution of HCl for 30 min and 
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counterstained with nuclear fast red. Microscopy was performed with a Nikon 90i for 
pictures in bright field with 10X and 40X objectives. 
In vivo targeted multimodal bioimaging of tumour in mice with the selected 
contrast agent (3.13) 
Procedure for RGD functionalisation was adapted from a previously described 
method
43
. The peptide cyclo [Arg-Gly-Asp-D-Phe-Lys(Ac-SCH2CO)], RGDpep was 
purchased from Peptide International. Basically, to a 1 mL solution of 3.11 ([Fe]= 1 
mg·mL
-1
) in PBS, 40µl of RGDpep (10 mg·mL
-1
 in an acetonitrile-water mixture 1:4) 
was added dropwise. After addition of 120 µl of a freshly prepared solution of 1 M 
hydroxylamine, the mixture was allowed to react 24h at room temperature. Remaining 
maleimide groups were quenched with cysteine (20 µl of a 5 mg·mL
-1
 solution) after 
which the mixture was reacted for an extra hour. Reaction mixture was first purified by 
steric exclusion chromatography on a PD-10 column (GE Healthcare) to discard the 
side products from the RGD activated BSA coated IONP (3.13). Remaining unreacted 
reagents were removed by ultrafiltration with Amicon®Ultra-0.5 mL (Ultracel®-100K, 
Merck Millipore Ltd.) and the probe finally redispersed in 0.5mL of PBS before in vivo 
experiments. 
Tumour allografts. We have used a murine breast adenocarcinoma cell line (EO771) 
cultured in DMEM+ 10% Newborn calf serum (Gibco, Life Technologies).Female 
C57BL6 mice, 8 weeks old, were bred and housed under pathogen-free conditions in 
our animal facilities at CNIC. Prior to injection, tumour cells were trypsin detached, 
washed twice, and resuspended in PBS to a final concentration of 10
6
 cells/13 μL. The 
cell suspension was then mixed with 5-μL growth factor–reduced Matrigel (BD Biocoat) 
and 2-μL trypan blue solution (Sigma Aldrich) and maintained on ice until injection. 
Mice were anesthetised with 5% Isofluorane (Abbott), laid on their backs, and injected 
with 20-μL cell suspension in Matrigel directly in the fourth mammary fad pad through 
the nipple with a Hamilton syringe.  Tumour growth was monitored weekly using digital 
callipers, and tumour volume was calculated according to the formula: L × W2/2 = 
mm
3
. Imaging studies were performed after 5 weeks after implant when tumours 
reached. 
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PET imaging. In vivo PET/CT Imaging in mice was performed with a nanoPET/CT 
small-animal imaging system (Mediso Medical Imaging Systems, Budapest, Hungary). 
List-mode PET data acquisition commenced 1 h, 24 h, 48 h and 72 h after bolus 
injection of 1 mCi of 
89
Zr labeled 3.13 through the tail vein of CD45 8 weeks female 
mice and additional acquisitions were recorded each 24h for 3 days. Acquisition and 
reconstruction were performed with proprietary Nucline software (Mediso, Budapest, 
Hungary). At the end of PET, microCT was performed for attenuation correction and 
anatomic reference. The PET images in a 105x105 matrix (frame rates: 3 x 10 min, 1 x 
30 min, 1 x 60 min) were reconstructed using a Tera-Tomo 3D iterative algorithm. 
Qualitative Image analysis in mice was performed using Osirix software (Pixmeo, 
Switzerland).  
MRI acquisition. In vivo MRI in mice was performed with an Agilent/Varian scanner 
(Agilent, Santa Clara, USA) equipped with a DD2 console and an active-shielded 
205/120 gradient insert coil with 130 mT/m maximum gradient strength and a 
combination of volume coil/two channel phased-array (Rapid Biomedical GmbH, 
Rimpar, Germany). CD45 eight weeks old female mice were anesthetised with 2% 
isoflurane (Abbott) and oxygen and positioned on a thermoregulated (38.7ºC) mouse 
bed and the respiratory cycle was monitored constantly. Ophthalmic gel was placed in 
their eyes to prevent retinal drying. Baseline images were acquired before i.v.a of 3.13 
([Fe]=1 mg per kg body weight). MR images of xenograft tumours were acquired at 24 
h intervals from injection up to 3 days. For each animal, eight consecutive axial 1 mm 
thick slices were acquired to image the liver. Images were acquired in free-breathing 
animals, using a gradient echo sequence with 4 ms/40 ms echo/repetition times, BW of 
100 kHz, FOV of 6 cm x 6 cm, for a total acquisition time of about 80 seconds; the flip 
angle (FA) was fixed at 20 degrees. 
Histological analysis. After last images (72 hours post i.v.a), tumours were extracted 
and fixed in 4% paraformaldehyde before being embedded in paraffin blocks. Sections 
were deparaffinised and rehydrate before staining with Perls’ Prussian blue to detect 
iron oxide cores. 
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Abstract 
 
Glycosides comprising hydrophilic sugar moiety conjugated to oleyl 
hydrophobic chains have promising antimitotic activity on cancer cell cultures 
but limited in vivo perspectives because of their low solubility in physiological 
media and rapid enzymatic degradation. Thermal degradation method yields 
high quality oleic acid coated iron oxide nanoparticles (OA IONP) with 
exceptional physicochemical properties of the core but dispersible only in 
organic solvents. We report here the synthesis of micelles formed by the OA 
IONP encapsulated within a hydrophilic layer of the amphiphilic glycosides. 
These nanomicelles were fully characterised especially their suitability as in 
vivo MRI contrast agents and for its in vitro antimitotic activity on cell cultures 
from rat glioma and from human lung carcinoma and compared with the 
activity of the corresponding free glycosides. The results show that the 
formulation of glycosides in the form of OA IONP encapsulated micelles have 
preserved antitumoural effects and in one case provides a significant 
therapeutic gain. Moreover, the micelles present excellent relaxometric 
properties for their use as contrast agent based T2 MRI. Ours findings suggest 
that synergetic bioactive hydrophilic nanostructures can be obtained to 
generate theranostic agents, from two entities previously not suitable for in 
vivo applications and strengthen the possibility to use biomolecules at the 
same time as coating for OA IONP micellar stabilisation and as drugs for 
therapy. 
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1. Introduction 
The most important application of nanotechnology in biomedicine is 
mainly confined to the field of oncology.
1
 Indeed, the singular structural 
properties of NP enable the design of easy tailoring drug delivery platform 
which answer the main challenges of chemotherapeutically-based cancer 
treatments, especially adding the specificity of a drug against tumour and not 
perturbing healthy cells and tissues.
2,3
 Nanotechnology provides targeting 
possibilities either by passive accumulation of the NP inside tumours as a 
result of the enhanced permeability and retention effect (EPR) (Figure 4.1) or 
actively by ligand attachment to the NP.
4–6
 This leads in many occasions to an 
improved pharmacokinetic, a local delivery in optimal dose ranges, the ability 
to overcome biological barriers as well as a reduced toxicity or minimum side 
effects by controlled release of the toxic drug.
7,8
 In the large family of 
nanomaterials, drug delivery using superparamagnetic iron oxide 
nanoparticles (IONP) is particularly interesting for the opportunity to target 
drugs to the pathological area by the application of a magnetic field, which can 
be externally applied, internally implanted or even spatially directed.
9,10
 
Furthermore, IONP are at the same time very good contrast agents for MRI, 
giving theranostic capabilities to the agent.
11,12
 Several studies of magnetic 
drug targeting in small animal models and clinical trials have already reported 
successful partial remission of the tumour.
13,14
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Figure 4.1. Scheme of the EPR effect. 
A family of synthetic glycosides has been recently proposed as 
inhibitors of glioma and adenocarcinoma cell proliferation.
15
 The molecules are 
derivatives of N-acyl-glucosamine and previous results indicate that the 
activity is increased if a long hydrocarbon chain is present at position C-1 of 
the glycoside scaffold. Other groups have shown that the conjugation of a 
sugar with an oleyl chain is beneficial for the antitumoural action.
16
 The 
proposed mechanism of growth inhibition suggest an alteration in the lipid 
metabolism; important changes of levels of glycosphingolipid and 
ganglioside
17,18
, two intermediates which have regulatory roles in tumour 
progression and are involved in pathways of cell death and proliferation.
19–21
 
However, in vivo preliminary experiments with the best candidates offered 
modest results.
22
 Because of their long alkyl chain, the compounds show low 
or no solubility in aqueous physiological medium and were also subjected to 
enzymatic degradation with reduced biological stability.
23
 Consequently, it was 
only possible to use intratumoural administration of drug dispersed in a 
DMSO/H2O mixture with BSA as carrier and only a single enzymatic resistant 
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thioglycoside derivative led to significant tumour growth inhibition at high 
repetitive doses.
22,24
 Regarding all these considerations, IONP based drug 
delivery system appears promising for stabilisation and targeting of the 
bioactive glycosides to the tumour site for improved activity or therapy. In this 
case the IONP, contrary to the other chapters, are used as a drug-delivery 
platform and the study of their imaging properties will be limited.  
In the different approaches of IONP drug delivery system described 
before, the therapeutic agents were covalently attached or electrostatically 
adsorbed onto the IONP coating/surface, dispersed into a polymer matrix, or 
encapsulated in amphiphilic nanostructures.
5,25
 All these approaches require a 
pre-existing hydrophilic coating with functional groups on the IONP platform. 
For this, the coprecipitation method which yields aqueous IONP is still 
preferred in the bibliography for its easiness and possibilities of further surface 
tailoring although the NP are of low quality (see the Introduction, Section 2.3). 
Moreover, additional steps are then required for the integration of the drugs.
26
 
Thermal degradation method is known to provide the best solution in terms of 
physicochemical properties (size, size dispersion, crystallinity, reproducibility) 
of the IONP but as we have already shown, thermal decomposition yields 
IONP only stable in organic solvent and thus requires an additional step for 
aqueous stabilisation of the NP before any integration of drugs.
27
 A general 
solution along this thesis is the stabilisation within a micelle, formed with 
amphiphilic polymers or molecules and the hydrophobic surfactant of the NP.
28
 
In this chapter, we address the possibility of directly stabilising OA IONP 
prepared by thermal degradation through micellisation with the bioactive 
glycosides, similarly to what we have done previously with PC.
29
 This unusual 
configuration where the therapeutic agent also acts as the micellar coating 
requires strong verification on the viability of the drug delivery system. First, 
one must test if the bioactive coatings satisfy the requirements of hydrophilic 
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matrix for in vivo use of the probes (improved colloidal stability to the NP, 
enhanced protection from opsonisation and biocompatibility, suitable 
relaxometric properties). Then it is crucial to check if the antitumoural activity 
is preserved in such micellar formulation of the therapeutic compounds.  
2. Results 
2.1 Synthesis of the glycoside IONP micelles 
Oleic acid coated Fe3O4 nanoparticles (OA IONP) were prepared by 
thermal degradation of iron organic precursors at high temperature blended 
with the OA surfactant.  
 
Figure 4.2. Scheme of the synthesis of the glycosides coated IONP micelles. 
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Characterisation and protocol are detailed respectively in Chapter 1, 
Section 2.1 and chapter General Materials and Methods. As we showed OA 
IONP colloidal solution was stable and monodispersed with a polydispersity 
index of 0.25 for a mean hydrodynamic size of 10 ± 3 nm in hexane. Iron oxide 
cores were spherical with a diameter of 7 ± 2 nm determined by TEM (Figure 
4.2a).Fernández-Mayoralas et al. described a family of synthetic glycoside 
derivatives as inhibitors of glioma and adenocarcinoma growth, of which we 
selected three compounds for the preparation of OA IONP encapsulated 
antitumoural micelles (Figure 4.2b). Main characteristic of GC22 (4.1), IG20 
(4.2), TFA-GC22 (4.3) and their antimitotic activities against C6 (glioma rats) 
and A549 (adenocarcinoma lung human) are described in Table 4.1.
15
 The 
corresponding OA IONP encapsulated micelles are named (4.4), (4.5) and 
(4.6) for respectively GC22 coated IONP micelles, IG20 coated IONP micelles 
and TFA-GC22 coated IONP micelles. In all cases, the compounds 4.1, 4.2 
and 4.3 have an oleyl chain moeity in α anomeric configuration at position C-1 
of the glucosamine scaffold, described as optimal for improved antitumoural 
bioactivity (Figure 4.2b and Table 4.1).
22
 GC22 4.1 -taken as reference-, 
presented an ID 50 below the micromolar range for the two cell lines. 
Influence of a different amide group (R1) at position C-2 (trifluoroacetamide, 
4.3) and the change induced by attachment of a negative hydrophilic 
oxosulfonyl group at position C-6 (R2), 4.2 were studied. If trifluoroacetamide 
group did not seem to strongly affect the antimitotic activity, the presence of 
the oxosulfonyl has a deleterious effect on the bioactivity, ID 50 ten times 
higher, >100 µM. 
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Table 4.1. Main characteristic and antimitotic activities of the glycosides used for the 
preparation of the glycoside coated IONP micelles. 
Name of the 
compound 
Formula 
M.W. (g.mol
-1
) 
Solubility ID 50 (activity) 
A549 C6 
GC22, (4.1) 
 
C
26
H
49
NO
6
 
471.67 
MeOH, EtOH, 
isopropanol, 
DMSO dioxane, 
H
2
O mixture 
10 15.5±0.3 
IG-20, (4.2) 
 
C
26
H
48
KNO
9
S 
589.82 
 
Low H
2
O solubility 
 
97 >100 
TFA-GC22, (4.3) 
 
C
26
H
46
F
3
NO
6
 
525.3 
MeOH, EtOH, 
isopropanol, 
DMSO dioxane, 
H
2
O mixture 
8.6 14.2±0.3 
Deeper information about the effects of the substituted groups on the 
glucosamine backbone on the inhibition of cancerous cell lines can be found in 
a previously published report.
15
 Chemistry for the preparations of such 
derivatives is well-known in the field and synthetic procedures can be obtained 
in ours and others’ publications.
15,30,31
 In brief, 4.1 was obtained from a 
stereoselective glycosylation of oleyl alcohol on α-D-glucosaminyl chloride 
peracetate 4.7 using acid promotor SnCl4 followed by a deacetylation step. 
From 4.1, protection of C-3 and C-4 positions with butane-2,3-dione led to an 
acetal intermediate 4.8 which yielded 4.2 after sulfation and acid deprotection 
hydrolysis. For synthesis of 4.3, the 2-amino-2-deoxy-D-glucose precursor 4.4 
was used and subjected to N-(trifluoroacetyl)ation next oleyl glycosylation via 
H2SO4-silica catalysation (Figure 4.3). 
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Figure 4.3. Synthesis of the glycosides GC22 (4.1), IG20 (4.2), TFA-GC22 (4.3). 
The hydrophobic OA IONP were then encapsulated by means of a 
nanoemulsion method, similar to the one used for PC and BSA NP, within 
micelles made of the oleyl glycosides to get 4.4, 4.5 and 4.6 micelles. 
Basically in the process the oleyl moeity of the glycoside intercalate with the 
OA aliphatic chain of the magnetite NP through hydrophobic van der Waals 
interactions while the hydrophilic sugar part lines up around the outer surface 
providing the water stability as shown in scheme of Figure 4.2.
29
 The 
nanostructure was defined as codependent because just like the OA IONP, 
the glycosides -except 4.2- are not soluble in water and only the pairing of 
both led to final hydrophilic micelles. In this sense OA IONP act in the same 
time as additional probe and as promoter of micelle formation since free 
glycosides did not form spontaneous micelles.  
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2.2 Physicochemical characterisation of the glycoside IONP 
micelles  
Hydrodynamic sizes of the micelles were in the range of ~50 nm 
(Table 4.2) with pdi below 0.25, the standard to consider a mono-dispersed 
population. TEM pictures confirmed that the NP were well dispersed with no 
aggregation (Figure 4.4a). However micelles hydrodynamic size´s increase 
indicates probably the encapsulation of few OA IONP within a same micelle or 
a slight aggregation in solution of different micelles. Absolute values of zeta 
potential are in all cases upper than 25 mV at physiological pH (Table 4.2), a 
key indicator of the good stability of the micellar colloidal dispersions by 
electrostatic repulsion. Micelle 4.4 shows a ζ potential around -25mV 
attributable to the glucosamine layer. Thus, 4.5 had a higher negative ζ 
potential (- 50 mV) because of the additional presence of the negatively 
charged oxosulfonyl group on the glucosamine scaffold. Surprisingly 4.6 had a 
positive ζ which maybe explain by the de-acetylation and formation of a 
positive amine group at position C2. FTIR, and MS of 3.6 are presented in 
Figure 4.4b and 4.4c as additional data for the characterisation of the micelle 
coatings. FTIR of the micelles confirmed the presence of the sugar in the outer 
layer with characteristic vibrations of the oleyl glucosamide observed at 620 
cm
-1
, 2920 cm
-1
 and 1700 cm
-1
, in addition to the peaks characteristic of OA 
IONP (detailed in Chapter 1, Section 2.1). Formation of the amine derivative of 
4.3 in the coating of the 4.6 micelle was also confirmed. IR spectra showed a 
strong absorption band at 3400 cm
-1
 corresponding to primary amine vibration 
(ν C-NH2) and adduct in the MS spectra corresponding to the MW of the 
glucoasime de-acetylated.  
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Figure 4.4. a) TEM pictures and b) FTIR of the glycosides coated IONP micelles c) MS 
of the 4.6 IONP micelle. 
Magnetic properties of 4.4, 4.5 and 4.6 IONP micelles are important 
features for their applications as magnetic drug targeting platforms and MRI 
contrast agents. NMR relaxometric properties were investigated and the 
longitudinal (r1) and transverse (r2) relaxivities were calculated in water 
suspensions. They were nearly similar for each micelle with high r2 (from 180 
to 220 s
-1
mM
-1
) and small r1 (below 5 s
-1
mM
-1
); a ratio particularly appropriate 
for T2-weighted MRI based contrast agent (Table 4.2).
32
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Table 4.2. Main characteristic of the glycoside coated IONP micelles. 
Glycoside IONP 
micelles 
Size 
(nm) 
pdi Zeta 
potential 
(mV) 
[Fe] 
(mg/ml) 
Cº  
[glyco] 
(mg/ml) 
Relaxometric 
values 
(s
-1
.mM
-1
) 
4.4 40.5 0.24 -27 0.6 ≈ 2.5 r1 2.7/r2 140 
4.5 52.2 0.15 -42 1.1 3.1 r1 4.4/r2 195 
4.6 49.1 0.17 +53 0.3 ≈ 2.5 r1 3.6/r2 137 
In vivo behaviour of the IONP micelles. When NP are used as drug 
delivery system, it is important to study its in vivo biological fate. Indeed the 
physicochemical properties of the NP (charge, curvature, composition, size) 
regulate their interactions with biological systems and determine their systemic 
circulation, clearance, interaction with cells, internalisation or subcellular 
localisation.
33
 Especially in cancer therapy, long vascular circulation times 
favour passive tumour targeting of the probes via the EPR.
3
 So we wanted to 
check if the glycosidic surface modification of the micelles promotes protection 
from opsonisation therefore increasing their vascular circulation times after in 
vivo injection. We measured the clearance rate of 4.4 in rat liver, from the loss 
of the MRI signal in this organ. The negative signal enhancement in the liver 
was measured at different times after i.v.a. by averaging signal intensities from 
a selected region of interest (ROI) and normalising to the basal image (Figure 
4.5). We observed a signal decrease reaching a minimum 20 minutes after 
injection. This value is in the average range of the lifetimes reported in 
literature of similar size.
34
 Indeed, coatings for NP made of glycoside or in 
general, sugars are described in literature as favourable for long circulation 
time in blood.
34–36
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Figure 4.5. Negative signal enhancement for a set of ROI in rat liver after i.v.a. of 4.4 
([Fe]=1mg.ml
-1
; 100 ul). 
2.3 In vitro inhibition activities of the glycosides coated IONP 
micelles  
We assessed if the glycosides under the IONP encapsulated micellar 
formulation have preserved their antimitotic activity in rat glioma (C6) and 
human lung carcinoma (A549 cell cultures). 4.4, 4.5 and 4.6 were designed for 
a final amount of bioactive coating molecules from 2.5 to 5 mg.ml
-1
. To know 
the exact concentration of the glycosides in the colloidal dispersion, micelles 
were lyophilised and partitioned in a water/ethanol mixture under sonication. 
After centrifugation, the supernatant containing the free glycoside was 
quantified by HPLC.  
The cells were treated with dilutions of the micelle solution and cell 
growth was measured at 48 hours by MTT assays. Control NP were also used 
in the experiment. Inhibitory activities of the micelles on rat glioma and lung 
carcinoma cells with respect to the molar concentration of the glycosides are 
shown respectively in Figure 4.6 and 4.7. For lung carcinoma cells, biological 
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activity is also determined in the presence of a magnetic field in the bottom of 
each well of the plate. The results of the 50% inhibitory dose values (ID50) 
compared with the ID50 of the free glycosides are summarised in Table 4.3.  
 
 
 
 
 
 
 
 
F
Figure 4.6. Inhibitory activities of the free glycosides (4.1, 4.2 and 4.3) and the 
glycosides coated IONP micelles (4.4, 4.5 and 4.6) with respect to their molar 
concentration against rat glioma cells (C6) after 48 hours incubation. 
As it can be seen, all 4.4, 4.5 and 4.6 inhibit proliferation of the both cancer 
cell lines with ID50 in the micromolar range. In general, the 50% inhibitory 
drug concentrations were in the same range but consistently lower in all 
micellar preparations that the correspondent free glycoside used in the 
formulation; with exception for 4.5, which had higher inhibitory activity as free 
molecule. In all the cases, these antitumoural effects were higher for the C6 
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cell line than the lung carcinoma both for the micellar formulations and free 
glycosides. 
 
 
 
 
 
 
 
 
 
Figure 4.7. Inhibitory activities of the free glycosides (4.1, 4.2 and 4.3) and the 
glycosides coated IONP micelles (4.4, 4.5 and 4.6) with respect to their molar 
concentration against lung carcinoma cells (A549) after 48 hours incubation. w/o : 
without magnet ; w m: with magnet. 
The greatest antimitotic activity was obtained for 4.6 on rat glioma 
cells. It can also be seen that when the biological activity against lung 
carcinoma cells (A549) is determined in the presence of magnetic field, the 
results are worse. This maybe because the magnet attracts straight away the 
NP in the centre of the plate thus they cannot disperse in all the plate where 
there is the cell culture. 
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Table 4.3. Comparison of the ID 50 of the free glycosides (4.1, 4.2 and 4.3) and the 
glycosides coated IONP micelles (4.4, 4.5 and 4.6). w/o : without magnet ; w m: with 
magnet. 
Compound 
ID50 (µM) 
C6 
ID50 (µM) 
A549 
4.1 15.5±0.3 10 
4.2 >100 97 
4.3 14.2±0.3 8.6 
4.4 
55 w/o m 100.5 w/o m 
95 w m 
4.5 
68.5 w/o m 64.4 w/o m 
91 w m 
4.6 
24.4 w/o m 40.3 w/o m 
42 w m 
3. Discussion 
We have synthesised a range of theranostic micelles formed of OA 
IONP stabilised in water by a coating made of different antitumoural oleyl 
glycosides. OA IONP were first prepared by thermal degradation of organic 
iron precursors at high temperature resulting in iron oxide cores of higher 
quality than the ones yielded by hydrolytic routes for optimum use as contrast 
agent and magnetically driven carrier as suggested by previous studies.
9,37
 
Three oleyl derivative glycosides previously reported as antitumoural were 
then used
15
 to create amphiphilic structures where in all the cases the oleic 
acid surfactant of the NP and oleyl moiety of the sugars formed a van der 
walls hydrophobic interaction pair while the hydrophilic part of the glycoside 
stands around the outer layer for aqueous stabilisation. We get this micellar-
like structure by spontaneous arrangement of the two entities under a 
nanoemulsion method.
29
 This approach is now currently used for preparation 
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of other NP based amphiphilic assemblies as it simplified and accelerates the 
synthesis and provides reproducible and highly homogeneous dispersion 
especially if compared to the other prevalent reverse evaporation method 
known in the field.
28
  
Our approach is different to normal controlled drug delivery system 
nanoparticle-based drug delivery system (e.g. liposomes/polymeric NP), in 
which the drug is usually incorporated by encapsulation (drug carrier vehicle) 
or by ionic/covalent conjugations onto a prior hydrophilic NP coating.
25
 This 
enables diffusion and releasing of the drug by diffusion or enzymatic cleavage 
once the NP has reached to the site of therapeutic interest. Additional surface 
conjugations of peptides, proteins or antibodies lead to active targeting 
multifunctional carrier for an even more efficient delivery.
11
 The originality of 
our probes lies in the fact that the stabilising biocompatible coating of the NP 
is by itself the active component of the drug and therefore should fulfil the 
requirements of the second role in the preparation whilst maintaining the 
therapeutic efficiency. For this reason, we first verified that the antitumoural 
activity was fully preserved upon the micelle formation. The presence of the 
oleyl conjugate on the glycosides was described as the main positive factor for 
cancerous cell growth inhibition but in the OA IONP encapsulated glycoside 
micelles; while the aliphatic chain is hindered inside the amphiphilic 
nanoassembly. Interestingly, although this should proceed against our 
purpose, bioactivity was maintained and in one case (4.5) was higher than the 
one of the free molecule coating component. We assume that under this 
micellar form, a better hydrophilicity is assured for the bioactive glycoside until 
cell uptake in a rich hydrophobic environment and a partial dissociation and 
oleyl-glycoside release of the assembly contents occurred. Besides, the free 
oleyl glycosides were previously used in vivo associated to the BSA protein, a 
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fatty acid transporter which plays a similar role than the micelle´s one 
described above.
22
  
One of the main challenges of chemotherapy against cancer is that it 
usually affects both tumours and healthy tissues. New strategies of targeting 
comprised the drug delivery platforms (either biological such as targeting 
organic ligand or physical such as magnetic guided NP) begin to bring 
different alternative, although the optimal solution is still getting specific activity 
of the drugs only against cancerous cells looking after the small differences in 
the tumoural cell biological pathway.
38
 Here, it will be a synthetic challenge to 
conjugate a targeting organic ligand on the micelle assemblies based drug 
delivery platform. However, in our case, oleyl glycoside acts on the activated 
lipid synthesis pathway of the tumoural cells, which need cell membrane 
materials to sustain the uncontrolled malign cell proliferation.
17
 This first 
property combined to the ones of IONP based drug delivery platform like the 
possible EPR effect which enhances the accumulation of NP in tumours, or 
magnetic guided delivery, can be a strong point for an in vivo chemotherapy 
with high specificity to the cancerous cells. On this purpose, EPR effects shall 
be facilitated by the size of the micelles which range around 50 nm and are 
particularly adapted for an easy accumulation/diffusion through the leaky 
vessels
39
 and also by the vascular circulation time after i.v.a determined in the 
same order or up to the reported standards for IONP of similar hydrodynamic 
size.
40
 This contributes to increase the chance of higher accumulation and to 
get bioactive local dose at optimal dose range of the glycosides.  
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4. Conclusion 
We have presented a theranostic micellar agent with anti-tumoural 
active glycosides acting as hydrophilic moiety to stabilize IONP at 
physiological conditions. We observed in all the cases that the use of this drug 
delivery formulation maintain or increase the therapeutic efficacy. Gathering all 
the information, glycosides coated IONP micelles has a slight adverse 
influence on the inhibitory activity but maintain antitumoural properties and get 
higher aqueous solubility and in vivo stability. These results are promising for 
future assessment in vivo of these theranostic micellar agents. 
5. Materials and Methods 
Materials and general synthetic methods 
All chemicals were of reagent grade or higher and were purchased from commercial 
suppliers or purified by standard techniques. Thin-layer chromatography (TLC) was 
performed on aluminum sheets 60 F254 Merck silica gel, and compounds were 
visualised by irradiation with UV light and/or by treatment with a solution of Ce2MoO4 
or 5% H2SO4 in EtOH, followed by heating. Flash column chromatography was 
performed using thickwalled columns, employing silica gel (Merck 60: 0.0400.063 mm). 
The eluent used is indicated, and solvent ratios refer to volume. Melting points are not 
corrected and were measured with a Reicher Jung Thermovar micromelting apparatus. 
Optical rotations were recorded on a Perkin-Elmer 241 Polarimeter (λ = 589 nm, 1 dm 
cell). 
1
H NMR spectra were registered at 400 or 300 MHz, and 13C NMR spectra were 
obtained at 100 MHz on a Varian INOVA spectrometers, using CDCl3, CD3OD, or D2O 
as the solvent at room temperature. Chemical shift values are reported in parts per 
million (δ). Coupling constant values (J) are reported in hertz (Hz), and spin 
multiplicities are indicated by the following symbols: s (singlet), d (doublet), t (triplet), q 
(quartet), and(multiplet). High-resolution mass spectra (HRMS) were recorded on an 
Agilent 6520 Accurate Mass Q-TOF spectrometer with an ESI source.  
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Synthesis 
Synthesis of OA IONP 
Protocol described in Chapter “General Materials and Methods” 
Synthesis of Oleyl 2-Acetamido-2-deoxy-β-D-glucopyraroside, GC-22 (4.1). 
A solution of 4.7 
41
 (500 mg, 1.37 mmol) and oleic alcohol (85%) (1.53 mL, 
4.11 mmol) in anhydrous CH3CN(55 mL) containing 4 Å molecular sieves was stirred 
at room temperature for 10 min. Then, SnCl4 (0.3 mL, 2.4 mmol) was added, and the 
reaction mixture was stirred at 55 ºC for 24 h. After this time, the mixture was heated at 
80 ºC (under reflux) and stirred for 1 h. The reaction mixture was cooled at room 
temperature, treated with Et3N (0.4 mL), filtered under Celite, and concentrated in 
vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc, 
1:1) to give the oleyl intermediate Oleyl 2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranoside (396 mg, 48%). [α]D -9.6º (c 1.1, MeOH). 
1
H NMR (400 MHz, CD3OD): 
δ 5.5-5.3 (m, 2H), 5.22 (dd, 1H, J = 10.5, 9.3 Hz), 4.98 (dd, 1H, J = 10.1, 9.5 Hz), 4.63 
(d, 1H, J = 8.5 Hz), 4.28 (dd, 1H, J = 12.4, 4.8 Hz), 4.11 (dd, 1H, J = 12.3, 2.4 Hz), 3.9-
3.7 (m, 2H), 3.6-3.4 (m, 2H), 2.1-2.0 (m, 13H), 1.90 (s, 3-H), 1.6-1.5 (m, 2H), 1.4-1.2 
(m, 22 H), 0.90 (t, 3H, J = 6.9 Hz) ppm. 
13
C NMR (100 MHz, CD3OD): δ 173.2, 172.3, 
171.9, 171.3, 130.9, 130.8, 102.1, 74.2, 72.8, 70.9, 70.2, 63.3, 55.5, 33.6, 33.1, 30.9, 
30.8, 30.8, 30.8, 30.7, 30.6, 30.5, 30.3, 30.2, 28.2, 28.1, 27.1, 23.7, 22.8, 20.7, 20.6, 
20.6, 14.5 ppm. HRMS (ESI) m/z calcd for C32H55NO9, 597.3897; found, 598.3970 (M + 
H)
+
. 
This intermediate was dissolved in MeOH (2 mL) and treated with a 0.1 M 
solution of NaOMe (10 mL). The reaction was stirred at room temperature for 2 h. After 
this time, the mixture was neutralised with Amberlite IR-120 (H
+
 form), filtered off, and 
concentrated. The residue was purified by silica gel column chromatography (EtOAc-
MeOH, 10:0 to 10:1) to give 4.1 (840 mg, quantitative) as a white solid; mp 155-160 ºC; 
[α]D -9.0º (c 0.5, MeOH). 
1
H NMR (400 MHz, CD3OD): δ 5.4-5.3 (m, 2H), 4.38 (d, 1H, 
J = 8.4 Hz), 3.9-3.8 (m, 2H), 3.69 (dd, 1H, J = 11.9, 5.5 Hz), 3.62 (dd, 1H, J = 10.3, 
8.4), 3.5-3.4 (m, 1H), 3.34 (d, 1H, J = 9.6 Hz), 3.25 (ddd, 1H, J = 9.6, 5.5, 2.4 Hz), 2.1-
1.9 (m, 7H), 1.5-1.4 (m, 2H), 1.3-1.2 (m, 26H), 0.88 (t, 3H, J = 7.0 Hz) ppm. 
13
C NMR 
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(100 MHz, CD3OD): δ 173.4, 130.6, 130.5, 102.3, 79.1, 78.8, 78.5, 77.4, 75.7, 71.8, 
70.5, 62.5, 57.1, 33,4, 32.8, 30.6, 30.6, 30.5, 30.5, 30.4, 30.40, 30.3, 30.3, 30.2, 30.9, 
30.1, 30.1, 29.9, 28.0, 26.9, 23.5, 23.0, 14.4 ppm. HRMS (ESI) m/z calcd for 
C26H49NO6, 471.3570; found, 472.3643 (M +H)+, 494.3461 (M+ Na)+. 
Synthesis of oleyl 2-acetamido-2-deoxy-6-O-(oxosulfonyl)-α-D-glucopyranoside 
potassium salt, IG-20 (4.2) 
A solution of 4.1 (100 mg, 0.21 mmol) in ethanol (1.5 mL) was treated with 
butane-2,3-dione (41 ul, 0.47 mmol), camphorsulfonic acid (10 mg, 0.04 mmol), and 
triethylorthoformiate (0.23 mL, 1.4 mmol) under Ar. The mixture was stirred for 3.5 h at 
60 °C. After cooling, the mixture was neutralised with triethylamine, concentrated, and 
purified by column chromatography (hexane-EtOAc, 1:1 to 0:1) to give a solid (98 mg), 
which was dissolved in anhydrous pyridine (5 mL) and then treated with SO3-pyridine 
complex (509 mg, 3.20 mmol), with stirring at room temperature under Ar for 1 h. After 
this time, the mixture was concentrated, and the residue was dissolved in methanol-
water (2:1, 7 mL), neutralised with a 0.5M KOH solution, and concentrated. The 
residue was purified by column chromatography (CH2Cl2-methanol, 6:1) to give 4.8 (95 
mg, 61%). 
1
H NMR (200 MHz, CD3OD): δ 5.4-5.3 (m, 2H), 4.83 (d, 1H) 3.4 Hz), 4.6-4.4 
(m, 2H), 4.3-3.4 (m, 8H), 2.2-2.0 (m, 7H), 1.6-1.2 (m, 36H), 1.0-0.9 (m, 3H). 
4.8 (79 mg, 0.11 mmol) was dissolved in a mixture of acetic acid-water (2:1, 
10 mL) and stirred at 65 °C for 3 h. The mixture was concentrated and the residue was 
purified by column chromatography (CH2Cl2-methanol, 5:1 to 4:1) to give 4.2 (42 mg, 
66%). [R]D: +69.0° (c 1.18, MeOH). 
1
H NMR (300 MHz, CD3OD): δ 5.4-5.3 (m, 2H), 
4.76 (d, 1H, J = 3.4 Hz), 4.26 (dd,1H, J = 2.4 Hz, J = 11.0 Hz), 4.18 (dd, 1H, J = 5.6 
Hz, J = 10.7 Hz), 3.89 (dd, 1H, J = 3.7 Hz, J = 10.7 Hz), 3.8-3.6 (m, 4H), 3.4-3.3 (m, 
2H), 2.0-1.9 (m, 7H), 1.6-1.5 (m, 2H), 1.3-1.2 (m, 22H), 0.90 (t, 3H, J = 6.8 Hz). MS 
(ES) m/z (calcd 589.3): 590.3 (M + 1). Anal. (C26H48KNO9S) C, H, N, S. 
Synthesis of oleyl 2-deoxy-2-trifluoroacetamido-α-D-glucopyranoside, TFA-GC22 
(4.3). 
N-trifluoroacetyl-D-glucosamine (1.18 g, 4.29 mmol), prepared from 4.4. as 
described in the literature 
30
, was dissolved in oleic alcohol (85%) (8 ml, 21.4 mmol) 
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and was treated with H2SO4-silica (35%) (236 mg). The reaction mixture was stirred 
under argon at 180 ºC for 20 min (TLC: EtOAc). After this time, the mixture was cooled 
at room temperature and purified by silica gel column chromatography (hexane-EtOAc, 
2:1 to 0:1) to give 4.3 (604 mg, 29%) as a white solid. Mp: 118-123 ºC. [α]D: +86.0º (c 
0.5, MeOH). 
1
H NMR (400 MHz, CD3OD): δ 5.4-5.3 (m, 2H), 4.86 (d, 1H, J=3.6 Hz), 
3.90 (dd, 1H, J=10.8, 3.6 Hz), 3.9-3.8 (m, 1H), 3.80 (t, 1H, J=1.9 Hz), 3.8-3.7 (m, 2H), 
3.60 (ddd, 1H, J=9.9, 5.5, 2.3 Hz), 3.5-3.3 (m, 2H), 2.1-1.9 (m, 4H), 1.8-1.5 (m, 2H), 
1.5-1.1 (m, 22H), 0.90 (t, 3H, J=7.0 Hz). 
13
C RMN (100 MHz, CD3OD): δ 159.2, (q, 
J=37.5 Hz), 117.5 (q, J=287.6 Hz), 130.8, 130.8, 97.7, 73.8, 72.3, 71.9, 68.98, 62.6, 
56.2, 33.1, 30.9, 30.9, 30.6, 30.6, 30.6, 30.5, 30.5, 30.4, 30.3, 28.1, 28.1, 27.3, 23.8, 
14.5 ppm. HRMS (ESI+) m/z (calcd 525.3283): 526.3345 (M-H)+, 543.3621 (M-NH4)+. 
HRMS (ESI+) m/z (calcd 525.3283): 526.3345 (M-H)+, 543.3621 (M-NH4)+. For 
preparation of H2SO4-silica catalyst (35%), silica gel (200-325 mesh) (10 g) was 
resuspended in ethylic ether (50 mL) and concentrated H2SO4 (3 mL) was slowly 
added drop by drop with stirring. During the absorption process, 10 min, the 
suspension was gently stirred at room temperature. After this time, the solvent was 
removed by distillation and the silica was dried under reduced pressure (2-4 mbar) and 
heated at 60 ºC for 3 h. 
Synthesis of glycoside coated IONP micelles 4.4, 4.5 and 4.6. 
The glycosides 4.1, 4.2 or 4.3 (10 to 20 mg) in ethanol (1 mL) was first dispersed in 15 
mL of phosphate buffer (pH=7.2, 5 mM). 1 mL of the suspension comprising OA IONP 
in hexane (10 to 15 mg.mL
-1
 in iron concentration) was then added to the solution and 
the resultant mixture was sonicated (Branson 250, 42 +/- 6 KHz) under robust stirring 
for 20 min at 37 ºC. Oil in water (o/w) nanoemulsion was further kept under sonication 
for 1 hour to evaporate all traces of hexane and ethanol resulting in the formation of a 
homogenous micellar aqueous solution. Aggregates were removed after filtration (0.22 
µm, PVDF membrane) and excess of free glycoside was removed by gel filtration in a 
PD-10 column (GE Healthcare). 
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Evaluation of 4.4 uptake in liver by MRI after i.v.a.  
Rat (n = 2, Wistar, 350 g) was anesthetised with 2% isoflurane in a mixture of N2/O2 
(80:20). Baseline images were acquired before the intravenous administration of 300 
µl, [Fe]=1.5 mg.ml
-1
 of 4.4 micelle. Magnetic resonance images of the rat´s liver were 
acquired at different times, from 5 minutes up to 1 hour after the injection. Specific 
region of interests (ROI) were selected and the reduction of the signal measured. After 
normalisation to the baseline, curve representing the kinetic of elimination of the liver 
was represented. 
MRI protocol. The images were acquired with a 7 T Biospec MRI spectrometer (Bruker, 
Ettlingen, Germany), using a transmitter/receiver quadrature coil of 25 mm inner 
diameter (Bruker, Ettlingen, Germany). Rat was kept anaesthetised with 2% isoflurane 
in a mixture of N2/O2 (80:20) via facial mask and placed prone in a custom-built plastic 
holder. The body temperature was kept constant using warm circulating water and the 
respiratory cycle was monitored constantly. 8 axial slices of 1 mm thickness were 
acquired to image the liver. The acquisition was performed in free-breathing animals, 
using a FLASH sequence. 
 
In vitro activity of the micelles 4.4, 4.5 and 4.6. Inhibition of A549 and C6 tumour 
cell proliferation 
Human A549 cell line and C6 rat glioma cell line were maintained in Dulbecco's 
modified Eagle's medium (DMEM) complete medium (Sigma-Aldrich, St. Louis, MO), 
supplemented with fetal bovine serum (FBS, 10%; GLinus, Madrid, Spain), glutamine 
(2 mM), penicillin (50 IU/mL), and streptomycin (50 mg/mL), at 37 ºC in a 5% CO2 
humidified atmosphere. Exponentially growing cells were seeded on 96-well plates 
(Beckton Dickinson, Le Pont de Claix, France), in DMEM complete medium, at a 
density of 1.5 x 104 cells/well for C6 cell and 5 x 103 cells/well for A549 cells 
respectively. The cells were allowed to attach with 5% of CO2 at 37ºC for overnight, 
and then, to serum starve the cells, the medium was replaced by 100 μL of fresh 
DMEM without FBS and maintained overnight. Stock solutions in EtOH of the free 
glycosides (4.1, 4.2 and 4.3) derivatives of or stock solutions in PBS of the micelles 
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(4.4, 4.5 and 4.6) were finally dissolved in DMEM complete medium for the treatments. 
The cells were treated with serial dilutions of glycoside derivatives or micelles for 48 h. 
For the experiments with micelles, some 96-well plates were placed over a 
MagnetoFACTOR-96 device (Chemicell) to produce a strong magnetic field to each 
well and increase the proximity of the nanoparticles to the cells. Also, IONP coated with 
azelaic acid and PC IONP (1.1) were tested (Azelaic-NP, obtained as described in 
previous work of us. 
42
) Cell proliferation was evaluated with an MTT assay (Sigma-
Aldrich), based on the conversion of the water-soluble MTT into an insoluble formazan. 
Briefly, after 48 h of compound treatment, the medium was replaced by 100 μL of 
fresh DMEM without phenol red containing MTT (5 mg/mL) solution, and cells were 
incubated for additional 3 h at 37 ºC with 5% CO2. After this time, the medium was 
removed, the precipitated formazan was dissolved in 100 μL of DMSO, and the 
solution optical density was measured at 595 nm in Spectramax Plus equipment 
(Molecular Devices Corporation). Absorption values were referred to positive 
proliferation controls (cells cultured in DMEM complete medium) and negative 
proliferation controls cells cultured in DMEM without FBS). Inhibition was expressed as 
an ID50 value, the compound concentration that reduced maximal proliferation by 50%. 
6. Bibliography 
(1) Ferrari, M. (2005) Cancer nanotechnology: opportunities and challenges. Nat. Rev. 
Cancer 5, 161–171. 
(2) Gupta, A. K., and Gupta, M. (2005) Synthesis and surface engineering of iron oxide 
nanoparticles for biomedical applications. Biomaterials 26, 3995–4021. 
(3) Cho, K., Wang, X., Nie, S., Chen, Z., and Shin, D. M. (2008) Therapeutic 
Nanoparticles for Drug Delivery in Cancer. Clin. Cancer Res. 14, 1310–1316. 
(4) Mccarthy, J., and Weissleder, R. (2008) Multifunctional magnetic nanoparticles for 
targeted imaging and therapy☆. Adv. Drug Deliv. Rev. 60, 1241–1251. 
(5) Veiseh, O., Gunn, J. W., and Zhang, M. (2010) Design and fabrication of magnetic 
nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliv. Rev. 62, 284–
304. 
(6) Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. (2000) Tumor vascular 
permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. 
Release Off. J. Control. Release Soc. 65, 271–284. 
(7) Alexis, F., Pridgen, E., Molnar, L. K., and Farokhzad, O. C. (2008) Factors Affecting 
the Clearance and Biodistribution of Polymeric Nanoparticles. Mol. Pharm. 5, 505–515. 
(8) Emerich, D. F., and Thanos, C. G. (2006) The pinpoint promise of nanoparticle-
based drug delivery and molecular diagnosis. Biomol. Eng. 23, 171–184. 
186 
 
(9) Arruebo, M., Fernández-Pacheco, R., Ibarra, M. R., and Santamaría, J. (2007) 
Magnetic nanoparticles for drug delivery. Nano Today 2, 22–32. 
(10) Alexiou, C., Schmid, R. J., Jurgons, R., Kremer, M., Wanner, G., Bergemann, C., 
Huenges, E., Nawroth, T., Arnold, W., and Parak, F. G. (2006) Targeting cancer cells: 
magnetic nanoparticles as drug carriers. Eur. Biophys. J. 35, 446–450. 
(11) Brigger, I., Dubernet, C., and Couvreur, P. (2002) Nanoparticles in cancer therapy 
and diagnosis. Adv. Drug Deliv. Rev. 54, 631–651. 
(12) Janib, S. M., Moses, A. S., and MacKay, J. A. (2010) Imaging and drug delivery 
using theranostic nanoparticles. Adv. Drug Deliv. Rev. 62, 1052–1063. 
(13) Lübbe, A. S., Bergemann, C., Huhnt, W., Fricke, T., Riess, H., Brock, J. W., and 
Huhn, D. (1996) Preclinical experiences with magnetic drug targeting: tolerance and 
efficacy. Cancer Res. 56, 4694–4701. 
(14) Lübbe, A. S., Bergemann, C., Riess, H., Schriever, F., Reichardt, P., Possinger, 
K., Matthias, M., Dörken, B., Herrmann, F., Gürtler, R., Hohenberger, P., Haas, N., 
Sohr, R., Sander, B., Lemke, A. J., Ohlendorf, D., Huhnt, W., and Huhn, D. (1996) 
Clinical experiences with magnetic drug targeting: a phase I study with 4’-
epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56, 4686–4693. 
(15) García-Alvarez, I., Corrales, G., Doncel-Pérez, E., Muñoz, A., Nieto-Sampedro, 
M., and Fernández-Mayoralas, A. (2007) Design and synthesis of glycoside inhibitors 
of glioma and melanoma growth. J. Med. Chem. 50, 364–373. 
(16) Fernández-Mayoralas, Alfonso, Nieto, Manuel, Casas, Josefina, García, Isabel, 
and Romero, Lorenzo. DERIVADOS DE N-TRIFLUOROACETILHEXOSAMINAS Y SU 
USO COMO INHIBIDORES DE LA DIVISION DE CELULAS TUMORALES. 
(17) García-Alvarez, I., Garrido, L., Doncel-Pérez, E., Nieto-Sampedro, M., and 
Fernández-Mayoralas, A. (2009) Detection of metabolite changes in C6 glioma cells 
cultured with antimitotic oleyl glycoside by 1H MAS NMR. J. Med. Chem. 52, 1263–
1267. 
(18) García-Álvarez, I., Egido-Gabás, M., Romero-Ramírez, L., Doncel-Pérez, E., 
Nieto-Sampedro, M., Casas, J., and Fernández-Mayoralas, A. (2011) Lipid and 
ganglioside alterations in tumor cells treated with antimitotic oleyl glycoside. Mol. 
Biosyst. 7, 129–138. 
(19) Birklé, S., Zeng, G., Gao, L., Yu, R. K., and Aubry, J. (2003) Role of tumor-
associated gangliosides in cancer progression. Biochimie 85, 455–463. 
(20) Lahiri, S., and Futerman, A. H. (2007) The metabolism and function of 
sphingolipids and glycosphingolipids. Cell. Mol. life Sci. C. 64, 2270–2284. 
(21) Bektas, M., and Spiegel, S. (2004) Glycosphingolipids and cell death. Glycoconj. 
J. 20, 39–47. 
(22) García-Álvarez, I., Groult, H., Casas, J., Barreda-Manso, M. A., Yanguas-Casás, 
N., Nieto-Sampedro, M., Romero-Ramírez, L., and Fernández-Mayoralas, A. (2011) 
Synthesis of Antimitotic Thioglycosides: In Vitro and in Vivo Evaluation of Their 
Anticancer Activity. J. Med. Chem. 54, 6949–6955. 
(23) Chojnowska, S., Kępka, A., Szajda, S. D., Waszkiewicz, N., Bierć, M., and Zwierz, 
K. (2011) Exoglycosidase markers of diseases. Biochem. Soc. Trans. 39, 406–409. 
(24) Driguez, H. (1997) Thiooligosaccharides in glycobiology, in Glycoscience 
Synthesis of Substrate Analogs and Mimetics (Driguez, H., and Thiem, J., Eds.), pp 
85–116. Springer Berlin Heidelberg, Berlin, Heidelberg. 
(25) Kingsley, J. D., Dou, H., Morehead, J., Rabinow, B., Gendelman, H. E., and 
Destache, C. J. (2006) Nanotechnology: a focus on nanoparticles as a drug delivery 
187 
 
system. J. Neuroimmune Pharmacol. Off. J. Soc. NeuroImmune Pharmacol. 1, 340–
350. 
(26) Hao, R., Xing, R., Xu, Z., Hou, Y., Gao, S., and Sun, S. (2010) Synthesis, 
Functionalization, and Biomedical Applications of Multifunctional Magnetic 
Nanoparticles. Adv. Mater. 22, 2729–2742. 
(27) Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., and Muller, 
R. N. (2008) Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, 
Physicochemical Characterizations, and Biological Applications. Chem. Rev. 108, 
2064–2110. 
(28) Nasongkla, N., Bey, E., Ren, J., Ai, H., Khemtong, C., Guthi, J. S., Chin, S.-F., 
Sherry, A. D., Boothman, D. A., and Gao, J. (2006) Multifunctional Polymeric Micelles 
as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems. Nano Lett. 6, 2427–
2430. 
(29) Phosphatidylcholine-coated iron oxide nanomicelles for in vivo prolonged 
circulation time with an antibiofouling protein corona. 
(30) Wolfrom, M. L., and Conigliaro, P. J. (1969) Trifluoroacetyl as an N-protective 
group in the synthesis of purine nucleosides of 2-amino-2-deoxy saccharides. 
Carbohydr. Res. 11, 63–76. 
(31) Fernández-Mayoralas, A., De La Figuera, N., Zurita, M., Vaquero, J., Abraham, G. 
A., San Román, J., and Nieto-Sampedro, M. (2003) Central neural tumor destruction 
by controlled release of a synthetic glycoside dispersed in a biodegradable polymeric 
matrix. J. Med. Chem. 46, 1286–1288. 
(32) Na, H. Bin, Song, I. C., and Hyeon, T. (2009) Inorganic Nanoparticles for MRI 
Contrast Agents. Adv. Mater. 21, 2133–2148. 
(33) Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, 
F., and Dawson, K. A. (2011) Physical−Chemical Aspects of Protein Corona: 
Relevance to in Vitro and in Vivo Biological Impacts of Nanoparticles. J. Am. Chem. 
Soc. 133, 2525–2534. 
(34) Moghimi, S. M., Hunter, A. C., and Murray, J. C. (2001) Long-circulating and 
target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283–318. 
(35) García, I., Marradi, M., and Penadés, S. (2010) Glyconanoparticles: 
multifunctional nanomaterials for biomedical applications. Nanomedicine 5, 777–792. 
(36) Lartigue, L., Innocenti, C., Kalaivani, T., Awwad, A., Sanchez Duque, M. del M., 
Guari, Y., Larionova, J., Guérin, C., Montero, J. G., Barragan-Montero, V., Arosio, P., 
Lascialfari, A., Gatteschi, D., and Sangregorio, C. (2011) Water-dispersible sugar-
coated iron oxide nanoparticles. An evaluation of their relaxometric and magnetic 
hyperthermia properties. J. Am. Chem. Soc. 133, 10459–72. 
(37) Mejías, R., Pérez-yagüe, S., Gutiérrez, L., Cabrera, L. I., Spada, R., Acedo, P., 
Serna, C. J., Lázaro, F. J., Villanueva, Á., Morales, P., and Barber, D. F. (2011) 
Biomaterials Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically 
guided in vivo delivery of interferon gamma for cancer immunotherapy. Biomaterials 
32, 2938–2952. 
(38) Liu, Y., Miyoshi, H., and Nakamura, M. (2007) Nanomedicine for drug delivery and 
imaging: A promising avenue for cancer therapy and diagnosis using targeted 
functional nanoparticles. Int. J. Cancer 120, 2527–2537. 
(39) Jang, S. H., Wientjes, M. G., Lu, D., and Au, J. L. S. (2003) Drug delivery and 
transport to solid tumors. Pharm. Res. 20, 1337–1350. 
188 
 
(40) Antonelli, A., Sfara, C., Battistelli, S., Canonico, B., Arcangeletti, M., Manuali, E., 
Salamida, S., Papa, S., and Magnani, M. (2013) New Strategies to Prolong the In Vivo 
Life Span of Iron-Based Contrast Agents for MRI. PLoS One (Louie, A., Ed.) 8. 
(41) Whistler, R. L., Wolfrom, M. L., and BeMiller, J. N. (1962) Methods in carbohydrate 
chemistry. Academic Press, New York. 
(42) Herranz, F., Morales, M. P., Roca, A. G., Desco, M., and Ruiz-Cabello, J. (2008) A 
New Method for the Rapid Synthesis of Water Stable Superparamagnetic 
Nanoparticles. Chem. - A Eur. J. 14, 9126–9130.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
191 
 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
192 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
193 
 
1- We have synthesised and fully characterised a new probe made of OA 
IONP encapsulated in a Phosphatydilcholine (PC) based micelle. These NP 
are valuable T2 MRI contrast agent with a significantly extended vascular 
lifetime above 10 hours. 
2- The protein corona adsorbed on PC IONP was fully elucidated at 3 different 
times and compared with those from standard IONP blood pool agent coated 
with PEG. Results allow correlating the antibiofouling character of the corona 
of PC IONP with its prolonged systemic circulation. 
3- We have demonstrated that PC IONP can be degraded by the enzyme PC-
PLC leading to the formation of aggregates and showing that this enzymatic 
reaction has effect on uptake and cytotoxicity of in vitro cell cultures of 
macrophage type I and II. 
4- We have employed this selective enzymatic property to use PC IONP for 
the specific detection of the atherosclerosis plaque. After i.v.a of the probe in a 
mice model of atherosclerosis, we were able to detect the accumulation of the 
nanoparticles in the plaque of the aorta by T2 MRI. Histology confirmed an 
entrapment of the probe inside the plaque elicited by the PC-PLC enzyme 
activity, and a slower uptake of PC IONP by the host macrophages. 
5- We have presented a new approach for the parallel multifunctionalisation of 
hydrophobic NP in a single step. The method is generic for different types of 
NP coated with aliphatic surfactants and uses the interactions with BSA pre-
functionalised modules. It can be a standard and simple methodology for the 
versatile preparation of NP incorporating functionalisation on demand of 
multimodal nanoparticles. 
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6- We have used this methodology for the preparation of a library of 13 
different multimodal agents based on IONP, UCNP and AuNP and with BSA 
modules for PET imaging, fluorescence imaging and targeting of tumours. All 
the probes show excellent colloidal properties, low toxicity and good 
bioacceptability. 
7- As proof of concept of the flexibility and suitability for different in vivo 
applications of the probes prepared by this modular approach, we prepared 
one IONP based candidate for targeted (RGD) PET/MRI multimodal in vivo 
imaging in a murine tumour model. 
8- We have designed innovative theranostic NP agents for cancer therapy. 
They are constructed by stabilizing OA IONP inside a micelle assembly made 
of antimitotic oleyl glycosides. We have illustrated the possibility to obtain 
hydrophilic nanostructures with higher aqueous solubility and in vivo stability 
from two entities previously not suitable for in vivo applications. 
9- We have demonstrated that these glycoside-coated IONP micelles have 
maintained or, in some cases, increased the antimitotic activity against two 
cancerous cell lines in vitro in comparison to the original free glycosides. 
These glycosidic biomolecules confer at the same time stabilisation as coating 
for OA IONP micellar and antitumoural chemotherapeutic properties. 
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Summary in English 
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Nanotechnology studies materials and systems whose structures and 
components exhibit novel or significantly improved physical, chemical and 
biological properties, phenomena and processes due to their nanoscale size. 
When nanotechnology is used specifically for medical applications, we refer 
then to “Nanomedicine”. It is nowadays mostly related to the application of 
nanostructures for treatment, diagnosis, monitoring and control of biological 
systems. The term Nanoparticle (NP) is used in medicine in a generic way 
including a wide range of distinct nanostructures some of them hybrid or 
combination of different ones. In this work we have focused in metallic 
nanoparticles since they show very interesting properties for imaging. NP have 
special structures which places them at the cross of many different disciplines. 
They are basically composed of a metallic core surrounded by an organic 
coating bound to the surface. The metallic core provides the size-dependent 
properties for which the material is most well-known. The surface of the NP is 
of paramount importance, it determines the targeting capabilities, colloidal 
stability and much of the in vivo fate of the NP. Most recent advances deal 
with the term functionalisation; the attachment of molecules on the surface of 
the particles to provide colloidal stability and/or biological targeting. Surface 
coating is responsible for a range of specific requirements for the in vivo 
biological use of the NP, which concern multidisciplinary fields such as 
biochemistry, molecular and cell biology, pharmacokinetics or toxicity. In this 
work, we proposed different functionalisations of various coatings of three kind 
of metallic NP (Iron oxide NP, UpConverting NP and Gold NP). These 
coatings tailoring aimed at applications in medical imaging and therapy in 
oncology and cardiovascular diseases. 
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In the Chapter 1, we report the synthesis of micellar Phosphatidylcholine-
coated Superparamagnetic Iron Oxide Nanoparticles as a new long circulation 
contrast agents for magnetic resonance imaging. Oleic acid-coated Fe3O4 
nanoparticles were first prepared via thermal degradation and then 
encapsulated into small clusters with a Phosphatidylcholine coating to obtain 
hydrophilic nanomicelles. A thoroughly characterisation confirmed the 
chemical nature of the coating and the excellent colloidal stability of these 
nanomicelles in aqueous media. Magnetisation and relaxivity properties 
proved their suitability as MRI contrast agent and in vitro cell viability data 
showed low toxicity. Vascular lifetime and elimination kinetics in liver were 
assessed by blood relaxometry and in vivo MRI in rats and compared with 
“control” particles prepared with a polyethylene glycol derivative. These 
micellar particles had a lifetime in blood of more than 10 hours, much longer 
than the control nanoparticles (~ 2 hours) really remarkable considering that 
the coating molecule is a small biocompatible zwitterionic phospholipid. The 
protein corona was characterised after incubation with rat serum at different 
times by high-throughput proteomics, showing a higher proportion of bound 
apolipoproteins and other dysopsonins for the Phosphatidylcholine particles. 
The antibiofouling properties of this corona and its resistance to the adsorption 
of proteins corroborate the observed enhanced stability and prolonged 
systemic circulation. 
In the Chapter 2, we propose iron oxide coated phosphatidylcholine micelles 
(PC IONP) as an imaging probe for the molecular characterisation of 
atherosclerotic plaque formation. Phosphatidylcholine-specific phospholipase 
C (PC-PLC) is involved in atherosclerosis as a regulator of apoptosis and 
autophagy in vascular endothelial cells (VECs). Because PC-PLC can 
specifically degrade the polar moiety of phosphatidylcholine, we examined if 
this enzymatic regulation could trigger the accumulation of PC IONP by 
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changing their colloidal stability. We first considered the in vitro interaction 
between PC-PLC and the iron oxide micelles in order to demonstrate the 
effectiveness of enzymatic cleavage of PC coating leading to the formation of 
hydrophobic aggregates. We then showed the consequences of this 
enzymatic degradation in the uptake of PC IONP and associated cytotoxicity 
effects in cellular cultures of macrophages. Finally, we studied the intravenous 
injection of PC IONP in ApoE-KO mice for multimodal in vivo visualisation and 
imaging characterisation of atherosclerotic plaques, underlining the 
importance of the interaction of the probe with the PC-PLC enzyme and the 
uptake by macrophages. The proposed probe represents a new platform for 
targeting of atherosclerosis thanks to an original enzymatically driven 
entrapment route, which opens promising bioapplications not only for specific 
diagnosis (quantification of plaque burden) but also to predict clinical relevant 
events for potential anti-inflammatory therapies in the context of 
atherosclerosis. Our approach allows studying the regulation of this pro-
atherogenic enzyme in the plaque progression and thus contributing with new 
molecular imaging solutions to understand different biochemical processes in 
the context of atheriosclerosis. 
In the Chapter 3,. we reports a generic modular strategy for the parallel one-
step multifunctionalisation of different hydrophobic nanoparticles. The method 
was designed and developed taking advantage of the natural non-covalent 
interactions between the fatty acid binding sites of the bovine serum albumin 
(BSA) and the aliphatic surfactants on different inorganic nanomaterials. As a 
general example of the approach, three different nanoparticles - iron oxide, 
upconverting nanophosphors and gold nanospheres- were nanomemulsioned 
in water with BSA. To support specific applications, multifunctional capability 
was incorporated with a variety of previously modified BSA modules. These 
modules include different conjugated groups, such as chelating agents for 
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68
Ga or 
89
Zr and ligand molecules for enhanced in vivo targeting. A large 
library of thirteen multimodal contrast agents was developed with this 
convergent strategy. This platform allows a highly versatile and easy tailoring 
option for efficient incorporation of functional groups. Finally, as demonstration 
of this versatility, a bimodal (PET/MRI) probe including a maleimide-
conjugated BSA was selectively sation with an RGD peptide for in vivo 
imaging detection of tumour angiogenesis 
In the Chapter 4, we used glycosides comprising hydrophilic sugar moiety 
conjugated to oleyl hydrophobic chains that have promising antimitotic activity 
on cancer cell cultures but limited in vivo perspectives because of their low 
solubility in physiological media and rapid enzymatic degradation. We report 
here the synthesis of micelles formed by the OA IONP encapsulated within a 
hydrophilic layer of the amphiphilic glycosides. These nanomicelles were fully 
characterised especially their suitability as in vivo MRI contrast agents and for 
its in vitro antimitotic activity on cell cultures from rat glioma and from human 
lung carcinoma and compared with the activity of the corresponding free 
glycosides. The results show that the formulation of glycosides in the form of 
OA IONP encapsulated micelles have preserved antitumoural effects and in 
one case provides a significant therapeutic gain. Moreover, the micelles 
present excellent relaxometric properties for their use as contrast agent based 
T2 MRI. Ours findings suggest that synergetic bioactive hydrophilic 
nanostructures can be obtained to generate theranostic agents, from two 
entities previously not suitable for in vivo applications and strengthen the 
possibility to use biomolecules at the same time as coating for OA IONP 
micellar stabilisation and as drugs for therapy. 
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1. Introducción 
 
La Nanotecnología es la ciencia que trata el diseño, la síntesis, la 
caracterización y la aplicación de materiales con al menos una dimensión 
menor de 100 nm. Además, debido a este tamaño, aparecen propiedades 
fisicoquímica nuevas o mejoradas respecto al material macroscópico. El 
tremendo desarrollo de la nanotecnología en los últimos años ha llevado a su 
aplicación en el campo de la medicina, dando lugar a la Nanomedicina, en la 
cual se engloba el presente trabajo.  
En la aplicación de la nanotecnología a la medicina es fundamental el uso 
de nanopartículas (NP). La variedad de dichos compuestos es inmensa, 
debido fundamentalmente al número de variables que se pueden modificar; 
tamaño del núcleo, tamaño hidrodinámico, composición del núcleo, 
composición del surfactante, carga superficial, etc. La estructura básica de 
una nanopartícula incluye un núcleo, que suele ser metálico o de óxidos 
metálicos, y una superficie que suele ser orgánica. Tradicionalmente el 
desarrollo de NP para imagen o terapia se ha centrado en la optimización del 
núcleo de la nanopartícula, dejando como secundario la superficie orgánica. 
En este trabajo sin embargo nos centraremos más en dicha superficie, en el 
desarrollo de nuevos métodos para su estabilización en medios acuosos, la 
funcionalización para una determinada actividad biológica y en el estudio de 
las interacciones in vivo de la superficie de las partículas con las proteínas 
presentes en el torrente circulatorio, lo que conoce como la “protein corona”. 
Una parte fundamental de esta aproximación es el concepto de 
“multifuncional”, entendiendo como tal una nanopartícula que puede integrar 
en su estructura sondas para varias técnicas de imagen más una molécula 
que permita la acumulación selectiva en el área de la patología o que por 
ejemplo incorpore un fármaco, permitiendo desarrollar el concepto de 
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“theranostics”, la combinación de terapia y diagnóstico en una sola sonda 
(Figura 5.1). La representación de la Figura 5.1 deja claro la importancia de la 
superficie de las NP en esta aproximación. 
 
 
 
Figura 5.1. Representación esquemática de una nanopartícula metálica multifuncional. 
 
La aplicación de NP en biomedicina tiene dos grandes campos de 
actuación; la imagen médica y el transporte de fármacos. En la presente tesis 
veremos ejemplos de las dos aplicaciones, desde el diseño de partículas para 
imagen dual PET/MRI hasta el desarrollo de nuevos antitumorales 
nanoparticulados. Las NP que emplearemos para dicha aproximación son de 
tres tipos; Óxido de hierro, Up-converting nanophosphors y partículas de Oro. 
 
Nanopartículas de Óxido de hierro (IONP). La importancia de estas 
partículas en aplicaciones biomédicas es de sobra conocida y cubren desde 
la imagen por resonancia magnética, el transporte de fármacos y la terapia 
por hipertermia, por citar las más destacadas. Estas NP pueden obtenerse 
con tamaños de núcleo de 2 a 50 nm y presentan una composición de 
Magnetita (Fe3O4), Maghemita (Fe2O3) o una mezcla de ambos óxidos. La 
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principal propiedad de estas NP, razón de su amplia rango de aplicaciones y 
consecuencia de su tamaño es el superparamagnetismo. De forma muy 
simple dicha propiedad se traduce en una respuesta magnética muy intensa 
por parte del material cuando se aplica un campo magnético externo y la 
pérdida de todo magnetismo cuando dicho campo es eliminado. En términos 
de imagen en MRI esta propiedad hace que, incluso a muy bajas 
concentraciones, la señal sea muy intensa en comparación con las sondas 
paramagnéticas. Como es sabido el fenómeno de la relajación en Resonancia 
Magnética Nuclear está principalmente gobernado por dos magnitudes, el 
tiempo de relajación longitudinal o T1 y el tiempo de relajación transversal o 
T2. Los agentes de contraste para MRI reducen ambos tiempos de relajación 
haciendo que la muestra vuelva antes a la situación de equilibrio térmico. Sin 
embargo, según las propiedades fisicoquímicas del agente el efecto será 
mayor sobre T1 o sobre T2. Las nanopartículas de óxido de hierro que 
presentan carácter superparamagnético y normalmente un momento 
magnético muy grande son ejemplo característico de agente T2. Dichas 
sondas, con las secuencias de pulso más habituales en imagen, proporcionan 
lo que se conoce como contraste negativo, es decir una área hipointensa en 
aquellas zonas donde las partículas se han acumulado. Dicho contraste para 
tejidos ricos en agua, por tanto con una señal “brillante”, son ideales y fáciles 
de identificar. Para otras aplicaciones son preferibles el uso de sondas T1, 
esto ha hecho que la investigación de métodos para desarrollar sondas de 
óxido de hierro para contraste T1 haya avanzado mucho en los últimos años. 
 
Up-converting nanophosphors. Recientemente se ha empezado a aplicar 
un nuevo tipo de nanomaterial, las que podríamos traducir como 
nanopartículas fluorescentes de conversión ascendente (UCNP, acrónimo 
derivado del inglés). Dichas partículas están compuestas por una matriz cuya 
composición puede ser muy variada y dopadas con diferentes metales. Una 
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de las combinaciones de matriz-dopantes más empleadas es aquella que usa 
NaYF4 como matriz y Yb
3+
, Er
3+
 o Tm
3+
 como dopantes. La principal 
característica de estas partículas es que, contrariamente a los fluoróforos 
tradicionales, la fluorescencia se produce de menor a mayor energía 
mediante la absorción de 2 o 3 fotones de forma secuencial. Esto hace 
posible por ejemplo excitar a longitudes onda tan grandes como 980 nm, en el 
infrarrojo cercano, y obtener emisión de fluorescencia a 800 nm, consiguiendo 
mayor penetración en el tejido y pudiendo realizar imagen de un ratón 
completo sin los problemas habituales en la imagen óptica con las sondas 
más habituales. 
 
 
 
 
 
 
 
 
 
 
 
Figura 5.2. Comparativa de los principios básicos de la fluorescencia tradicional y la 
fluorescencia por conversión ascendente. 
 
De las distintas matrices que como decíamos se pueden emplear en este 
trabajo nos hemos centrado en β-NaGdF4:Yb,Tm@β-NaGdF4. Dichas 
partículas consisten en una matriz de NaGdF4 la cual además de ser una 
buena matriz para el fenómeno de la conversión ascendente permite realizar 
imagen T1 en MRI gracias a la presencia del Gd en la estructura. Dicha matriz 
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está dopada con Yb
3+
 como activador y Tm
3+
 como dador del fenómeno de 
conversión ascendente, además se añade una “concha” (shell) del mismo 
material, NaGdF4, sin dopar lo cual aumenta la eficacia de la fluorescencia al 
aislar el material del disolvente. 
 
Nanopartículas de oro. El último nanomaterial con el que se trabaja en 
esta tesis son las nanopartículas de oro. La importancia de este material en 
las aplicaciones biomédicas de la nanotecnología es bien conocida. Ello se 
debe a varias de sus propiedades, especialmente a la resonancia del plasmón 
de superficie que hace que estas partículas presenten propiedades ópticas 
muy interesantes en función del tamaño de partícula. Dicha propiedad es 
utilizada ampliamente para una gran variedad de aplicaciones como sensores 
y transporte de fármacos. Además y dado el elevado peso atómico del Au las 
nanopartículas de este material también se emplean como agentes de 
contraste en CT, aunque esta última propiedad no será desarrollada en este 
trabajo. 
 
Síntesis y funcionalización. Por lo que se refiere a la síntesis de estos tres 
nanomateriales hay una gran variedad de métodos. De las distintas opciones 
es ampliamente reconocido que la síntesis mediante descomposición térmica 
de precursores orgánicos es la que proporciona nanopartículas con las 
mejores características, especialmente en el caso de las IONP y UCNP. La 
síntesis de esta forma genera nanopartículas hidrófobas con lo que para su 
empleo en condiciones fisiológicas deben ser transformadas en hidrófilas. 
Este hecho solía citarse como desventaja de este método, sin embargo, este 
trabajo es una buena muestra de que más que una desventaja es una 
oportunidad para, en un solo paso, conseguir la estabilidad en agua y la 
biofuncionalización en lugar de largas y complejas modificaciones que 
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resultan en un menor rendimiento y un empeoramiento de las propiedades 
coloidales de las partículas. 
 
2. Nanomicelas de óxido de hierro recubiertas con 
fosfatidilcolina: largos tiempos de circulación en sangre y 
estudio de la corona proteica. 
 
En este apartado se describe la síntesis de nanopartículas 
superparamagnéticas de óxido de hierro recubiertas con fosfatidilcolina (PC) 
como nuevos agente de contraste para T2 en MRI. Las IONPs recubiertas de 
ácido oleico fueron sintetizadas mediante la descomposición de Fe(acac)3 a 
elevada temperatura. Como se aprecia en la figura 5.3 se obtienen partículas 
de unos 10 ± 3 nm de tamaño hidrodinámico, monodispersas, y un tamaño de 
núcleo, medido por TEM de 7 ± 2 nm, valores típicos para la síntesis 
mediante este proceso. Tanto la estructura cristalina como la composición del 
surfactante fueron caracterizados, por rayos-X, espectrometría de masas e 
Infrarrojo, dando los resultados esperados. 
 
 
 
 
 
 
 
 
 
Figura 5.3. a) tamaño hidrodinámico de las IONPs recubiertas de ácido oleico 
 
213 
 
Finalmente el carácter superparamagnético de la muestra fue confirmado 
mediante medidas del momento magnético en un campo externo, dando la 
curva típica sin histéresis ni coercitividad y un valor de magnetización de 
saturación de 70 emu.g
-1
 Fe. 
A continuación dichas partículas fueron funcionalizadas con PC mediante 
un método de nanoemulsión, generando micelas en las que se encuentran 
agrupadas varias IONP y con el grupo polar de la PC hacia el exterior de la 
micela. El método de la nanoemulsión consiste en mezclar un volumen 
pequeño de IONPs hidrófobas en hexano con un volumen mucho mayor de la 
PC disuelta en tampón fosfato. Esto conlleva la formación de una monocapa 
de PC, la cual ocurre de forma espontanea al 1% de concentración. A 
continuación y mediante sonicación se induce la evaporación del hexano y la 
formación de las micelas como situación energéticamente más favorable 
(Figura 5.4). 
Figura 5.4. Nanoemulsión para la síntesis de IONP recubiertas con fosfatidilcolina. 
 
De esta forma se obtuvieron micelas estables en agua de 74.9 nm de radio 
hidrodinámico con un PDI muy bajo de 0.14. El aumento de tamaño respecto 
a las partículas hidrófobas se debe en este caso a que cada micela engloba 
varias partículas de oleico originales. Para evaluar la estabilidad de las 
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micelas se midió el potencial Z a distintos valores de pH así como el cambio 
en el tamaño hidrodinámico en distintos tampones de fuerza iónica elevada 
(Figura 5.5). La figura 5b muestra cómo, a pesar de un valor de potencial Z 
bajo a pH 7 (-11.5 mV, Figura 5.5.a), las partículas muestran una gran 
estabilidad incluso en PBS 10x. 
Figura 5.5. a) Potencial Z de las nanomicelas de PC en función del pH. b) Cambio en 
el tamaño hidrodinámico en función del tampón y del tiempo. 
 
La composición superficial de las micelas fue estudiada de nuevo 
empleando FTIR y espectrometría de masas, así como mediante 
termogravimetría. Los resultados en los tres casos fueron los esperados, 
confirmando la presencia de la molécula en la superficie de la micela. Las 
propiedades magnéticas fueron estudiadas obteniendo un valor similar al de 
las IONP hidrófobas, 60 emu.g
-1 
Fe. En cuanto a la relaxometría, para 
determinar cómo de adecuadas para MRI son estas micelas, se obtuvieron 
unos valores de 1.3 s
-1
mM
-1
 y 147.4 s
-1
mM
-1
 para r1 y r2 respectivamente, 
confirmando la utilidad de estas partículas como agentes T2 para MRI. 
Después de comprobar la falta de toxicidad de las partículas en 
fibroblastos, se estudió el tiempo de circulación en sangre. El conseguir que 
las nanopartículas circulen por el torrente sanguíneo después de una 
inyección intravenosa es un requisito indispensable tanto para imagen como 
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para el transporte de fármacos. Para conseguir esto las partículas deben ser 
“invisibles” para el sistema inmune ya que de otra forma son rápidamente (4-5 
minutos) transportadas al hígado y bazo. A efectos comparativos se 
sinterizaron micelas, mediante el mismo proceso, pero empleando un 
polímero anfifílico derivado de polietilenglicol al ser este el estándar más 
empleado para la síntesis de nanopartículas hidrófilas.  
 
Tabla 5.1. Principales características fisicoquímica de PC IONP y P80 IONP. 
 PC IONP P80 IONP 
Tamaño hidrodinámico (nm) 74.9 25 
PDI 0.14 0.19 
Potencial zeta  (pH=7.1) (mV)  -11.5 -4 
Magnetizacion de saturación 70 65 
Relaxividad (s
-1
.mM
-1
) r1: 1.3 
r2 : 147.4 
r1 : 2.3 
r2 : 127.2 
Tiempo de circulación en sangre (relaxometría) 10 h 2h 
 
Como puede apreciarse en la tabla 5.1 las nanopartículas de 
referencia, P80 IONP, presentan un tiempo de circulación en sangre muy 
elevado de 2 horas, medido por relaxometría y por MRI. Sin embargo, en el 
caso de las nanomicelas de PC el tiempo de circulación es 
extraordinariamente largo, 10 horas. Este hecho nos llevó a interesarnos por 
la composición de la corona proteica. Dicha corona consiste en la formación 
de una capa de proteínas que rodean a cualquier nanopartícula tan pronto 
entra en el torrente sanguíneo. La composición de dicha corona es dinámica y 
está determinada por la composición y tamaño de la nanopartícula. Aunque 
hasta hace relativamente poco este hecho era totalmente ignorado en la 
actualidad está claro que la composición de dicha corona determina en gran 
medida el destino de las partículas. Por ejemplo en nuestro caso estudiamos 
la composición de la corona de las PC IONP y P80 IONP para comprobar si la 
razón del diferente tiempo de circulación residía ahí. Para ello las dos 
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partículas se incubaron con suero a distintos tiempos (15, 90 y 180 minutos), 
se aislaron los complejos NP-proteínas y su composición se analizó mediante 
high-throughput LC-MS. La sensibilidad de la técnica nos permitió identificar 
más de 300 proteínas. En resumen, el análisis semicuantitativo de la corona 
proteíca permitió identificar una mayor proporción de disopsoninas en todos 
los puntos para las PC IONP lo que justifica su mucho mayor tiempo de 
circulación en sangre. 
Figura 5.6. Porcentaje relativo en peso de proteínas a) disopsoninas y b) opsoninas, 
clasificadas por su función biológica, en las coronas de PC IONP y P80 IONP a 
distintos tiempos. 
 
3. Caracterización de la placa de aterosclerosis mediante 
“trampa enzimática” de nanopartículas recubiertas de 
fosfatidilcolina. 
 
En este apartado nos propusimos estudiar el empleo de las PC IONP 
anteriormente descritas como sondas para la detección de la placa de 
aterosclerosis. La hipótesis para este estudio se basa en la abundante 
presencia de la enzima Fosfolipasa-C en la placa. Dicha enzima está 
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implicada en la regulación de fenómenos de apoptosis y autofagia de las 
células del endotelio vascular. Además, su actividad catalítica se basa en la 
degradación específica de la cabeza polar en la molécula de fosfatidilcolina. 
Por lo tanto nuestra hipótesis consistió en que, si las PC IONP se acumulan 
en la placa, debido a su composición podrían quedar “atrapadas” en la zona 
de la lesión por la acción de la fosfolipasa-C. Dicha enzima degradaría las 
cabezas polares que dan estabilidad coloidal a las partículas, de esta forma 
perderían dicha estabilidad y se acumularían de forma selectiva allá donde la 
enzima es activa. El efecto final sería similar al que se consigue con la 
18
F-
fluorodeoxiglucosa en PET, la acumulación metabólica de la sonda. En primer 
lugar se probó esta aproximación in vitro con la enzima activa y se monitorizó 
la evolución del tamaño y de los valores de relaxividad en función del tiempo y 
de la concentración de enzima (figura 5.7). Como se observa en la Figura 5.7 
el efecto es el esperado al eliminar la cabeza polar que estabiliza la micela y 
volver a tener nanopartículas con carácter hidrófobo. El mismo efecto se 
observa al medir la relaxividad, un aumento del T2 al agregarse las 
nanopartículas. El mismo comportamiento se observó al analizar la captación 
por parte de los macrófagos de las PC IONP. Los macrófagos M1, 
proinflamatorios, presentan una expresión mucho mayor de la enzima que los 
M2, antiinflamatorios. Esta diferencia se comprobó que se correlaciona 
perfectamente con una mayor captación de las PC IONP por parte de los M1. 
Debido a la sobreexpresión de la enzima en estos la cantidad de 
nanopartículas atrapadas es también mucho mayor.  
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Figura 5.7. a) evolución del tamaño hidrodinámico de las PC IONP (0.035 mg Fe ml
-1
), 
desde 5 minutos a 180 minutos, al incubar las partículas a 37ºC con fosfolipasa-C (0.6 
U). b) Relaxividad T2 de las PC IONP (0.035 mg Fe .ml
-1
) al incubarlas con distintas 
concentraciones de enzima (0.1 U, 0.3 U and 0.6 U). 
 
Con estos resultados decidimos probar nuestra hipótesis in vivo. Para ello 
se emplearon ratones ApoE-KO de 48 semanas, 18 semanas en dieta 
hipercolesterolémica. La imagen se realizó en un equipo de MRI de 7 T, basal 
y 24 horas después de la inyección de las partículas. Como se aprecia en las 
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imágenes seleccionadas en la figura 5.8 la acumulación es claramente visible 
en la zona de la lesión con la típica señal hipointensa, así como con la 
cuantificación que demuestra la reducción en la intensidad de la señal en 
comparación con la imagen basal y referenciándolo al músculo del animal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. a) Imágenes en T2 de ratones apoE-KO antes de la inyección y 24 horas 
después b) Cuantificación de la señal relativa placa-músculo basal y a 24 horas. 
 
En resumen creemos que en este apartado demostramos la acumulación 
selectiva de las PC IONP en la placa de aterosclerosis debido a tres factores; 
1) El largo tiempo de circulación de las nanopartículas, visto en el apartado 
anterior, 2) la acumulación de apoliproteínas en la corona proteica, también 
visto en el primer partado y 3) la degradación enzimática por parte de la 
fosfolipasa-C. Estos tres factores puestos en conjunto explican la 
basal 24 hours
0.0
0.2
0.4
0.6
0.8
1.0
P
la
q
u
e
 t
o
 m
u
s
c
le
 
R
O
Is
 r
e
la
ti
v
e
 s
ig
n
a
l
**
basal 24 h
220 
 
acumulación pasiva de las partículas en la zona de la lesión y su posterior 
retención por la actividad de la enzima. 
 
4. Multifuncionalización paralela de nanopartículas: Síntesis 
modular en un solo paso para imagen molecular in vivo. 
La capacidad de sintetizar sondas multifuncionales es una de las 
principales ventajas del uso de nanopartículas. Sin embargo hasta la fecha 
dicha multifuncionalización suele llevarse a cabo mediante largos y tediosos 
procesos sintéticos que, entre otras cosas, tienen efectos perjudiciales para la 
estabilidad coloidal de las nanopartículas. Con esta idea nos planteamos 
desarrollar un método que permitiera, en solo paso, la obtención de 
nanopartículas estables en agua y con propiedades multifuncionales. Para 
ello el primer paso fue la síntesis de partículas hidrófobas recubiertas de 
ácido oleico. El propósito de esta aproximación era obtener un método 
sencillo, convergente, que se pudiera aplicar a una gama variada de 
nanopartículas, por esta razón se sintetizaron IONP, UCNP y AuNP 
recubiertas de oleico por el mismo método descrito en anteriores capítulos. 
Nuestra aproximación en paralelo se basa en el empleo de la Albúmina (BSA) 
como agente que proporcione estabilidad en agua y que pueda ser 
prefuncionalizado. De esta forma el primer paso era comprobar si se podía 
emplear la BSA para la estabilización directa de las NP hidrófobas. Para ello 
se aplicó el proceso de la nanoemulsión previamente descrito pero usando la 
BSA en lugar de la PC. La interacción, en este caso, se produce entre las 
cadenas hidrófobas de ácido oleico y los centros receptores de sustancias 
hidrófobas que están presentes en la BSA. Dicha emulsión produjo NP 
estables en agua, BSA IONP, BSA UCNP y BSA AuNP de unos 100 nm de 
tamaño. Las partículas fueron caracterizadas y la presencia de BSA en la 
superficie confirmada por entre otras técnicas, espectrometría de masas.  
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Además, se llevaron acabo reacciones control para descartar que la BSA 
estuviera simplemente adsorbida sobre la superficie hidrófoba de las 
partículas. Para ello, previo a la nanoemulsión, la BSA se incubó con una 
concentración elevada de ácido oleico libre de forma que nos aseguramos 
que los centros receptores están saturados. Estas OA-BSA fueron utilizadas 
entonces en el proceso de nanoemulsión, sin embargo esta vez fue imposible 
obtener partículas estables en agua, recuperándose las partículas hidrófobas 
originales en los tres casos. 
Una vez que el método demostró ser capaz de generar partículas estables 
en agua lo aplicamos a la síntesis de sondas multifuncionales. Para ello se 
llevó a cabo la prefuncionalización de los diferentes módulos de BSA; con un 
fluoróforo (Alexa647), otro con DOTA, un agente quelante para 
68
Ga, otro con 
DFO, un agente quelante para 
89
Zr y por último con maleimida para la unión 
de biomoléculas a través de grupos tioles libre. 
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Figura 5.9. a) módulos prefuncionalizados para la síntesis, b) proceso de nanoemulsión y c) librería de nanopartículas 
multifuncionalizadas por combinación de los distintos módulos. 
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Con esta aproximación se preparó una librería de 13 nanopartículas 
diferentes (Figura 5.9), desde partículas para fluorescencia y MRI, para PET y 
MRI a partículas para, al menos dos técnicas de imagen, y la posibilidad de 
unir alguna biomolécula vía el grupo maleimida. Las principales 
características fisicoquímicas de la librería de nanopartículas fueron 
estudiadas; tamaño hidrodinámico, composición superficial, valores 
relaxométricos, propiedades ópticas y magnéticas, algunas de dichas 
propiedades se recogen en la tabla 5.1. 
 
Tabla 5.1. Librería de nanopartículas preparada, principales propiedades 
fisicoquímicas y modalidades de imagen en las que pueden ser empleadas. 
BSA NP % 
modified 
BSA 
Size 
(nm) 
pdi Zeta 
potential 
(mV) 
Imaging 
properties 
BSA IONP n.a. 97.2 0.18 -19.7 T2 MRI 
BSA UCNP n.a 94.3 0.19 -17.9 T1 MRI/  
Fluorescence 
BSA AuNP  n.a. 102.5 0.15 -9.5 UVvis/ 
fluorescence 
(Alexa647)BSA IONP 3% 
Alexa647  
93.0 0.15 -13.5 T2 MRI / 
Fluorescence 
(Alexa647)BSA AuNP 3% 
Alexa647  
108.9 0.22 -11.1 UVvis / 
fluorescence/ 
FRET 
(DOTA)BSA IONP 8 % 
DOTA  
104.9 0.17 -10.8 T2 MRI / PET 
(DOTA)BSA UCNP 8 % 
DOTA  
78.7 0.20 -25.7 T1 MRI /  
Fluorescence / 
PET 
(DOTA)BSA AuNP 8 % 
DOTA  
87.5 0.13 -19.8 PET / UVvis 
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Tabla 5.1. (Cont.)      
(Mal.)BSA UCNP 30 % Mal  100.9 0.15 -23.1 T1 MRI /  
Fluorescence / 
targeting 
(Alexa647)(DOTA)(Mal.)BSA 
IONP 
6% 
Alexa647  
3 % 
DOTA  
30 % Mal  
 
90.2 0.19 -8.9 T2 MRI / PET / 
Fluorescence / 
targeting 
(DFO)(Mal.)BSA IONP 20 % 
DFO  
20 % Mal  
 
91.9 0.18 -13.9 T2 MRI / PET / 
targeting 
(Alexa647)(DFO)(Mal.)BSA 
IONP 
6% 
Alexa647  
20 % 
DFO  
15 % Mal  
78.4 0.16 -12.0 T2 MRI / PET / 
Fluorescence / 
targeting 
(DFO)(RGD)BSA IONP 20 % 
DFO  
20 % 
RGD  
94.2 0.15 -14.5 T2 MRI / PET / 
Angiogenesis 
Finalmente, como demostración de la utilidad de esta aproximación 
se desarrolló una sonda triple la cual contenía óxido de hierro en el núcleo, el 
agente quelante DFO en la superficie para el marcaje con 
89
Zr y el péptido 
RGD para la detección de zonas de angiogénesis.  
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Figura 5.10. a) Imagen PET de (
89Zr
)(
RGD
)BSA IONP a diferentes tiempos post-
inyección en modelo murino alograft de tumores; b) imagen T2-MRI del mismo ratón 
previo a la inyección de la sonda y 24 horas post-inyección; c) Intensidad de la señal 
en la zona tumoral por PET (azul) y MRI (rojo) a diferentes tiempos y d) actividad 
medida en contador gamma de distintos órganos (72 h post-inyección). 
 
Los resultados obtenidos al inyectar dicha sonda en modelos tumorales en 
ratones se recoge en la figura 5.10. En dicha figura puede apreciarse 
claramente la acumulación en la zona tumoral por PET (Figura 5.10 a) y por 
T2-MRI (Figura 5.10 b). Como puede apreciarse la cuantificación de la señal 
en la zona del tumor claramente coincide con los resultados de la imagen. 
Asimismo la biodistribución muestra una gran acumulación de actividad en la 
zona del tumor, además de la típica en hígado y bazo. Finalmente, la 
histología del tumor confirmó la presencia de óxido de hierro mediante el uso 
de azul de Prusia como tinción. 
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4. Micelas de óxido de hierro recubiertas con glicósidos con 
propiedades antitumorales.E 
El uso de conjugados entre glicósidos y cadenas alifáticas derivadas del 
ácido oleico han demostrado poseer propiedades prometedoras dada su 
capacidad antimitótica en cultivos de células cancerosas pero limitadas 
posibilidades de actuación in vivo debido a su baja solubilidad en medio 
fisiológico y rápida degradación enzimática. Dada la estructura de estos 
glicósidos (Figura 5.11 b) nuestra hipótesis se basó en que el empleo de 
dichos compuestos podría llevar a la obtención de estructuras tipo liposomas 
en las que la doble capa lipídica estuviera formada entre las cadenas 
alifáticas del ácido oleico de las nanopartículas de óxido de hierro y las 
cadenas hidrófobas de los glicósidos. De esta forma la estructura glicosídica, 
polar, quedaría hacia el exterior dando estabilidad en agua a las 
nanopartículas y, en un solo paso, se habría conseguido la estabilización en 
agua y la introducción de funcionalidad biológica a las nanopartículas. 
 
 
 
 
 
 
 
 
 
 
Figura 5.11. Esquema general de la síntesis de micelas de óxido de hierro recubiertas 
de glicósidos. 
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Las tres micelas así sintetizadas fueron caracterizadas y sus 
principales propiedades se recogen en la tabla 5.2. 
 
Tabla 5.2. Caracterización de las micellas. 
Glicósido 
IONP micela 
Tamaño 
(nm) 
pdi potential 
Z 
(mV) 
[Fe] 
(mg/ml) 
[glicósido] 
(mg/ml) 
Relaxometría  
(s
-1
.mM
-1
) 
IV.IV 40.5 0.24 -27 0.6 ≈ 2.5 r1 2.7/r2 140 
IV.V 52.2 0.15 -42 1.1 3.1 r1 4.4/r2 195 
IV.VI 49.1 0.17 +53 0.3 ≈ 2.5 r1 3.6/r2 137 
 
El tiempo de circulación en sangre de las nanopartículas, valor clave 
para su utilización in vivo especialmente en aplicaciones de transporte de 
fármacos, fue de unos 20 minutos para las tres micelas. Este valor además de 
ser similar al de partículas sintetizadas mediante rutas mucho más complejas, 
es más que suficiente para su utilización. A continuación se estudió la 
capacidad antitumoral de las micelas sintetizadas en cultivos celulares con 
células de glioma de rata (Figura 5.12) y humanas de tumor pulmonar (Figura 
5.13) y se comparó con el resultados de los glicósidos libres. 
 
 
 
 
 
 
 
228 
 
 
 
 
 
 
Figura 5.12. Actividades inhibitorias de los glicósidos libres (4.1, 4.2 y 4.3) y de las 
micelas glicosido-IONP (4.4, 4.5 y 4.6) con respecto a su concentración molar en 
células de glioma de rata (C6) después de 48 h de incubación. 
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Figura 5.13. Actividades inhibitorias de los glicósidos libres (4.1, 4.2 y 4.3) y de las 
micelas glicosido-IONP (4.4, 4.5 y 4.6), con y sin imán en la placa de cultivo, con 
respecto a su concentración molar en células humanas de tumor pulmonar (A549) 
después de 48 h de incubación. 
 
De estos resultados lo más interesante es el caso de la micela 4.5 ya 
que consigue unas muy buenas actividades inhibitorias en ambas líneas 
celulares con un glicósido que no muestra actividad, en glioma, o la que 
presenta es muy baja, en tumor pulmonar. El siguiente paso en este proyecto 
será el estudio de estas micelas in vivo en modelos tumorales para 
comprobar si se produce el mismo efecto inhibitorio. 
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General Materials and Methods 
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Synthesis of OA IONP, OA UCNP and OM AuNP  
The OA IONP were synthesised using iron acetylacetonate as precursor and phenyl 
ether as solvent based on a method we published before.
7
 A mixture of Fe(acac)3 
(0.71 g, 2 mmol), 1,2-hexadecanediol (2.38 g, 10 mmol), oleic acid (1.69 g, 6 mmol), 
oleylamine (1.60 g, 6 mmol) and phenyl ether (20 mL) was added to a three-neck flask. 
The reaction mixture was heated under mechanical stirring and a flow of nitrogen gas 
up to a temperature of 200 ºC. This temperature was maintained for 120 min and the 
solution was then heated under reflux at 254 ºC for 30 min with a nitrogen balloon on 
the top of the condenser. Subsequently, the solution was cooled to room temperature. 
To remove side products, ethanol was added to the reaction mixture and the resulting 
solution was centrifuged at 8500 rpm for 10 min. The supernatant was decanted, n-
hexane (20 mL) and oleic acid (0.05 mL) were added to the NP, and the suspension 
was centrifuged at 8500 rpm to remove aggregates and obtain a stable suspension. 
The OA UCNP in this case refers to the OA coated NaGd74.5%F4:Yb25%, Tm0.5% 
@NaGdF4 nanoparticles. In a typical procedure
44
, lanthanide precursors GdCl3.6H2O 
(2.235 mmol; 830.7 mg) Yb.6H2O (0.75 mmol; 290.6 mg) TmCl3.6H2O (0.015 mmol; 
5.73 mg) were mixed in a three neck round bottom flask with a mixture of 30 mL oleic 
acid and  45 mL 1-octadecene. The mixture was heated to 130ºC during 30 min to 
obtain a homogeneous and optically clear lightly brownish solution. Reaction mixture 
was then cooled to room temperature before the dropwise addition of a 30 mL 
methanolic solution containing NaOH (0.3 g) and NH4F (0.446 g). The solution was 
kept stirring for 30 min and then temperature was raised until 110ºC with moderate 
vacuum in order to completely evaporate the methanol. Then a thermic treatment 
under nitrogen atmosphere was applied by increasing the temperature rapidly at 300ºC 
and maintaining it for 90 min. Finally the solution was cooled down to room 
temperature and the nanoparticles were next precipitated by addition of ethanol (30 
mL) and methanol (20 mL). After centrifugation at 5000 rpm for 20 min, the supernatant 
was decanted and nanoparticles collected for other two washes with ethanol. Finally 
the OA coated NaGd74.5%F4:Yb25%, Tm0.5% were dried before being dispersed and 
stabilised in n-hexane (30 mL). The procedure for the core addition synthesis was very 
234 
 
analogous. GdCl3.6H2O (2 mmol; 0.7434 g) was added to a three neck round bottom 
flask with a mixture of 20 mL oleic acid and 30 mL of 1-octadecene and was heated at 
130ºC during 30 min to obtain a homogeneous solution. Temperature was cooled down 
to 25ºC for the addition of 20 mL of n-hexane solution of the NaGd74.5%F4:Yb25%, Tm0.5% 
previously prepared (2 mmol). After evaporation of the n-hexane at 100ºC, solution was 
brought back again to room temperature before the dropwise addition of a 20 mL 
methanolic solution containing NaOH (0.2 g) and NH4F (0.2964 g). A thermic treatment 
under nitrogen atmosphere was then applied by increasing the temperature rapidly at 
300ºC for 90 minutes. Finally the solution was cooled down and the core/shell 
nanoparticles were next precipitated by addition of ethanol (30 mL). The nanoparticles 
were washed with ethanol thrice by centrifugation cycles (5000 rpm, 20 min). The 
obtained OA coated NaGd74.5%F4:Yb25%, Tm0.5% @NaGdF4, abbreviated OA UCNP 
were finally dispersed in n-hexane. 
The OM AuNP were synthesised through the thermal decomposition route.
45
 Briefly, 
100 mg of HAuCl4.xH2O was added in a 1:1 mixture of toluene and oleylamine (20 mL 
net volume). Following a brief sonication, so as to homogenize the solution, the mixture 
was transferred to reflux system, with continuous stirring at 80
o
C and under inert 
atmosphere, for 3 h. The sample thereafter was cooled down to room temperature, and 
an equal amount of n-hexane added to it. After this, ethanol purification was done in 
order to remove the excess of oleylamine. This involved addition of ethanol to the 
above solution and centrifugation at 12000 rpm at 15
o
C for 30 minutes. After 3 
consecutive washings, the precipitate was finally re-dispersed in 10 mL of n-hexane.  
Physicochemical characterisation of the NPs 
The hydrodynamic size, polydispersity index and zeta potential of the nanomicelles 
were measured with a Zetasizer Nano ZS90 (Malvern Instruments, UK) using folded 
capillary cells. Morphology and core size were determined using a 200-keV JEOL- 
2000 FXII transmission microscope (Jeol Ltd. Japan) at the National Center of Electron 
Microscopy of the University Complutense of Madrid. For the preparation of the 
sample, a drop of a dilute magnetic nanoparticle suspension was placed on a carbon-
coated copper grid and the solvent allowed to evaporate at room temperature (RT) for 
235 
 
24h. Fourier transform infrared spectroscopy (FT-IR) spectra were obtained on a 
Perkin Elmer Spectrum 400 Series spectrometer (Perkin Elmer, USA); each spectrum 
was obtained by averaging 32 interferograms with a resolution of 1 cm
-1
. 
Thermogravimetric analysis (TGA) spectra were obtained with a Seiko TG/ATD 320 U, 
SSC 5200 (Seiko Instruments, Japan) at the Institute of Materials Science of the 
University Autónoma of Madrid. The dried PC NPs were heated from 20ºC to 1000ºC 
at 10ºC/min under an air flow of 100 ml.min-1. Mass spectrometry was performed with 
in a Bruker Esquire 3000 apparatus (Bruker Daltonik, Germany) equipped with an ESI 
source and an ion trap analyzer, coupled to an Agilent 1100 capillary LC system 
(Agilent Technologies, USA). The sample was diluted 1/10 in water/methanol (1:1) 
before the LC/MS analysis. The analysis were carried out by FIA (flow injection 
analysis), working in both polarities, using a 0.1% formic acid/methanol (50/50) mix as 
the mobile phase to promote ionisation, at 0.1 mL/min.  
Magnetic characterisation. Magnetic characterisation of the samples was carried out in 
a vibrating sample magnetometer using 100 µL of solution in a special sample holder. 
Magnetisation curves were recorded at room temperature by first saturating the sample 
in a field of 1 T. The magnetisation values were normalised to the amount of iron to 
yield the specific magnetisation (emu/g Fe). The initial susceptibility of the suspensions 
was measured in the field range ±100 Oe, and the saturation magnetisation values 
(Ms) were evaluated by extrapolating to infinite field the experimental results obtained 
in the high field range where the magnetisation linearly increases with 1/H. For 
determination of the NMR relaxometric values, the T2 and T1 relaxation times were 
measured in a Bruker MQ60 (Bruker Biospin, Germany) with a T2 cp and T1 ir mb 
sequences. The relaxation rate Ri values (1/Ti, s-1,i = 1, 2), obtained from the 
measured relaxation times (Ti, s) were corrected by subtracting the water relaxation 
rate in the absence of the contrast agent. Linear fitting of the data gives straight lines 
whose slopes are the relaxivities (ri, s
-1
 mM
-1
) related to the iron concentration (mM): Ri 
= Rbi + ri [Fe]. 
 
